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Abstract 
Background 
 
Vivax malaria is a neglected disease. Recent reversal of the trend towards declining 
incidence has emphasized the importance of sustainable control strategies to move 
towards elimination. Although a more holistic approach will be needed to eliminate this 
poverty related disease, there is an irrefutable and urgent need for new treatments. 
Optimizing current therapeutic regimens is the first step to meet this demand.  
 
This thesis was conceived as a treatment optimization development plan to provide 
information about new approach to treat vivax malaria using drugs normally used for P. 
falciparum treatment, namely Artemisinin-based Combination Therapy (ACT), in 
combination with a short course of a hypnozoiticidal drug.  The intervention proposed 
was ACT with a concomitant short course of primaquine (total dose 3–4.2 mg/kg). 
 
Methods 
 
In this thesis, the safety, efficacy and effectiveness of these regimens has been thoroughly 
investigated in four pieces of work, (i) a systematic review to evaluate primaquine at 
alternative dosing schedules for preventing recurrence in people with plasmodium vivax 
malaria (chapter II); (ii) a retrospective open cohort to evaluate vivax recurrence in Brazil 
(chapter III); (iii) A randomized clinical trial (RCT) to evaluate the safety and efficacy of 
ACTs to treat malaria vivax in Brazil (chapter IV); and (iv) the evaluation of the 
pharmacokinetics/ pharmacodynamics of chloroquine and Artemisinin based 
Combination Therapies with primaquine within the RCT (chapter V).  
 iii 
Main results 
1) Systematic review to evaluate primaquine at alternative dosing schedules for 
preventing recurrence in people with Plasmodium vivax malaria results: 
The systematic review shows that are no difference in P. vivax recurrences at 6 months 
when using the same total dose of primaquine (0.5 mg/kg/day to 210 mg) over 7 days as 
compared to 14 days (RR 0.96, 95% CI 0.66 to 1.39) 
2) Retrospective open cohort to evaluate vivax recurrence in Brazil results: 
In Brazil, age ≤ 3 years, being male, literate, not-indigenous and having domestic working 
activities were identified as risk factors for recurrence. There was no difference in time 
to recurrence or recurrence frequency between patients treated with 14-day or 7–9 day 
primaquine regimens HR = 1.02 (0.96–1.09) and RR = 0.97 (0.90–1.04), respectively. 
The use of chloroquine alone was associated with a RR=1.43 (1.29–1.58, p < 0.0001) 
increased risk of P. vivax recurrence compared to patients who used chloroquine 
combined with short-course primaquine. The time to recurrence was longer in recipients 
of both primaquine and ACTs compared to patients treated with chloroquine alone or 
with concomitant primaquine, HR = 2.2 (1.62–2.99, p < 0.0001), HR = 1.27 (0.97–1.66, 
p = 0.08), respectively. 
3) Randomized clinical trial (RCT) to evaluate the safety and efficacy of ACTs to treat 
malaria vivax in Brazil results: 
The cure rate of all three treatment arms was greater than 90% at 28 and 42 days. Cure 
rates were below 90% in all three treatment groups at day 63, although the 95% 
confidence interval included 90% for all three treatments. Most of the adverse events 
were mild in all treatment arms.  Significant drops in haemoglobin were rare.  
4) Pharmacokinetics/ pharmacodynamics of chloroquine and Artemisinin based 
Combination Therapies with primaquine results: 
 iv 
Most recurrences in the ASMQ (67%), CQ (80%) and AL (85%) groups were considered 
related relapses. 8/9 (88.9%) of the patients with impaired CYP2D6 activity relapsed with 
related parasite compared to 18/25 (72%) with normal activity (RR= 1.23, 0.88;1.72, 
p=0.40). There were no associations between the measured PK parameters and 
recurrence.  Patients with longer chloroquine half-lives had more pruritus (RR=1.09, 
1.03;1.14, p=0.001).  
 
Conclusion 
 
The data presented here have increased the body of evidence to support the 
recommendation that short course primaquine regimens can be adopted into World Health 
Organization treatment guideline. However, although shorter course primaquine may 
improve adherence and the effectiveness of vivax treatment worldwide, there is still room 
for further improvements in treatment. One potential approach is to replace chloroquine 
by ACTs. 
 
This thesis further investigated the efficacy of ACTs with concomitant use of primaquine 
short course in a randomized clinical trial in Brazil. This study demonstrated that their 
efficacy meet World Health Organization criteria. Through this study and the subsequent 
pharmacokinetic and pharmacodynamic evaluation, we endeavoured to addressed the 
relative lack of information about the safety of the concomitant use of ACT and daily 
primaquine. We conclude that all regimens were well tolerated. 
 
 v 
Finally, the use of routine health information systems evaluated the effectiveness of these 
regimens and provided a basis for future studies of the deployment of new treatments 
nationwide in Brazil.  
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Bibliographic review 
In need of new treatments 
 
The world has experienced unprecedented advances in health technology during the last 
few decades. Unfortunately, the benefits of these innovations in health have not been 
evenly distributed among all populations. Progress on the development and deployment 
of tools to fight illnesses that afflict low income populations has not occurred at  the same 
pace as research and development (R&D) to treat the diseases that affect the wealthiest 
(2001, World Health Organization.).  
 
The concept of neglected diseases emerged around the beginning of this century (MSF, 
2001). Initially, they were called neglected because people suffering them could not 
afford the cost of the medicines, and investment in R&D for new treatments was 
neglected. Later renamed Neglected Tropical Diseases (NTD), the concept was rapidly 
accepted by many, including the World Health Organization (WHO)  and the social 
responsibility agenda of the pharmaceutical industry (World Health Organization., 2012). 
The considerable progress has been undeniable (World Health Organization., 2017), but 
also highlighted the drawbacks of the concept: new diseases will emerge and some 
diseases will be left behind.  Vivax malaria is one those left behind.  
 
Vivax malaria is not listed as one of the seventeen Neglected Tropical Diseases by WHO 
(World Health Organization., 2016) However, there has been recent international 
agreement that the importance of vivax malaria has been neglected (Carlton et al., 2011, 
Baird, 2007, Mendis et al., 2001, World Health Organization., 2015a), and there is an 
 3 
irrefutable need for  better treatments (Price et al., 2011) with higher acceptability and a 
better safety profile. Furthermore, as for any other infectious disease, resistant parasites 
will always emerge requiring new treatment approaches. Finally, as the public health 
agenda moves from control to eradication of malaria (malERA, 2017b) the treatment 
emphasis might transition from curing individuals to stopping transmission.   
 
The ideal and desirable features of any new treatment is described in a strategic document 
named Target Product Profile (TPP). While it is not a regulatory requirement, the US 
food and Drug Administration (FDA) issued a guidance on the subject (FDA, 2017), and 
it is widely used by pharmaceuticals industries, or by Public-Private Product Partnerships 
(PPP), such as Medicines for Malaria Venture (MMV) (Burrows et al., 2017). The TPP 
drives agreement among the stakeholders, whether industry, academic or the community.   
Whilst the screening and design of new molecules is important, most TPPs suggests 
incremental innovations may also have a place. Indeed, the malaria TPP starts with 
optimizing current treatments (Burrows et al., 2017). 
 
The logic behind optimizing current treatments is that the R&D of a new chemical entity 
may take around 15 years (Burrows et al., 2017) and we cannot wait longer. Some 
successful stories of drug developments to treat neglected diseases followed the simple 
rule of “first picking the low hanging fruits”. One example is the development of 
combination therapies. The use of combination therapy is broadly indicated in infectious 
diseases guidelines. It is a tool to increase treatments’ potency and prevent resistance 
emerging.  The introduction of the Artemisinin-based Combination Therapies (ACTs) in 
malaria was a landmark change in P. falciparum treatment (White and Olliaro, 1996, 
Nosten et al., 1998). The emergence of multidrug-resistant falciparum persuaded the 
 4 
WHO to include ACTs in the malaria treatment guidelines in 2006 (World Health 
Organization. Roll Back Malaria Dept., 2006), and this P. falciparum treatment 
recommendation (World health Organization., 2015c) has been adopted in most 
countries. Currently, even as decreased artemisinin efficacy against P. falciparum is 
correlated with the Kelch13 molecular marker (Ariey et al., 2014), the evaluation of safety 
and efficacy of new ACT combinations still ongoing. As in HIV and tuberculosis 
treatment, triple or quadruple drug combinations may be the next generation of 
antimalarial treatments (Shanks et al., 2015, U.S. National Institutes of Health, 2017) 
(NCT02453308). 
 
When considering optimizing current treatments, or incremental innovations, among 
many questions, we ought to ask ourselves: Can low toxicity old drugs be repurposed  
(Watkins and Sibley, 2011)?  Can new regimens, formulations or presentations delay  the 
effectiveness decay (malERA, 2017a)? Can the current treatment regimens be shortened 
(more patient friendly) without compromising efficacy (Milligan R, 2017)?  
 
This thesis was conceived as treatment optimization development plan, similar  to a drug 
development plan, (ICH, 1997) to provide information about  a new approach to treat 
vivax malaria using P. falciparum treatment (ACT) in combination with a short course of 
a hypnozoiticidal drug.  The intervention proposed was ACT with concomitant short 
course of primaquine (7–9 days: total dose 3–4.2 mg/kg). 
 
Herein, the primaquine regimen evaluated was the one that Brazilian National Malaria 
Control Program recommends for radical vivax malaria cure, a seven days primaquine 
treatment (total dose from 3 mg/kg to 4.2 mg/kg) (Ministério da Saúde do Brasil., 2010), 
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a total dose that retain efficacy in some parts of the world (John et al., 2012). This 
guideline of seven days concurrent primaquine helps to address the need to improve 
adherence treatment (World Health Organization., 2015a).  
 
In this thesis, the efficacy and effectiveness of this primaquine regimen in preventing 
relapses (Abdon et al., 2001a) has been  thoroughly investigated in three pieces of work,  
a Cochrane review (chapter II) (Milligan R, 2017), a cohort study (chapter III)  (Daher et 
al., 2019) and a clinical trial (chapter IV and V)   (Daher et al., 2018a). The potential for 
short course primaquine has recently been demonstrated by preliminary results from  the 
largest clinical trial ever in primaquine short course regimens suggesting that a high-dose 
primaquine course (7 mg/kg total dose given over 7 days) is non-inferior to the same dose 
given over 14 days (Taylor, 2018). The impact on  adherence still needs to be further 
investigated (Pereira et al., 2011, Osorio-de-Castro et al., 2015), arguably, short courses 
improve completeness of treatment, particularly in oligo symptomatic, asymptotic/ 
chronic patients (Chen et al., 2016).  
 
Vivax treatment using ACT has been recommended by WHO since 2010 (World Health 
Organization., 2010a), as it has equivalent P. vivax schizonticidal activity to chloroquine 
(Gogtay et al., 2013) and where chloroquine-resistant P. vivax exists, WHO recommends 
replacing this drug with ACTs. There are compelling arguments to look for a simpler and 
unified treatment for both malarias.  A single radical treatment for both malarias is useful 
in co-endemic areas with unreliable species diagnosis (Douglas et al., 2010). It is also the 
treatment of choice for mixed infections. It can also prevent hypnozoite activation causing 
P. vivax relapse  following P. falciparum infections (White, 2011). The logistical 
efficiencies of stock and supply management are an additional advantage for policy 
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makers.  Higher levels of ACT procurement are an incentive to maintain ACT production 
at industrial scale should falciparum treatment needs reduce. Finally, the availability of 
more than one efficacious vivax treatment helps with public health resistance 
management, as it may avoid selective pressure over a single therapeutic regimen. In this 
scenario, the ACT could be chosen as first line treatment because of the pill burden and 
daily intakes, food restrictions, potential suppressive activity in sporozoites (Clyde et al., 
1976), drug interactions and safety profile.  
 
Despite these advantages, an ACT and primaquine combination to treat malaria is far 
from an ideal new treatment safety profile. It is not appropriate for those who are 
pregnant, children aged <6 months, or G6DP deficient populations. These restrictions 
impose serious limitations on the deployment of ACT with primaquine as an elimination 
tool in many parts of the world, specially, in P. falciparum infected patients that do not 
need full primaquine dose to achieve radical cure.  
 
In order to provide additional evidence about the proposed intervention, a series of studies 
were conducted and published.  The studies published during the period of 2016-19 were: 
(i) a systematic review to evaluate primaquine at alternative dosing schedules for 
preventing recurrence in people with plasmodium vivax malaria (chapter II); (ii) a 
retrospective open cohort to evaluate vivax recurrence in Brazil (chapter III); (iii) A 
randomized clinical trial (RCT) to evaluate the safety and efficacy of ACTs to treat 
malaria vivax in Brazil (chapter IV); and (iv) The evaluation of pharmacodynamics/ 
pharmacokinetics relationship in the RCT (chapter V).  
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This thesis produced some evidence to help to answer these questions about the 
optimization of the vivax treatment. Providentially, a new single dose anti-hypnozoite 
drug, tafenoquine was first registered in the FDA in 2018 (FDA, 2018). Unfortunately, 
the low hanging fruit approach might still be needed for a while.  Tafenoquine is from the 
same drug class than primaquine. Its long half-life causes many concerns and its wide 
deployment requires a yet to be available quantitative point of care G6PD deficiency 
diagnosis and intense pharmacovigilance. New classes of drugs are in the R&D pipeline 
although none are anti-relapse molecules (Burrows et al., 2017). The pharmaceutical 
industry’s inertia has been replaced with new ideas from PPPs, academics and 
communities and new unprecedented advances in health technology are expected. The 
antimalarial history is moving fast. 
 
History of malaria treatment 
 
The history of the first anti-malarial dates back to the seventeenth century, nevertheless 
it resembles the chronicle of R&D for most current medicines. It reflects great 
commercial and political interests, propriety rights (Greenwood, 1995), disputes on 
innovations and public health concerns. It makes an interesting case study for the 
economic sciences on how colonial empires strategies on chemistry (Crawford, 2014) and 
industrial pharmaceutical practices nowadays look-alike. Nevertheless, the lessons 
learned can provide fascinating insights on the need to shift the R&D focus from one that 
is market-driven to one that is public health driven.  
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This history began in South America. Cinchona is a tree native to the tropical Andean 
forests of western South America. The method for administering Cinchona or Quina’s 
bark in an infusion to treat malaria was described by Jesuit pharmacists, in the Schedula 
Romana. It is the first time an efficacious malaria treatment was recorded in the western 
medical literature and dates back to 1630.  The history of the plants characterization and 
its uses is full of disputes, but considering the medical knowledge of the Andean native 
population which included  performing trepanation as early as 400 BC during the Inca 
Empire (Andrushko and Verano, 2008), it is not surprising that there is evidence that local 
healers knew the medicinal proprieties of Cinchona bark before the Jesuits (Crawford, 
2014). The history unfolds to reinforce the narrative of the colonizer, as the tree is named 
after the wife of the Spanish viceroy in Lima, Countess of Chinchón.  
 
It was not until nineteenth century that the Peruvian government made the sales of 
Cinchona’s seeds forbidden. The aim was to protect a growing lucrative market that 
begun in 1820, when the Parisian chemistries, Pelletier and Caventou, isolated the 
alkaloid with high antimalarial activity. Quinine was named after the indigenous name of 
the tree, Quina (Oliveira and Szczerbowski, 2009). The efforts of the Peruvian 
government were in vain. The English and Germans smuggled the seeds and established 
plantations in India and Siri Lanka, respectively. Quinine facilitated the English imperial 
enterprise in Africa and south east Asia (Greenwood, 2002), but their plants had low 
concentrations of quinine. Soon after, the Dutch government sponsored the research on 
the best species of Cinchona and broke the Loja Spanish monopoly of high quality trees. 
By the time of  the World War I, the Netherlands had already taken over the market from 
South America for quinine, amassing enormous profits (Oliveira and Szczerbowski, 
 9 
2009). Any resemblance to pharmaceutical propriety protection nowadays is not mere 
coincidence. 
 
 The need for cheaper and faster quinine production was an important accelerator of the 
chemical industry as we know today, BASF (Badische Anilin-& Soda-Fabrik), AGFA 
(Aktiengesellschaft für Anilinfabrikation) and Bayer & Hoechst are amongst the 
industries that applied the knowledge from the synthesis of the initial compound into dyes 
to the developing textile industry. The perceived shortcomings of quinine before the 
WWII reignited the interest in the synthetic antimalarials  (Greenwood, 1995). During 
WWII, allies took part in the R&D race, as the plantations were in German and Japanese 
occupied territories. Only in 1947, could synthetic quinine be partially produced (Oliveira 
and Szczerbowski, 2009), but by then chloroquine had already been synthetized. 
Resochin was discovered in 1934 by Germans researchers, however it was the North 
Americans who named it as chloroquine during WWII. Years later they acknowledged 
the molecule was the same (Greenwood, 2002). The antimalarial R&D efforts during the 
WWII are remarkable, even considering the limited knowledge of malaria life cycle in 
man and the ethical standards required nowadays (Sweeney, 2000).  
 
Chloroquine was one of the most important and successful drugs deployed against 
malaria. Along with vector control (DDT) it was one of the main tools of the WHO 
malaria eradication campaign launched in 1955 (Wellems and Plowe, 2001).  The 
campaign aims were deemed unachievable in 1969, but chloroquine use kept on 
increasing over the decades up to hundreds of tons (sufficient to provide hundreds of 
millions of treatments annually) by the 80’s (McBride, 2010), >190 ton/year in Africa 
alone. In 1985 the global production of chloroquine reached 1300 tones/year 
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(Organization, 1990). This drug pressure was a tremendous driving force to the selection 
of chloroquine resistant parasites that replaced the chloroquine sensitive P. falciparum 
(Wellems and Plowe, 2001). Fortunately, this was not the case for P. vivax. The slow 
emergence of resistance of P. vivax may be due to the fact that standard chloroquine plus 
primaquine treatment has always been a combination therapy (World Health 
Organization., 2015a).  
 
The 8-amino-quinolone class were the first promising synthetic antimalarials during the 
20’s (Baird and Rieckmann, 2003). Although the initial compounds (pamaquine or 
plasmoquine, quinacrine and mepacrine) were rejected due to safety profile concerns, 
primaquine, a close structural analog is the current drug of choice to treat the latent 
hepatic forms of P. ovale and P. vivax. The US WWII antimalarial R&D made many 
attempts to discover a new molecule or therapeutic approaches that would prevent 
relapse, but only after revisiting the initial studies performed in India with plasmoquine, 
the strategy made a U-turn and lead to the development of a new series of 8-
aminoquinolines (Sweeney, 2000).  
 
Primaquine, an 8-aminoquinoline, was first made available to US troops in the 50’s (Baird 
and Rieckmann, 2003). The clinical trials were conducted with soldiers returning from 
the Korean war, including a comparison with pamaquine (Alving et al., 1953). 
Primaquine affects mainly the hepatic forms, but it is active against blood stages of vivax 
(Pukrittayakamee et al., 1994), and gametocytes in falciparum infections (Recht J, 2014). 
Concomitant use with chloroquine also has synergic effects on primaquine blood levels 
(Pukrittayakamee et al., 2014). 
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For most of the world, the first-line treatment recommendation for vivax malaria of 
chloroquine and primaquine  has not changed since the 50’s (Mendis et al., 2001) . In 
2019, it is still the best vivax treatment option. It would not be a problem if this treatment 
was a safe single dose tablet, but the 14 days’ treatment course is toxic to the carriers of 
the most common human genetic deficiency (G6PD deficiency), is contraindicated in 
pregnant women and is difficult to take. There are also concerns about chloroquine 
resistance emergence (Price et al., 2014), the main partner drug for primaquine. Treatment 
for  chloroquine-resistant P. vivax, includes Artemisinin-based Combination Therapies  
(World Health Organization., 2010a). In Brazil, P. vivax accounted for  88% of the  
malaria burden (193,917 cases)  in 2017 (Secretaria de Vigilância em Saúde, 2019). This 
means that other therapeutic options need to be ready available in case of the emergence 
of chloroquine-resistant vivax malaria.  
 
Artemisia annua is a Chinese medicinal plant known for more than 2000 years with its 
first medical record dating back to 168 B.C. In a later 340 A.D. record it already 
recommended as a treatment for fever and chills.  The antimalarial component, 
artemisinin was isolated by Chinese scientists in 1972. The first use in humans were 
published in 1979 (Global Partnership to Roll Back Malaria.). This speed of this 
outstanding initiative was a Chinese effort to help the Vietnamese army during the war 
against US  (Premji, 2009).  Today artemisinin-based drugs are the main backbone of all 
P. falciparum treatments worldwide. They are remarkably safe and well tolerated (Nosten 
and White, 2007). Its use has been demonstrated to be safe in pregnancy, including the 
first trimester (Mosha et al., 2014).  
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The safety profile of ACT is often defined by their partner drug (Nosten and White, 2007), 
and although they have been used for the last 20 years, there is a lack of data on the safety, 
pharmacodynamics and pharmacokinetic of these regimens with concomitant use of 
primaquine for the radical cure of vivax (World Health Organization., 2015a).  
 
Mefloquine was developed in a partnership with the industry (Hoffman-La Roche), WHO 
and the US army (Global Partnership to Roll Back Malaria.), first as a preventive agent 
and soon after as a treatment (Trenholme et al., 1975). The single dose treatment was a 
breakthrough, but it did not last long. Clinical treatment failures due to resistance rapidly 
appeared in Asia when the drug was made widely available (Global Partnership to Roll 
Back Malaria.). The evidence that the combination of mefloquine with artesunate restored 
its efficacy and averted the further development of resistance changed the paradigm of 
malaria treatment (Nosten et al., 2000) to the current ACT.  
 
In order to improve adherence and prevent resistance (due to single drug use), a fixed 
dose combination of artesunate and mefloquine was developed. It was an innovative 
approach to drug development that result in a south-south technology transfer and local 
production in middle income countries, Brazil and India. This was the very first product 
in the world resulting from this new drug development model proposed by DNDi (Wells 
et al., 2013).  The safety profile of the mefloquine single dose was a concern, especially 
regarding early vomiting in the paediatric population, the group most in need. The long 
half-live of the drug allowed splitting the total dose over three days (once a day during 
three days) and improving tolerability in this population to the level of other ACTs 
(Sirima et al., 2016). 
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The history of artemether lumefantrine fixed dose combination (AL) is also unique. 
During the 1980s and 1990s, the Chinese army evaluated the use of both drugs in 
combination. From 1994 onwards, this work was undertaken in collaboration with 
Novartis, in the first joint development programme of a western pharmaceutical company 
and the Chinese government. The low efficacy of the four doses regimen was an initial 
concern, but a new six dose (twice a day during three days) regimen evaluated in Thailand 
proved to have cure rates > 90% and was well tolerated.  In 2008, MMV developed the 
AL dispersible tablets for pediatric populations (Premji, 2009). 
 
This thesis evaluated two fixed combination treatments: artesunate plus mefloquine and 
artemether plus lumefantrine; both are the first line P. falciparum treatments in Brazil 
(Ministério da Saúde do Brasil., 2010). 
 
Epidemiology of malaria in Brazil 
 
As early as 1905, malaria control actions were implemented in Brazil. Initial successful 
innovative interventions were put in place such as the first example of indoors anti-adult 
mosquito control (Ferreira and Castro, 2016). During the early 40’s, the eradication of 
Anopheles gambiae in Brazil (Deane, 1988) led to nationwide anti-malarial campaigns. 
At that point, 2/3 of the 80 million Brazilian population lived in risk areas, leading to 6-
8 million cases and 80,000 malaria related deaths/year (de Pina-Costa et al., 2014). 
Vector control using DDT and chloroquine use led to the lowest incidence ever, 36,900 
cases in 1961 (Ferreira and Castro, 2016). The Malaria Eradication Campaign and 
further diagnosis, treatment and control measures promoted the virtual elimination of 
malaria from many areas of Brazil ( 
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Figure 1). 
 
Figure 1 Malaria endemic areas in 1960 and 2014 (Ferreira and Castro, 2016) 
 
 
 
Not all innovative strategies were successful, though. The Pinnoti’s strategy comprising 
deploying chloroquine in the cooking salt to control malaria in the most isolated areas, 
raised concerns about drug stability, effectiveness of low dose drug, drug resistance 
emergence and, last but not least, food taste (Silva and Hochman, 2011, Clyde, 1966). 
 
The Amazon region was a geopolitical and economic frontier in the 70’s and 80’s, 
deforestation was sponsored by the federal government to promote logging, agriculture 
and livestock. Infrastructure projects including roads, dams, and hydroelectric plants, but 
also gold mining encouraged the massive influx of non-immune populations, especially 
to two states in the Amazon basin, Rondônia and Pará.  In 1985, these two states 
accounted for 73 % of all malaria cases in the country (Cruz Marques, 1987).  
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In 1988, an equitable Brazilian National Health System was created and health care access 
improved.  Renewed efforts from the public health sector started in 90’s with massive 
national and international investments, resulting in the reduction of malaria related deaths 
from 7/1000 to 1.8/1000 populations, and averting 1.9 million new cases of malaria and 
231,000 deaths between 1988 and 1995 (Loiola et al., 2002, Akhavan et al., 1999). 
However, the lack of the sustainability of the funding and centralized action in the federal 
government undermined these efforts, there were more than half million cases per year 
during the nineties and the record peak malaria incidence was 637,470 cases in 1999 
(Siqueira et al., 2016b). 
 
The subsequent Plan of Intensified Control of Malaria in Amazon Region (PIACM) 
focused on decentralization of malaria control actions to state and municipality levels, 
high political commitment, strengthening of patient centered care with early diagnosis 
and treatment and vector control, all of which started to reverse  the 90’s epidemiological 
trends (Siqueira et al., 2016b).   
 
At that point, the first-line regimens for uncomplicated falciparum malaria recommended 
by the Ministry of Health of Brazil were quinine plus doxycycline for seven days or a 
single dose of mefloquine. In 2006 Artemisinin-based Combination Therapies (ACTs) 
were introduced and an evaluation with 26,000 patients demonstrated P. falciparum 
malaria incidence rates decreased, with lower hospital admission rates, and a reduced 
proportion of P. falciparum/ P. vivax infections in the Jurua Valley (Santelli et al., 2012). 
The impact of ACT deployment on the P. falciparum/ P. vivax ratio was also 
demonstrated in a national malaria surveillance system (SIVEP-malaria) (Oliveira-
Ferreira et al., 2010). 
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P. vivax malaria has become the predominant species since 1990, as it is more refractory 
than P. falciparum to the current control strategies (Ferreira and Castro, 2016). In 1988, 
both falciparum and vivax had the same incidence. In the following year, P. falciparum 
was the cause of 44,3% of malaria cases. In 2009, P. vivax represented 84% of all cases 
and P. falciparum only 16% (Oliveira-Ferreira et al., 2010). In 2014, the same 
falciparum/vivax ratio was sustained (Figure 2).  
Figure 2. Malaria incidence in Brazil. 
 
Absolute number of malaria cases in Brazil in the 1960–2015 period is shown as total cases (red bars) and 
due to Plasmodium vivax (pale blue bars) corresponding to the left y axis. The Plasmodium falciparum:P. 
vivax ratio is shown as a blue line (right y axis, Pf:Pv ratio) (Siqueira et al., 2016b). 
 
In 2014, 143.552 malaria cases were reported (Secretaria de Vigilância em Saúde, 2015). 
It represents a 19% decline in comparison to 2013, which is an incidence decrease of the 
same magnitude as that occurring globally over  the same period (World Health 
Organization., 2015d). In 2014, the total number of cases of malaria was the lowest in the 
last 35 years and it was in line with the goal of 75% malaria incidence reduction by 2015 
(World Health Organization., 2005). P. vivax was the most frequent cause of 
hospitalizations (65%) due to malaria in the Brazilian Amazon region (total of 203). In 
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the same year, 13 deaths were due to confirmed P. vivax, out of the 38 malaria deaths in 
Brazil (Secretaria de Vigilância em Saúde, 2015).    
 
Unfortunately, this trend has not been sustained (
 
 
 
 
), and 193,917 malaria cases were reported in the Malaria National Surveillance System 
(SIVEP) in 2017. P. vivax was still the most prevalent species, 88% of all cases. (Figure 
4 Confirmed case of malaria in Brazil in 2017 by  species  
 
 
) (Secretaria de Vigilância em Saúde, 2019).  
Figure 3 Confirmed case of malaria in Brazil from 2009 to 2017 (Pan American Health 
Organization., 2019) 
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Figure 4 Confirmed case of malaria in Brazil in 2017 by  species  
 
 
 
This recent failure in malaria control may be related to the fusion of the National Malaria 
Control Programme with the chikungunya, zika and dengue control programme, and a 
possible loss of political commitment in fighting malaria. As the total incidence 
decreases, the care cost per patient rises, posing a political dilemma in resources 
constrained health systems. The political crisis in Venezuela has also contributed to the 
increased incidence rate in the borders (Figure 5). 
 
Figure 5. 2017 malaria incidence map of Brazil, from Pan American Health Organization 
(Pan American Health Organization., 2019) 
 
0
5000
10000
15000
20000
25000
JAN	 FEB MAR	 APR MAI	 JUN	 JUL	 AUG SEP OCT	 NOV	 DEZ	
P.f P.v F+V P.m Non- F TOTAL
 19 
    
 
Worldwide data for the period 2015–2017 highlight that no significant progress in 
reducing global malaria cases in this timeframe anywhere in the world, except  in South 
East Asia (World Health Organization., 2018). 
 
In Brazil, the alarming growing malaria burden in 2017 (Secretaria de Vigilância em 
Saúde, 2019), with P. vivax accounting for 88% of the cases, means that other therapeutic 
options need to be ready available in case of emergence of chloroquine-resistant vivax 
malaria.  
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Vivax resistance in Brazil  
 
From a practical public health perspective, it is important to detect lack of efficacy of any 
current therapeutic regimen due to resistance. A national control programme should 
consider changing the first line treatment, if its cure rate is below 90% in a study 
conducted according to WHO methods for surveillance of antimalarial drug efficacy 
(World Health Organization., 2009).  The study presented here (Daher et al., 2018a) 
adopted this approach as it is the most meaningful result to guide public health policy 
change, however it is not the most sensitive test for surveillance of chloroquine-resistant 
vivax. 
 
Surveillance for the emergence of chloroquine-resistant vivax is of paramount 
importance, but poses several methodological challenges when interpreting results. 
Ideally, in order to avoid bias due to drug-drug interactions, the evaluation of any anti-
infective resistance must be conducted using a single drug treatment. This methodological 
approach increases the sensitivity of the test, but on the other hand it loses its external 
validity, meaning these results cannot be extrapolated to real life, as a single drug 
treatment is not recommended to treat malaria.     
 
Plasmodium vivax chloroquine resistance in vivo is defined as failure to produce 
parasitological clearance during 28 days in the presence of the sum of CQ and its main 
active metabolite, desethylchloroquine (DCQ) above therapeutic levels (>100 ng/ml) in 
whole blood (Baird et al., 1997).  Although this threshold to define chloroquine resistance 
has been widely accepted, this may need further investigation (World Health 
Organization., 2009) and updates.  
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The estimate of the minimal effective concentration (MEC) and time to recurrence were 
based on clinical data, including drug plasma levels from 1945.  In 1997, this threshold 
(>100 ng/ml) was updated based on whole blood samples of 101 Indonesian patients 
using a high-performance liquid chromatography method described in 1983 (Patchen et 
al., 1983, Baird et al., 1997). There are three possible concerns that should be considered 
when interpreting CQ- resistance based on this definition:  (i) analytical methods of the 
40s.  (ii) plasma CQ levels versus whole blood DCQ+CQ levels, and (iii) time to 
recurrence. As the ratio of plasma and whole blood CQ concentrations range from 5 to 
10, the estimated MEC is in the range of 75 to 150 ng/ml whole blood. Likewise, the time 
to recurrence was based on clinical data from non-immune single exposed patients and it 
may be prolonged to 35 days in this population depending on the pattern of relapse in the 
geographic area of infection. However, 28 days follow up may be a short time and it 
might not reflect time to relapse of people harboring multiple broods of hypnozoites 
accumulated over years of exposures. Finally, this definition does not allow 
differentiation between the degree of resistance, i.e., parasites surviving the maximum 
drug exposure (failure to  clear parasitaemia), recrudescence after initial clearance and 
those relapsing from hypnozoites penetrating waning levels of drugs in 28 days would all 
be considered resistant, although the clinical approach and public health relevance of 
these findings are entirely distinct (Baird, 2004).  
  
Other classifications have been adopted to define chloroquine resistant vivax irrespective 
of the drug blood level. The WorldWide Antimalarial Resistance Network (WWARN) 
Vivax Survey  contains data from 237 clinical trials and 26 case reports since 1960 (2019). 
This group considers category 1 evidence of CQ resistance to be an incidence of 
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recurrence greater than 10% by day 28 (with a lower 95%CI  >5%). This group reported 
that in Brazil since 1960 (Figure 6), one trial had reported category 1 CQ resistance (de 
Santana Filho et al., 2007), one trial had reported  category 2 CQ resistance  (at least 5% 
recurrences by day 28 and lower 95%CI  >5%) (Marques et al., 2014) and two case reports 
had described CQ resistance  (Garavelli and Corti, 1992, Alecrim et al., 1999). Over the 
same period, 13 studies showed vivax CQ susceptibility (Margarete do Socorro et al., 
2015, Pinto et al., 2003, Machado et al., 2003, Silva et al., 2003, Abdon et al., 2001b, Da 
et al., 1989, Llanos-Cuentas et al., 2014, Villalobos-Salcedo et al., 2000, Orjuela-Sánchez 
et al., 2009, Negreiros et al., 2016, Pereira et al., 2016a, Duarte et al., 2001, Pedro et al., 
2012),  
Figure 6.  WorldWide Antimalarial Resistance Network (WWARN) Vivax Surveyor, 
Brazil from 1960 to 2019 
 
 
Red= Category 1 evidence; Orange= Category 2 evidence; Green= Case reports; Blue= Uncategorised: 
Studies that do not fall into any of the above categories, or include imported cases from mixed regions are 
coloured in blue.  
 
It is important to note that the quality of malaria trials has been consistently improving in 
the last 10 years in Brazil; during this period, no trial using the nationally recommended 
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treatment guideline showed evidence of resistance (Margarete do Socorro et al., 2015, 
Negreiros et al., 2016), including the study described herein (Daher et al., 2018a). 
 
An important consideration is the role of the role of primaquine. However, when 
primaquine administration was withheld till 28 days or later  (Siqueira et al., 2016a, 
Ladeia-Andrade et al., 2019), pharmacokinetics (PK) evaluation show CQ, DCQ drug 
levels above 100ng/ml in patients who fail, characterizing CQ-resistance. In the area with 
the highest malaria incidence rates in Brazil, Acre, the failure rate (2.2%) of the sequential 
CQ-PQ regimen (Ladeia-Andrade et al., 2019) did not provide clinical evidence of 
resistance, but drug levels of 6 out of 8 patients who had parasitological failure did 
suggest CQ-resistant parasites. Similarly, in Bolivia, a neighbour country of Acre, using 
CQ monotherapy, 6/10 CQ-resistant failures were detected by the criteria of failure with 
drug levels above 100 ng/ml (Añez et al., 2015). These results underestimated the efficacy 
of the regimen, as they did not take in account the synergic effect of chloroquine and 
primaquine (Alving et al., 1955, Commons et al., 2018, Pukrittayakamee et al., 1994), 
however,  as malaria control is relaxed in Brazil and neighbour countries, these results 
are a matter of great concern. 
 
As the political situation and public health systems has deteriorated in recent years in 
South America, the need for therapeutic options ready to be deployed in case of the 
emergence of chloroquine resistance is an unfortunate reality.  
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Malaria is a poverty related disease 
 
The failure to progress over the last few years should not discourage the fight against 
malaria, but conversely it highlights the need of ongoing political commitment and 
continuous innovations and improvements in the current strategies.  
 
Technological innovations have crucial roles to play (Tse et al., 2019).  The deployment 
of tafenoquine, a major change in vivax malaria treatment, is keenly awaited. 
Nevertheless, its large-scale deployment is restricted currently by the lack of a point of 
care test of G6PD. Meanwhile every little help to reduce malaria incidence is welcome. 
Incremental improvement in the Brazilian malaria treatment are still ongoing. Current 
studies demonstrated that the Brazilian guidelines to treat recurrences (7 days primaquine 
in same total dose than the 14 days’ regimen) has acceptable cure rates (Daher et al., 
2018b) (Pereira et al., 2016b). 
 
Incremental treatment improvement is the main aim of this thesis, but malaria control and 
future elimination is much broader, and there is a clear need of an integrated approach. 
This should comprise vector control, diagnosis and early treatment, a better use of routine 
data, and social issues as the underfunding of the local health systems, education in health, 
civil society engagement and environmental management. As we understand malaria as 
a poverty related disease (Silva Santelli, 2016), we may move the focus from a disease 
centered perspective to a community and patient centered one; this means a fundamental 
shift from a flawed neglected disease concept to widening it to neglected populations 
(Ehrenberg and Ault, 2005).  A more holistic approach of malaria control, ought to pursue 
a state of complete physical, mental and social well-being, meaning the health of the 
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population (1946). The experience of  many countries where malaria has been eliminated 
shows that advances in better living conditions are of utmost importance (Rieckmann, 
2006), and there is not a single magic bullet to eliminate this tenacious parasites 
(malERA, 2017b).  
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Chapter II 
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Introduction Chapter II 
 
The need to prevent P. vivax relapses in North American soldiers returning from the 
Korean war led the FDA to approve primaquine in 1952. The regimen approved was 
15mg once a day for 14 days. This regimen was based on efficacy results against Korean 
strains (Arnold et al., 1954, Coatney et al., 1953, Alving et al., 1953, Jones et al., 1953), 
rather than the overall efficacy against all strains of P. vivax. This regimen was also 
designed to tackle the needs of military personal and did not necessarily address the 
effectiveness requirements of the endemic area population, nor patient centered approach 
were considered. Choice of the dose was also heavily influenced by the need to avoid 
hemolytic anemia in African Americans who might not have adequate medical 
supervision (Hill et al., 2006).  
 
The Korean war has still not formally ended and almost 70 years later, the assembling of 
evidence on the efficacy of vivax treatment seems to follow the same pace as the peace 
talks. This chapter presents some evidence to fill this knowledge gap, in particular 
exploring the most suitable dose regimen of primaquine for civil populations in endemic 
areas. 
 
It has long been suggested that it is the total dose of primaquine, rather than the duration 
of treatment, that determines efficacy (Clyde and McCarthy, 1977b). Shorter course 
primaquine may improve adherence and the effectiveness of vivax treatment worldwide. 
This chapter explores alternative primaquine patient-friendly regimens, as the Brazilian 
treatment guidelines that includes a daily total dose from 3 mg/kg to 4.2 mg/kg for 7-9 
days (Ministério da Saúde do Brasil., 2010). Although there are studies that have 
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evaluated doses as high as 1 mg/kg/day (Chu and White, 2016) for 7 days to address the 
susceptibility of the South East Asia vivax strains, the shortest duration possible may not 
be limited only by a higher frequency of adverse events associated with  high daily doses, 
but it also may be limited by an apparent lack of efficacy when the treatment duration is 
shorter than five days (Carmona-Fonseca and Maestre, 2009).  
 
The main challenges in assessing the efficacy of vivax treatments efficacy has been, and 
remains, the inability to differentiate reinfection and relapse. Initial studies addressed this 
issue by removing any risk of reinfection, moving the patients (soldiers) to non-endemic 
areas after treatment or evaluating treatment response in experimental P. vivax 
inoculations in penitentiary population in US (Cooper et al., 1950, Coatney and Getz, 
1962, Comfort, 2009). This is a major constrain on the conduction of vivax clinical trials 
nowadays, as the patients must be recruited in non-autochthonous transmission areas.  
 
In order to overcome this, new molecular approaches, methodological tools and 
innovative initiatives are being developed. To overcome the lack of large trials, data from 
many small trials in non-endemic areas can be aggregated in pooled analysis of individual 
patient data, helped by the shift towards more open data and thriving clinical trial data 
repositories (Pisani et al., 2016, Commons et al., 2018).   
 
Methodological tools, such as systematic reviews, can gather published information and 
help draw conclusions about the overall evidence available. Previous systematic and 
critical literature reviews have shown evidence of the efficacy of short course primaquine 
(0.5 mg/kg/day) (Carmona Fonseca, 2015, John et al., 2012, Zuluaga-Idarraga et al., 
2015). However, distinct patterns of time to relapse associated with different geographic 
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areas (Battle et al., 2014), different study designs, including follow up times and 
comparators, and the susceptibility of the vivax strains worldwide adds complexity in 
drawing  overall conclusions. For instance, in East Asia and Oceania, the recommended 
doses of primaquine is 0.5 mg/kg/day rather than standard 0.25 mg/kg/day for 14 days, , 
where tropical frequent-relapse strains are prevalent and there is allegedly “more resistant 
to primaquine" (Organization, 2015). This  might be another knowledge gap as during 
the primaquine initial drug trials, the 30 mg/day for 14 days treatment arm was dropped 
due to safety concerns (Jones et al., 1953) and 30 mg/day for seven days primaquine was 
demonstrated to be effective against Chesson strain vivax (Clyde and McCarthy, 1977a) 
in non comparative trials. Herein we conduct a new meta-analysis that provides a more 
precise estimate of the effects on the efficacy and safety of alternative primaquine 
regimens for radical cure of P. vivax malaria compared to the WHO recommended 14 
days of primaquine (0.25 or 0.5 mg/kg/day).  
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A B S T R A C T
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
To assess the efficacy and safety of alternative primaquine regimens for radical cure ofP. vivax malaria compared to the standard 14 days
of primaquine 0.25 mg/kg/day.
B A C K G R O U N D
Malaria is a potentially life-threatening disease caused by the Plas-
modium parasite, which is transmitted by the bite of an infected
female Anopheles mosquito. There are five species of Plasmod-
ium malaria parasites that can cause malaria disease in humans,
of these, Plasmodium vivax and Plasmodium falciparum are gen-
erally recognized as the most significant threat to human health
(WHO2016a). In 2015, there were an estimated 212million cases
of malaria worldwide, with 429,000 attributable deaths (WHO
2016b). By 2030, the World Health Organization (WHO) aims
to reduce malaria case load and mortality by at least 90% (WHO
2016a).
Historically, P. vivax infection was thought to be a milder form of
malariawithminimalmorbidity, with the greater focus for research
on P. falciparum, because of the high number of deaths it causes
(Bassat 2016). In recent years the morbidity and mortality of P. vi-
vax have been shown to have been underestimated, with evidence
of direct fatality and contribution to mortality in patients who
have other co-morbidities, such as malnutrition, human immun-
odeficiency virus (HIV), or co-existing infections (Baird 2013;
Bhattacharjee 2013;Rizvi 2013; Singh 2013; Battle 2014;Douglas
2014; Kochar 2014; Arévalo-Herrera 2015; Baird 2015b). Re-
peated P. vivax infections through childhood and adulthood also
affect personal well-being, development, and education and can
thus negatively impact economic development, both for the indi-
vidual and the community (Mendis 2001).P. vivaxmalaria in preg-
nancy is associated with maternal anaemia, spontaneous abortion,
stillbirth, and lowbirthweight, with especially poor pregnancy out-
comes for women with severe infection (McGready 2012; Rijken
2012; Brutus 2013).
Description of the condition
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P. vivax infection caused an estimated 13.8million cases of malaria
in 2015 and is responsible for almost half of the global cases of
malaria outside of Sub-Saharan Africa (WHO 2015c). The geo-
graphical distribution ofP. vivax malaria is more widespread than
any of the other forms of human malaria - around 35% of the
world’s population is thought to be at risk, with two-thirds of cases
occurring in South-East Asia (WHO 2015a). Co-infection with P.
falciparum is also common inmany regions (Kumar 2007;Mueller
2009). As malaria control accelerates, the P. vivax proportion in
co-endemic areas tends to rise compared to that of P. falciparum,
which highlights the importance and challenge of this infection
(John 2012).
P. vivax is also important as many countries progress towards
malaria elimination, as it is increasingly recognized as a potential
roadblock to eradication (Cibulskis 2015; Bassat 2016). Despite a
reduction in the number of cases of P. vivax malaria over the past
20 years, it has several characteristics that enable it to evade con-
trol (Newby 2016). The early appearance of gametocytes in the
blood, often prior to symptoms of malaria, increases the chance
of onward transmission by mosquitoes (WHO 2015a). P. vivax
differs to P. falciparum in that as well as having a blood stage
schizontal infection, hypnozoites develop in the liver that can be
dormant for weeks to months before developing into an infec-
tion (Llanos-Cuentas 2014). It is not known what triggers these
relapses. There is difficultly in distinguishing between relapse, re-
crudescence (subpar treatment of the initial blood stage infection),
and reinfection (new infection with P. vivax) (Betuela 2014). A
study in Papua New Guinea suggested that relapses cause four-
fifths of P. vivax infections, so are important in sustaining trans-
mission (Robinson 2015). Parasites show high genetic diversity,
even in countries that are at malaria elimination stage, where you
would expect reduced transmission to result in reduced diversity
(Koepfli 2015). P. vivax is likely underestimated worldwide as the
dormant liver stage is not detected in routine surveys (Gething
2012). Submicroscopic infections (asymptomatic infection reser-
voirs) may also lead to underdiagnosis or misdiagnosis. A system-
atic review showed that across all study sites the polymerase chain
reaction (PCR) prevalence of P. vivaxwas significantly higher than
that identified by light microscopy (Cheng 2015). The effect that
this may have on P. vivax malaria studies is unclear. There are dif-
ferent strains of P. vivax, which have varying relapse patterns, and
this can further complicate matters (White 2016). The Chesson,
or tropical, strain is commonly found in South East Asia, Oceania,
and parts of the Indian subcontinent and has the shortest relapse
interval of about three weeks (if untreated), while the temperate
strain may relapse after months (John 2012).
Currently primaquine, an 8-aminoquinoline, is the only drug
available on the market for treating the hypnozoite stage of infec-
tion (Ashley 2014). One of the main barriers in P. vivax treatment
is the reluctance to use primaquine due to it causing haemolysis
in patients with glucose-6-phosphate-dehydrogenase (G6PD) de-
ficiency. G6PD deficiency is the commonest enzyme deficiency
worldwide and affects red blood cells, by leading to their premature
lysis (Nkhoma 2009). G6PD deficiency is common in countries
where P. vivax malaria is endemic, with an estimated population
prevalence of 8% (Howes 2012). Within G6PD deficiency there
are differing phenotypes,meaning some peoplemay bemildly sen-
sitive to primaquine, while others may be very sensitive and expe-
rience life threatening haemolysis (Baird 2015a), which explains
the varying responses to primaquine. In many countries where P.
vivax is pre-dominant, locally available testing for G6PD is not
available (Baird 2015b). A newer alternative, tafenoquine, another
8-aminoquinoline, has completed phase III trials and is on track
for submission to the Food and Drug Administration (FDA) in
2017 (MMV 2016). Tafenoquine has shown promise in reducing
relapses, but there are increased safety concerns in patients with
undiagnosed G6PD deficiency compared to primaquine, due to
its longer half-life (Rajapakse 2015).
Description of the intervention
People with P. vivax malaria require treatment with a blood stage
antimalarial drug to treat the schizont infection, and a drug to
treat the hypnozoite stage (radical cure). The WHO recommends
treatment with either chloroquine or an artemisinin-based com-
bination therapy (ACT) for the blood-stage infection, followed by
treatment with 0.25 to 0.5 mg/kg primaquine for 14 days (WHO
2015b). ACTs and chloroquine have been shown to be effective
and comparable in treating the blood stage infection of P. vivax
malaria (Gogtay 2013). A previous Cochrane Review showed that
primaquine regimes of five days or fewer had similar relapse rates
to placebo or no primaquine. Of the comparisons included in the
systematic review, a regime of 0.25 mg/kg (15 mg) a day of pri-
maquine for 14 days had the lowest relapse rates of P. vivax infec-
tion (Galappaththy 2013). There were no trials at that time that
compared higher doses of primaquine at 14 or seven days.
Primaquine was first made available to American soldiers in the
1950s (Baird 2004). Its mechanism and metabolism is not widely
understood, but it has a broad spectrumof activity against thePlas-
modium parasite. As well as preventing relapse of P. vivax malaria
by targeting the latent and developing hypnozoites in the liver,
it is also used in malaria prophylaxis (Baird 2003). It is absorbed
from the gastrointestinal tract, has a half life of about four to nine
hours, and crosses the placenta in pregnancy (Baird 2004). New
advancements in studying P. vivax in humanized mice may lead to
a greater understanding of themechanism of action of primaquine
(Mikolajczak 2015).
Adverse effects of primaquine include
production of methaemoglobin, an oxidated state of haemoglo-
bin which cannot transport oxygen to tissues. Methaemoglobi-
naemia (an abnormal build-up of methaemoglobin) can result in
cyanosis when levels exceed 10% of the usual haemoglobin level
(Vale 2009). As described above, primaquine causes haemolysis in
people with G6PD deficiency, which leads to severe intravascular
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haemolysis and anaemia (Ashley 2014). When taken on an empty
stomach it can cause abdominal pain and gastrointestinal upset
(Vale 2009). Primaquine cannot be given in pregnancy or early
infancy as the G6PD status of the baby is unknown and there
would be risk of haemolysis and possible termination if the foetus
was G6PD-deficient. There is currently debate about whether the
levels of primaquine in breast milk would be sufficient to cause
haemolysis in a G6PD-deficient baby, but it is not recommended
at this time.
How the intervention might work
TheWHOadvises that 0.25mg to0.5mg/kg of primaquine for 14
days should be used for radical cure of P. vivax malaria in patients
over six months old, excluding people with G6PD deficiency and
patients who are pregnant or breastfeeding (WHO 2015b). There
has been suggestion of failure of the 0.25 mg/kg/14-day dosing
regimen of primaquine for the Chesson strain of P. vivax, which is
what was behind the suggestion of the increased dosing of 0.5 mg/
kg/day. In the last review, Galappaththy 2013, there were no trials
found which compared higher doses of primaquine to the 14-day
regime. The WHO recommends a weekly dose of 0.75 mg/kg for
eight weeks for patients with G6PD deficiency but the evidence
for this is low quality as there are few high-quality trials (WHO
2015b).
The 14-day course of primaquine, which can lead to adherence
issues in patients, as well as safety concerns about haemolysis in
places where G6PD testing is not available, means that shorter
courses of primaquine are desirable. Failure to treat the hypnozoite
stage of P. vivax malaria leads to repeated relapses, morbidity, and
persistent infection. The logic framework for developing effica-
cious and safe treatment regimes for P. vivax is illustrated in Figure
1.
Figure 1. Logic framework: treatment outcome pathways in Plasmodium vivax liver hypnozoite infection
It has long been suggested that it may be the total dose of pri-
maquine that is important in treatment of the hypnozoite stage
rather than the length of the course (Schmidt 1977). If a higher
dose of primaquine could be administered safely over a shorter
period of time, this may improve adherence rates, thus reducing
relapse rates and morbidity and mortality resulting from P. vi-
vax infection. There are small trials from the 1970s that suggest
that shorter, higher dose regimes were as efficacious as the 14-day
courses (Clyde 1977), and there is also evidence of similar efficacy
(Saint-Yves 1977). At the time of the last review (Galappaththy
2013) there were no recent large high-quality trials that had in-
vestigated the use of higher doses given over seven days. We plan
to include any such trials in this Cochrane Review.
3Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria (Protocol)
Copyright © 2017 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
Why it is important to do this review
The use of primaquine for radical cure of P. vivax malaria contin-
ues to pose a therapeutic dilemma for healthcare providers in areas
without adequate screening for G6PD status. Clinicians must ei-
ther chose to give primaquine and risk haemolysis if the patient is
G6PD-deficient, or withhold treatment and accept the complica-
tions of ongoing parasite infection and relapses. This is why when
clinicians choose to treat with primaquine they prefer a lower dose
over a more prolonged period - although this then risks difficulties
with adherence and thus reduced efficacy.
From the previous systematic review on primaquine with chloro-
quine for radical cure (Galappaththy 2013), we know 14 days of
0.25mg/kg or 15mg/day (210mg total dose) is better than shorter
regimens of similar daily doses and placebo. Amajor problem with
the radical cure of P. vivax is difficulty with the adherence of the
14-day course of primaquine, which has led to many countries
shortening the regime. Peru was once such example, although a
study revealed that patients often still discontinued the therapy
after around three days, when they started to feel better (Grietens
2010). A study that compared directly observed therapy (DOT)
for 14 days of primaquine, versus non-DOT primaquine found
that the vivax relapse ratewas significantly lower in theDOTgroup
(Takeuchi 2010). These problems have led to amore urgent call for
shorter treatment regimes. Various trials are investigating regimens
that improves dosing and duration of treatment, to improve ad-
herence and reduce the potential for incomplete treatment and de-
velopment of resistance. As mentioned previously, the significance
of the total cumulative primaquine dose given, rather than length
of course, is one avenue of investigation. In areas where G6PD
screening is present, using higher dosing regimes over shorter time
periods, if at least similarly efficacious, could improve adherence
and reduce morbidity associated with P. vivax parasitaemia.
WHO guidelines suggest a higher dosing regimen of primaquine
for areas with the tropical strain of P. vivax (WHO 2015b), al-
though the previous Cochrane Review, Galappaththy 2013, did
not find any trials that assessed this. Therefore investigating the
evidence base for this is important. The 2015 WHO guidelines
also suggest an alternate dosing regimen of weekly primaquine,
which may be safer in patients with G6PD. In the last Cochrane
Review, only data from one trial assessed this, so it will be useful
to see if there is any further evidence to substantiate this guidance.
In this Cochrane Review, we will exclude comparisons between
blood stage drug (chloroquine/ACT) with and without pri-
maquine as the rationale for primaquine use has been sufficiently
demonstrated in a previous Cochrane Review (Galappaththy
2013). Similarly, we will not include comparisons that look at
different blood stage drugs compared using the same dose of pri-
maquine as an update to an existing Cochrane Review will address
this (Gogtay 2013). However, we will stratify our results according
to partner drug, as there is increasing evidence that primaquine is
metabolized via the CYP2D6 pathway and efficacy may thus be
affected if the blood stage antimalarial drug is a CYP2D6 inhibitor
(Bennett 2013). This review will exclude comparisons of regimens
that do not use the control of 14 days of primaquine at 0.25 mg/
kg/day. Also, it will not include comparisons of primaquine reg-
imens of 0.25 mg/kg daily for less than 14 days as Galappaththy
2013 has already assessed these shorter, same daily dose regimens.
Currently there is a lack of consensus among studies as to what the
minimum time frame for follow-up of relapse in P. vivax malaria
should be. TheWHOguidance on clinical trials inmalaria sets out
standard follow-up for blood (or schizontal) stage infection as 28
days after treatment commencement, but has no clear definition
on the follow-up period for radical cure in primaquine studies. It
states that “follow up varies from three months to a year in the lit-
erature, and should be adapted to regional parasite characteristics”
(WHO 2009). In a recent review, John 2012 described relapse
of the tropical strain of P. vivax as typically three weeks, but this
varies according to blood stage treatment: “three weeks following
quinine therapy” and “six to eight weeks following chloroquine”
(White 2011). With exposure to primaquine - even if radical cure
is not achieved - relapsesmay be at longer intervals (Sutanto 2013).
In the Cochrane Review (Galappaththy 2013), the period of fol-
low-up was 30 days after starting primaquine treatment. Despite
this, the definition of relapse used in the review was the presence
of P. vivax parasites more than 28 to 30 days after the full course of
primaquine in people living in a non-endemic area (Murphy 1993;
Looareesuwan 1997). Because of the varying lengths of relapse
time in P. vivax malaria, as well as the longer schizonticidal half-
life in ACTs, 28 days from treatment commencement may not al-
low true assessment of radical cure. It also makes assessment of the
weekly primaquine regime difficult, as the follow-up time is before
the eight-week treatment course has finished. In this Cochrane
Review we plan to assess parasitaemia at 3, 6, and 12 months fol-
low-up, in keeping with WHO guidance. We intend to describe
the length of follow-up across studies, and then group them into
meaningful lengths of follow-up, depending on the regimen.
We intend to answer the following questions by comparing the
new regimens to the standard regimen of 14 days of primaquine
at 0.25 mg/kg (15 mg adult dose).
• Are higher doses (0.5 mg/kg or 30 mg primaquine/day for
14 days) more efficacious and safe compared to standard therapy
(0.25 mg/kg/day for 14 days), in all areas, or only in areas where
they are standard treatment (for tropical P. vivax strains in Asia,
Pacific)?
• Are shorter, higher dose regimes (0.5 mg/kg or 30 mg
primaquine/day for 7 days) as efficacious and safe compared to
standard therapy (0.25 mg/kg/day for 14 days)?
• Are weekly dosing regimens (0.75 mg/kg or 45 mg/week for
8 weeks) as efficacious and safe compared to standard therapy
(0.25 mg/kg/day for 14 days)?
O B J E C T I V E S
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To assess the efficacy and safety of alternative primaquine regimens
for radical cure ofP. vivax malaria compared to the standard 14
days of primaquine 0.25 mg/kg/day.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCT).Wewill exclude quasi-RCTs.
Types of participants
Adults and children with confirmed clinical and parasitological
(light microscopy or polymerase chain reaction (PCR), or both)
diagnosis of P. vivax malaria. We will include trials that have ex-
cluded people with glucose-6-phosphate-dehydrogenase (G6PD)
deficiency, and trials that included populations that had not been
screened for G6PD deficiency.
Types of interventions
Intervention
Any regimen of either chloroquine or an artemisinin-based com-
bination therapy (ACT) plus primaquine with any of the follow-
ing.
• Higher daily doses for 14 days.
• Shorter regimens with the same total dose.
• Using weekly dosing regimens.
Control
Standard regimen of 14 days of primaquine at 0.25 mg/kg (15 mg
adult dose) plus either chloroquine or an ACT.
Wewill include trials that use chloroquine or ACTas the treatment
for blood-borne infection, andwewill stratify by the schizonticidal
agent.
Types of outcome measures
Primary outcomes
• P. vivax parasitaemia detected (by light microscopy or
polymerase chain reaction (PCR), or both) at 3 months, 6
months, and 12 months follow-up.
Secondary outcomes
• P. vivax parasitaemia detected (by light microscopy or
polymerase chain reaction (PCR), or both) at one to three
months follow-up.
Adverse effects
• Serious adverse effects (fatal, life-threatening, or requiring
hospitalization).
• Adverse effects that result in discontinuation of treatment.
• Events known to occur with primaquine (cyanosis,
leucopenia, methaemoglobinaemia, hypertension, cardiac
arrhythmia, abdominal pain, nausea, vomiting, or haemolysis) or
those due to a comparator drug used along with primaquine.
• Anaemia or change in haemoglobin status.
• Other adverse effects.
Search methods for identification of studies
We will attempt to identify all relevant studies regardless of lan-
guage or publication status (published, unpublished, in press, or
in progress).
Electronic searches
We will search the following databases: the Cochrane Infectious
Diseases Group (CIDG) Specialized Register; the Cochrane Cen-
tral Register of Controlled Trials (CENTRAL), published in the
Cochrane Library; MEDLINE (PubMed); Embase (OVID); and
LILACS (BIREME), using the search terms detailed in Appendix
1 (Lefebvre 2011). We will also search the World Health Orga-
nization (WHO) International Clinical Trials Registry Platform
(http://www.who.int/ictrp/search/en/) and ClinicalTrials.gov (
https://clinicaltrials.gov/), to identify ongoing trials, using “vivax”
and “primaquine” as search terms.
Searching other resources
We will check the reference lists of all studies identified by the
above methods for other potentially relevant studies. We will con-
tact researchers working in the field and the World Health Or-
ganization (WHO) for unpublished and ongoing trials. We will
also search the reference lists and included studies of the Cochrane
review by Galappaththy 2013.
Data collection and analysis
Selection of studies
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Two review authors will independently screen the titles and ab-
stracts of the search results to identify potentially eligible trials,
and will code the articles as either ’retrieve’ or ’do not retrieve’. We
will obtain the full-text reports of potentially eligible trials and will
assess them for inclusion in the review using a predesigned eligi-
bility form based on the inclusion criteria. We will resolve discrep-
ancies through discussion or, if required, we will consult a third re-
view author. Where necessary we will contact the trial authors for
clarification of trial methods. We will list the excluded trials and
the reasons for exclusion in a ’Characteristics of excluded studies’
table. Where there are multiple reports relating to the same trial,
we will include all reports. However, we will only extract data from
the most up-to-date report that includes the specified outcome.
We will detail the trial selection process in a PRISMA diagram.
Data extraction and management
Two review authors will independently extract data from the in-
cluded trials using a data extraction form, designed for this review,
in keeping with Cochrane guidance (Higgins 2011).
For each included trial we plan to extract a minimum of the fol-
lowing data if available.
• Study design.
• Endemicity/population demographics.
• G6PD status of participants (known/unknown).
• CYP2D6 status (if available).
• Blood stage antimalarial drug choice.
• Dose/duration/timing of treatment arms.
• Supervised or non-supervised therapy.
• Duration of follow-up.
• Adverse events.
• Reported outcomes.
We will resolve any differences in data extraction through discus-
sion and consult a third review author if there is any discrepancy.
We will enter the extracted data into Review Manager 5 (RevMan
5) (RevMan 2014). We will contact the authors of primary trials
in case of any doubts regarding missing data or methodological
details of the trial. We will note the limitations in the included
studies.
We will group comparisons as illustrated in Table 1.
Assessment of risk of bias in included studies
Two review authors will independently assess the risk of bias of
each included trial using the Cochrane ’Risk of bias’ assessment
tool, and discuss any differences of opinion. In the case of missing
or unclear information, we will contact the trial authors for clar-
ification. We will summarize the results using Cochrane ’Risk of
bias’ tables (Higgins 2011).
Measures of treatment effect
For dichotomous data, we will compare interventions using risk
ratios to measure treatment effect. Where trial authors present
data as odds ratios, we will recalculate the effect. We will define
statistical significance as P < 0.05 and for all resultswewill calculate
95% confidence intervals (CIs). For comparable trials, we will
perform meta-analyses if there is sufficient data.
Unit of analysis issues
For this Cochrane Review, cluster-randomized designs would be
inappropriate for evaluating the research questions. If trials that
have used cluster-randomization meet our inclusion criteria we
would expect the results to have been controlled for clustering.
If they have not, we will contact the trial authors for an estimate
of the intra-cluster correlation coefficient (ICC) value. We will
analyse clustered data using the methods outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
We will split trials that include more than two comparison groups
and will analyse them as individual pair-wise comparisons. If there
is a shared control group we will split the control group so that
participants are only counted once in the overall meta-analysis.
Dealing with missing data
We will analyse missing data using available case analysis if we
judge the trial to be at low risk of bias for incomplete outcome
data. We will attempt to contact trial authors to obtain missing or
unclear data. If the missing data render the result uninterpretable,
we will exclude the data from meta-analyses and clearly state the
reason for exclusion. If the missing data means that results are
interpretable but likely to be at high risk of bias, we may use
imputation methods to investigate the impact of the missing data.
We will analyse extracted data on an intention-to-treat basis where
there is no missing data.
Assessment of heterogeneity
Wewill inspect forest plots for overlapping CIs.We will also apply
the Chi² test as a statistical test for the presence of heterogeneity,
with a P value of 0.10 used to indicate statistical significance, and
we will compute the I² statistic to quantify the percentage of the
variability in effect estimates that is due to heterogeneity rather
than sampling error (chance). We will investigate possible causes
of heterogeneity by subgroup analysis. If substantive heterogeneity
persists, which we define as an I² statistic value of greater than
50%, we will use a random-effects meta-analysis.
Assessment of reporting biases
Wewill examine the likelihood of reporting bias using funnel plots
provided that there is a sufficient number of included trials.
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Data synthesis
We will analyse the data using Review Manager 5 (RevMan 5)
(RevMan 2014). We will assess the certainty of the evidence
for each outcome measure using the Grading of Recommenda-
tions Assessment, Development and Evaluation (GRADE) ap-
proach and we will construct ’Summary of findings’ tables using
GRADEpro Guideline Development Tool (GDT) (GRADEpro
GDT 2014).We will stratify results according to blood stage part-
ner drug. Length of follow-up will vary with regimes and between
studies. We will describe regimes and follow-up periods and de-
fine sensible groupings for follow-up. If there is sufficient data, we
will also perform subgroup analyses according to CYP2D6 status
(when available), geographical region/endemicity, length of fol-
low-up, and directly observed therapy (DOT) or non-DOT.
Subgroup analysis and investigation of heterogeneity
We will group the analysis by drug regimen. We will describe the
interventions and outcomes in all included trials. We will conduct
an inventory of length of follow-up against each drug regimen and
then group P. vivax parasitaemia relapse by appropriate groupings
for length of follow-up.
Sensitivity analysis
We will assess the risk of bias that contributed data to the meta-
analyses for the prespecified outcomes with sensitivity analyses
against concealment of allocation.
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A D D I T I O N A L T A B L E S
Table 1. Data extraction: Grouping of comparisons to address the review objectives
Objective Intervention Control
Are higher doses more effective (0.5 mg/
kg or 30 mg primaquine/day for 14 days),
in all areas, or only in areas where they are
standard treatment (Asia, Pacific)?
Blood-stage antimalarial drug with pri-
maquine 0.5 mg/kg (30 mg) per day for 14
days (total dose 420 mg)
Both intervention and control groups must
have received the same treatment: either
CQ or ACT for the blood-borne stage of
infection
Blood-stage antimalarial drug with pri-
maquine 0.25 mg/kg (15 mg) per day for
14 days (total dose 210 mg)
Both intervention and control groups must
have received the same treatment: either
CQ or ACT for the blood-borne stage of
infection
Are shorter, higher dose regimes of pri-
maquine over 7 days as effective as treat-
ment over 14 days (is the total dose rather
than the length of treatment the important
factor)?
Blood-stage antimalarial drug with pri-
maquine 0.5 mg/kg (30 mg) per day for 7
days (total dose 210 mg)
Both intervention and control groups must
have received the same treatment: either
CQ or ACT for the blood-borne stage of
infection
Are weekly dosing regimens (0.75 mg/kg
or 45 mg/week for 8 weeks) as effective?
Blood-stage antimalarial drug with pri-
maquine 0.75/kg (45 mg) per week for 8
weeks (total dose 360 mg)
CQ = Chloroquine
ACT = Artemisinin-based combination therapy
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A P P E N D I C E S
Appendix 1. Detailed search strategy
Search set Search terms
1 primaquine [Title/Abstract]
2 “Primaquine”[Mesh]
3 1 or 2
4 “Plasmodium vivax “ [Title/Abstract]
5 “Plasmodium vivax”[Mesh]
6 “vivax malaria ” [Title/Abstract]
7 “Malaria, Vivax”[Mesh]
8 4 or 5 or 6
9 3 and 8
Search terms used in combination with the search strategy for retrieving trials developed by the Cochrane Collaboration (Lefebvre
2011).
This is the preliminary search strategy for MEDLINE (PubMed). We will adapt it for other electronic databases and we will report all
search strategies in full in the final version of the review.
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A B S T R A C T
Background
Malaria caused by Plasmodium vivax requires treatment of the blood-stage infection and treatment of the hypnozoites that develop in the
liver. This is a challenge to effective case management of P vivax malaria, as well as being a more general substantial impediment to malaria
control. The World Health Organization (WHO) recommends a 14-day drug course with primaquine, an 8-aminoquinoline, at 0.25 mg/kg/
day in most of the world (standard course), or 0.5 mg/kg/day in East Asia and Oceania (high-standard course). This long treatment course
can be difficult to complete, and primaquine can cause dangerous haemolysis in individuals with glucose-6-phosphate dehydrogenase
(G6PD) deficiency, meaning that physicians may be reluctant to prescribe in areas where G6PD testing is not available. This Cochrane
Review evaluated whether more patient-friendly alternative regimens are as efficacious as the standard regimen for radical cure ofP vivax
malaria.
Objectives
To assess the efficacy and safety of alternative primaquine regimens for radical cure of P vivax malaria compared to the standard or high-
standard 14 days of primaquine (0.25 or 0.5 mg/kg/day), as well as comparison of these two WHO-recommended regimens.
Search methods
We searched the Cochrane Infectious Diseases Group (CIDG) Specialized Register; the Cochrane Central Register of Controlled Trials (CEN-
TRAL); MEDLINE (PubMed); Embase (Ovid); and LILACS (BIREME) up to 17 December 2018. We also searched the WHO International Clinical
Trials Registry Platform (ICTRP) and ClinicalTrials.gov, and checked the reference lists of all studies identified by the above methods.
Selection criteria
Randomized controlled trials (RCTs) of adults and children with P vivax malaria using any regimen of either chloroquine or an artemisinin-
based combination therapy (ACT) plus primaquine with either higher daily doses for 14 days, shorter regimens with the same total dose,
or using weekly dosing regimens; compared with the usual standard regimens recommended by the WHO (0.25 or 0.5 mg/kg/day for 14
days), or a comparison of these two WHO-recommended regimens.
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Data collection and analysis
Two review authors independently assessed trial eligibility and quality, and extracted data. We calculated risk ratios (RRs) with 95% con-
fidence intervals (CIs) for dichotomous data. We grouped efficacy data according to length of follow-up. We analysed safety data where
this information was included.
Main results
High-standard 14-day course versus standard 14-day course
Two RCTs compared the high-standard 14-day regimen with the standard 14-day regimen. People with G6PD deficiency and pregnant
or lactating women were excluded. We do not know if there is any difference in P vivax recurrences at 6 months with 0.5 mg/kg/day pri-
maquine therapy for 14 days compared to 0.25 mg/kg/day primaquine therapy for 14 days (with chloroquine: RR 0.82, 95% CI 0.47 to 1.43,
639 participants, very low-certainty evidence; with chloroquine or an ACT: RR 1.11, 95% CI 0.17 to 7.09, 38 participants, very low-certain-
ty evidence). No serious adverse events were reported. We do not know whether there is a difference in adverse events with the higher
dosage (very low-certainty evidence).
0.5 mg/kg/day primaquine for 7 days versus standard 14-day course
Five RCTs compared 0.5 mg/kg/day primaquine for 7 days with the standard 14-day course. There may be little or no difference in P vivax
recurrences at 6 to 7 months when using the same total dose (0.5 mg/kg/day to 210 mg) over 7 days as compared to 14 days (RR 0.96, 95%
CI 0.66 to 1.39; 1211 participants; low-certainty evidence). No serious adverse events were reported. There may be little or no difference
in the number of adverse events known to occur with primaquine between the primaquine shorter regimen as compared to the longer
regimen (RR 1.06, 95% CI 0.64 to 1.76; 1154 participants; low-certainty evidence). We do not know whether there is any difference in the
frequency of anaemia or discontinuation of treatment between groups (very low-certainty evidence). Three trials excluded people with
G6PD deficiency, and two did not provide this information. Pregnant and lactating women were either excluded or no details were provided
regarding their inclusion or exclusion.
0.75 mg/kg primaquine/week for 8 weeks versus high-standard course
One RCT compared weekly primaquine with the high-standard 14-day course. G6PD-deficient patients were not randomized but were
included in the weekly primaquine group. Only one G6PD-deficient participant was detected during the trial. We do not know whether
weekly primaquine increases or decreases recurrences of P vivax compared to the 14-day regimen at 11 months' follow-up (RR 3.18, 95%
CI 0.37 to 27.6; 122 participants; very low-certainty evidence). No serious adverse events and no episodes of anaemia were reported.
Three other RCTs evaluated different alternative regimens and doses of primaquine, but one of these RCTs did not have results available,
and two used regimens that have not been widely used and the evidence was of very low certainty.
Authors' conclusions
Although limited data were available, the analysis did not detect a difference in recurrence between the 7-day regimen and the standard
14-day regimen of 0.5 mg/kg/day primaquine, and no serious adverse events were reported in G6PD-normal participants taking 0.5 mg/
kg/day of primaquine. This shorter regimen may be useful in G6PD-normal patients if there are treatment adherence concerns. Further
large high-quality RCTs are needed, such as the IMPROV trial, with more standardised comparison regimens and longer follow-up to help
resolve uncertainties.
16 September 2019
Update pending
Authors currently updating
The update is due to be published in December 2019.
P L A I N   L A N G U A G E   S U M M A R Y
Primaquine to cure people with Plasmodium vivax malaria: comparing dosing schedules
Plasmodium vivax malaria can sometimes cause potentially life-threatening illness, and the infection continues to make many people
unwell. The infection includes a liver stage, and this requires primaquine to eradicate it and prevent the infection recrudescing. However,
the current dosing schedule requires 14 days of daily treatment.
What are the concerns about primaquine?
Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria (Review)
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Primaquine is the only drug currently recommended to treat the liver parasites in P vivax malaria. It can cause anaemia in people with
glucose-6-phosphate dehydrogenase (G6PD) deficiency, which is a relatively common genetic blood disorder. Shorter regimens would
help reduce the risk of default with the current two-week regimen.
What does the research say?
We summarized trials that compared the World Health Organization (WHO)-recommended primaquine regimen of 15 to 30 mg per day
for 14 days with the same or higher doses of primaquine given over different lengths of time to determine whether alternative regimens
were as successful as the recommended courses at preventing future episodes of P vivax malaria. We searched for trials up to 17 December
2018, and included nine randomized controlled trials (studies in which participants are assigned to one of two or more treatment groups
in a random manner) in our analysis.
When using 30 mg per day compared to 15 mg per day primaquine therapy for 14 days, we do not know if there is any difference in P vivax
recurrences at 6 months (very low-certainty evidence). No serious side effects were reported, but it is unclear whether or not there is a
difference in other side effects between doses (very low-certainty evidence).
When using 30 mg primaquine per day for 7 days compared to 15 mg per day for 14 days, there may be no difference in P vivax recurrences
at 6 to 7 months (low-certainty evidence). No serious adverse events were reported. There may be no difference in the number of side
effects known to occur with primaquine between the two treatment regimens (low-certainty evidence).
We do not know whether weekly primaquine increases or decreases recurrences of P vivax compared to the 14-day regimen at 11 months'
follow-up (very low-certainty evidence).
Further large high-quality RCTs are needed, such as the IMPROV trial, to help improve the certainty of the evidence around alternative
regimens.
How up-to-date is this review?
The review authors searched for studies up to 17 December 2018.
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Summary of findings for the main comparison.   ‘Summary of findings' (main comparison)
0.5 mg/kg/day for 7 days versus standard 14-day regimen for radical cure of P vivax malaria
Patient or population: adults and children with confirmed clinical and parasitological P vivax malaria
Setting: India, Peru, Brazil
Intervention: 0.5 mg/kg/day primaquine for 7 days (adult dose 30 mg)
Comparison: standard 14-day course of primaquine (0.25 mg/kg/day, adult dose 15 mg)
Anticipated absolute effects*
(95% CI)
Outcomes
Risk with
standard 14-
day course
primaquine
Risk with
0.5mg/kg/
day pri-
maquine for
7 days
Relative ef-
fect
(95% CI)
№ of partici-
pants
(trials)
Certainty of the evidence
(GRADE)
Comments
Recurrence of P vivax
parasitaemia
Follow-up: range 6
months to 7 months
89 per 1000 86 per 1000
(59 to 124)
RR 0.96
(0.66 to 1.39)
1211
(4 RCTs)
⊕⊕⊝⊝
LOWa,b
Due to risk of bias and impre-
cision
There may be little or no difference be-
tween 0.5 mg/kg/day primaquine for 7
days and the standard 14-day course.
Serious adverse effects See comment See comment — 1427
(5 RCTs)
— No events reported.
Adverse events that re-
sult in the discontinua-
tion of treatment
3 per 1000 3 per 1000
(0 to 20)
RR 1.04
(0.15 to 7.38)
1154
(4 RCTs)
⊕⊝⊝⊝
VERY LOWc,d
due to risk of bias and impre-
cision
We do not know if there is any difference
in adverse events that result in treatment
discontinuation between 0.5 mg/kg/day
primaquine for 7 days and the standard
14-day course.
Adverse effects known
to occur with pri-
maquine
44 per 1000 47 per 1000
(28 to 78)
RR 1.06
(0.64 to 1.76)
1154
(4 RCTs)
⊕⊕⊝⊝
LOWc,e
Due to risk of bias and impre-
cision
There may be little or no difference in the
frequency of adverse events known to oc-
cur with primaquine between 0.5 mg/kg/
day primaquine for 7 days and the stan-
dard 14-day course.
Anaemia or change in
haemoglobin status
0 per 1000 0 per 1000
(0 to 0)
RR 3.0 (0.51 to
174.01)
240
(1 RCT)
⊕⊝⊝⊝
VERY LOWf,g,h
We do not know if the occurrence of
anaemia differs between the 2 treatment
regimens.
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Due to risk of bias, indirect-
ness, and imprecision
Adverse events known
to occur with chloro-
quine
0 per 1000 0 per 1000
(0 to 0)
RR 9.40
(0.51 to
174.01)
779
(1 RCT)
⊕⊝⊝⊝
VERY LOWi,j,k
Due to risk of bias, indirect-
ness, and imprecision
We do not know if there is a difference
in the number of participants experi-
encing adverse events known to occur
with chlorquine between the 2 treatment
groups.
*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
Abbreviations: CI: confidence interval; RCT: randomized controlled trial; RR: risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aDowngraded once for risk of bias: Rajgor 2014 IND, which contributed the most weight to the meta-analysis, was at high risk of selection bias due to no allocation concealment
and high risk of attrition bias. Although Pareek 2015 IND was at risk of selection bias as well as other bias for being funded and carried out by drug company, it only contributed
a small amount of weight to the meta-analysis.
bDowngraded once for imprecision: wide CIs - may be 34% reduction in malaria recurrences or 40% increase with 0.5 mg/kg/day primaquine for 7 days.
cDowngraded once for risk of bias: Rajgor 2014 IND was at high risk of selection bias due to no allocation concealment and high risk of attrition bias. Pareek 2015 IND was at risk
of selection bias as well as other bias for being funded and carried out by drug company.
dDowngraded twice for serious imprecision: very few events (only four events occurring in one trial, Rajgor 2014 IND), very wide CIs.
eDowngraded once due to imprecision: wide CIs.
fDowngraded once due to risk of bias: Pareek 2015 IND was at risk of selection bias and other bias (funded and performed by drug company).
gDowngraded once for indirectness: only one study conducted in G6PD-normal adults in India (Pareek 2015 IND).
hDowngraded twice for serious imprecision: only one event, very wide CIs.
iDowngraded once for risk of bias: Rajgor 2014 IND at risk of bias selection bias due to no allocation concealment and attrition bias.
jDowngraded once for indirectness: only one study conducted in G6PD-normal adults in India (Rajgor 2014 IND).
kDowngraded twice for serious imprecision: few events, very wide CIs.
 
 
Summary of findings 2.   ‘Summary of findings' table 2
High-standard 14-day regimen versus standard 14-day regimen for radical cure of P vivax malaria
Patient or population: adults and children with confirmed clinical and parasitological P vivax malaria
Setting: India
Intervention: high-standard 14-day course of primaquine (0.5 mg/kg/day, adult dose 30 mg)
Comparison: standard 14-day course of primaquine (0.25 mg/kg/day, adult dose 15 mg)
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Anticipated absolute effects*
(95% CI)
Outcomes
Risk with
standard 14-
day course
primaquine
Risk with
high-stan-
dard 14-day
course pri-
maquine
Relative ef-
fect
(95% CI)
№ of partici-
pants
(studies)
Certainty of the evidence
(GRADE)
Comments
Recurrence of P vivax par-
asitaemia
follow-up: range 6 months
to 7 months
Blood-stage treatment:
chloroquine
81 per 1000 66 per 1000
(34 to 116)
RR 0.82
(0.47 to 1.43)
639
(1 RCT)
⊕⊝⊝⊝
VERY LOWa,b,c
due to indirectness, risk of bias,
and imprecision
We do not know if there is any differ-
ence in P vivax recurrences between
high-standard or standard 14-day
courses of primaquine given with
chloroquine.
Recurrence of P vivax par-
asitaemia
follow-up: range 6 months
Blood-stage treatment:
chloroquine or an ACT
100 per 1000 111 per 1000
(17 to 709)
RR 1.11 (0.17
to 7.09)
38
(1 RCT)
⊕⊝⊝⊝
VERY LOWd,e,f
due to indirectness, risk of bias,
and imprecision
We do not know if there is any differ-
ence in P vivax recurrences between
high-standard or standard 14-day
courses of primaquine given with
chloroquine or an ACT.
Serious adverse effects 0 per 1000 0 per 1000
(0 to 0)
Not estimable 816
(2 RCTs)
— No events reported.
Adverse events that result
in the discontinuation of
treatment
5 per 1000 21 per 1000
(5 to 98)
RR 4.19
(0.90 to 19.60)
778
(1 RCT)
⊕⊝⊝⊝
VERY LOWa,b,d,g
due to indirectness, risk of bias,
and imprecision
We do not know if there is any differ-
ence in adverse events resulting in
treatment discontinuation between
high-standard or standard 14-day
courses of primaquine.
Adverse effects known to
occur with primaquine
13 per 1000 34 per 1000
(12 to 95)
RR 2.72
(0.98 to 7.57)
778
(1 RCT)
⊕⊝⊝⊝
VERY LOWa,b,h
due to indirectness, risk of bias,
and imprecision
We do not know if there is any differ-
ence in adverse events known to oc-
cur with primaquine between high-
standard or standard 14-day courses
of primaquine.
Adverse events known to
occur with chloroquine
0 per 1000 0 per 1000
(0 to 0)
RR 9.43
(0.51 to
174.47)
778
(1 RCT)
⊕⊝⊝⊝
VERY LOWa,b,h
due to indirectness, risk of bias,
and imprecision
We do not know if there is any dif-
ference in adverse events associat-
ed with chloroquine between the 2
treatment groups.
*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
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Abbreviations: ACT: artemisinin-based combination therapy; CI: confidence interval; RCT: randomized controlled trial; RR: risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aDowngraded once for indirectness: only one trial conducted in India in G6PD-normal adults (Rajgor 2014 IND).
bDowngraded once for risk of bias: open-label - no allocation concealment, risk of selection bias; risk of attrition bias - high percentage not completing six months' follow-up
with minimal explanation.
cDowngraded once for imprecision: wide CIs - range of 58% reduction in malaria recurrences at 6 months with high-standard 14-day course of primaquine to 43% increase in
number of malaria recurrences.
dDowngraded once for indirectness: only one trial conducted in India in G6PD-normal adults (Saravu 2018 IND).
eDowngraded once for risk of bias: no blinding, high rate of loss to follow-up.
fDowngraded once for imprecision: wide CIs - range of 83% reduction in malaria recurrence to 609% increase in malaria recurrences with the high-standard 14-day regimen.
gDowngraded once for imprecision: wide CIs 0.9 to 19.6 - range of 10% reduction in adverse events with high-standard 14-day course to 186% increase in adverse events.
hDowngraded once for imprecision: wide CIs.
 
 
Summary of findings 3.   ‘Summary of findings' table 3
0.75 mg/kg primaquine/week for 8 weeks versus high-standard 14-day regimen for radical cure of P vivax malaria
Patient or population: adults and children with confirmed clinical and parasitological P vivax malaria
Setting: Pakistan
Intervention: 0.75 mg/kg primaquine/week for 8 weeks (adult dose 45 mg)
Comparison: high-standard 14-day course primaquine (0.5 mg/kg/day, adult dose 30 mg)
Anticipated absolute effects*
(95% CI)
Outcomes
Risk with
high-stan-
dard 14-day
course pri-
maquine
Risk with once-
weekly 0.75
mg/kg pri-
maquine for 8
weeks
Relative effect
(95% CI)
№ of partici-
pants
(trials)
Certainty of the evidence
(GRADE)
Comments
Recurrence of P vivax
malaria
Follow-up: 8 months
0 per 1000 0 per 1000
(0 to 0)
RR 7.00
(0.38 to 127.32)
126
(1 RCT)
⊕⊝⊝⊝
VERY LOWa,b,c
due to risk of bias, indirectness,
and imprecision
We do not know if weekly pri-
maquine reduces the risk of
malaria recurrences when com-
pared to the high-standard 14-
day course.
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Recurrence of P vivax
malaria
Follow-up: 11
months
19 per 1000 59 per 1000
(7 to 511)
RR 3.18
(0.37 to 27.60)
122
(1 RCT)
⊕⊝⊝⊝
VERY LOWa,b,d
due to risk of bias, indirectness,
and imprecision
We do not know if weekly pri-
maquine reduces the risk of
malaria recurrences when com-
pared to the high-standard 14-
day course.
Serious adverse ef-
fects
0 per 1000 0 per 1000
(0 to 0)
Not estimable 129
(1 RCT)
— No events reported.
Anaemia (haemoglo-
bin < 7 g/dL)
0 per 1000 0 per 1000
(0 to 0)
Not estimable 129
(1 RCT)
— No events reported.
*The risk in the intervention group (and its 95% CI) is based on the assumed risk in the comparison group and the relative effect of the intervention (and its 95% CI).
Abbreviations: CI: confidence interval; RCT: randomized controlled trial; RR: risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aDowngraded by 1 for risk of bias: Leslie 2008 PAK was at high risk of bias for randomization process, allocation concealment, and incomplete outcome data.
bDowngraded by 1 for indirectness: only one study conducted in Pakistan, only one G6PD-deficient adult included in one trial (in weekly arm).
cDowngraded by 2 for serious imprecision: few events, very wide CIs.
dDowngraded by 2 for serious imprecision: few events, very wide CIs.
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B A C K G R O U N D
Malaria is a potentially life-threatening disease caused by the Plas-
modium parasite, which is transmitted by the bite of an infected
female Anopheles mosquito. Five species of Plasmodium malaria
parasites can cause malaria disease in humans, of which Plasmodi-
um vivax and Plasmodium falciparum are the most important (WHO
2016). In 2017, an estimated 219 million cases of malaria occurred
worldwide and an estimated 435,000 people died from the disease
(WHO 2018). The World Health Organization (WHO) aims to reduce
malaria case load and mortality by at least 90% by 2030 (WHO
2016).
Historically, P vivax infection was thought to be a milder form of
malaria, and researchers have focused on P falciparum due to the
high number of deaths it causes (Bassat 2016). In recent years, it's
been shown that the morbidity and mortality of P vivax have been
underestimated, with evidence of direct fatality and contribution
to mortality in patients who have other comorbidities, such as mal-
nutrition, HIV, or coexisting infections (Baird 2013; Bhattacharjee
2013; Rizvi 2013; Singh 2013; Battle 2014; Douglas 2014; Kochar
2014; Arévalo-Herrera 2015; Baird 2015b). Repeated P vivax infec-
tions through childhood and adulthood also affect personal well-
being, development, and education and can thus negatively impact
economic development, both for the individual and the communi-
ty (Mendis 2001). P vivax malaria in pregnancy is associated with
maternal anaemia, spontaneous abortion, stillbirth, and low birth-
weight, with especially poor pregnancy outcomes for women with
severe infection (McGready 2012; Rijken 2012; Brutus 2013).
Description of the condition
P vivax infection caused an estimated 7.5 million cases of malaria
in 2017 (WHO 2018). The geographical distribution ofP vivax malar-
ia is more widespread than any of the other forms of human malar-
ia, with around 35% of the world’s population thought to be at risk
(Howes 2016) ). Co-infection with P falciparum is also common in
many regions (Kumar 2007; Mueller 2009). As malaria control ac-
celerates, the P vivax proportion in co-endemic areas tends to rise
compared to that of P falciparum, which highlights the importance
and challenge of this infection (John 2012).
P vivax is important because as many countries progress towards
malaria elimination, the parasite becomes a roadblock to eradica-
tion (Cibulskis 2015; Bassat 2016). Despite a reported 45% reduc-
tion in P vivax malaria cases between 2010 and 2016 (WHO 2017),
the parasite has several characteristics that enable it to evade con-
trol (Newby 2016). The early appearance of gametocytes in the
blood, often prior to symptoms of malaria, increases the chance
of onward transmission by mosquitoes (Mendis 2001). P vivax dif-
fers from P falciparum in that as well as having a blood-stage in-
fection, hypnozoites develop in the liver that can be dormant for
weeks to months before developing into an infection (White 2011).
What triggers these relapses is not well-understood. There is diffi-
culty in distinguishing between relapse (hypnozoite activation), re-
crudescence (subpar treatment of the initial blood-stage infection),
and re-infection (new infection with P vivax) (Imwong 2007). A study
in Papua New Guinea suggested that relapses cause four-fiShs of P
vivax infections (Robinson 2015), reinforcing the importance of re-
lapse in sustaining transmission (White 2011). Parasites show high
genetic diversity, even in countries that are at malaria elimination
stage (Koepfli 2015). P vivax is likely underestimated worldwide, as
the dormant liver stage is not detected in routine surveys (Geth-
ing 2012). Submicroscopic infections and asymptomatic infection
reservoirs may also lead to underdiagnosis or misdiagnosis. A sys-
tematic review showed that across all study sites, the polymerase
chain reaction (PCR) prevalence of P vivax was significantly higher
than that identified by light microscopy (Cheng 2015). The effect
this may have on P vivax malaria studies is unclear.
There are different strains of P vivax according to geographical re-
gion/endemicity areas, with relapse patterns that vary by latency
(time to first relapse), likelihood of relapse, and frequency of relaps-
es, which further complicates the assessment of efficacy of drugs
on relapses (Battle 2014; White 2016). Strains commonly found in
Southeast Asia and Oceania (including the ‘Chesson’ strain isolated
from an individual infected in Papua New Guinea) have the shortest
latency time to relapse, starting as early as three weeks after first
infection (if untreated with a hypnozoiticidal drug) (Ehrman 1945).
These areas correspond to zones 10 and 12 in Battle 2014. Indian
and Pakistan strains (zone 8) exhibit heterogeneity in relapse laten-
cy, incidence, and frequency, while South American strains (zone 3)
have a pattern of short latency to first relapse and less frequent re-
lapses than in zones 10 and 12 (Battle 2014). The temperate strains
(which include those from Korea in zone 11) relapse much more
slowly (John 2012; Battle 2014). Strains of the type in zones 10 and
12, referred to here as 'East Asia and Oceania', are recommended
to receive higher doses of primaquine (the high-standard course of
0.5 mg/kg/day rather than standard 0.25 mg/kg/day for 14 days) to
prevent relapses (WHO 2015), apparently based on research done
in the 1950s and 1960s (Coatney 1953; Jones 1953; Vivona 1961;
Maffi 1971; Clyde 1977), although not all these studies were done
with strains from the targeted geographic area.
Primaquine, an 8-aminoquinoline, has until very recently been the
only drug available on the market for treating the hypnozoite stage
of infection (Ashley 2014). One of the main barriers in P vivax treat-
ment is the reluctance to use primaquine due to it potentially caus-
ing haemolysis in patients with glucose-6-phosphate dehydroge-
nase (G6PD) deficiency. G6PD deficiency is the most common en-
zyme deficiency worldwide and affects red blood cells by leading to
their premature lysis (Nkhoma 2009). G6PD deficiency is common
in countries where P vivax malaria is endemic, with an estimated
population prevalence of 8% (Howes 2012). Within G6PD deficien-
cy, there are differing phenotypes, meaning some people may be
mildly sensitive to primaquine, while others may be very sensitive
and experience life-threatening haemolysis (Baird 2015a), which
explains the varying responses to primaquine. In many areas where
P vivax is predominant, testing for G6PD deficiency is not available
locally (Baird 2015b). In 2018 the US Food and Drug Administra-
tion (FDA) approved a newer alternative, another 8-aminoquinoline
known as tafenoquine (MMV 2018), which has shown promise in re-
ducing relapses, but there are increased safety concerns in patients
with undiagnosed G6PD deficiency compared to primaquine, due
to its longer half-life (Rajapakse 2015).
Description of the intervention
People with P vivax malaria require treatment with an antimalari-
al drug to treat the blood-stage infection, and a drug to treat the
hypnozoite stage (radical cure). The WHO recommends treatment
with either chloroquine or an artemisinin-based combination ther-
apy (ACT) for the blood-stage infection, with 0.25 to 0.5 mg/kg/day
primaquine for 14 days for the liver stages (WHO 2015). Artemisinin-
based combination therapies and chloroquine have been shown to
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be effective and comparable in treating the blood-stage infection
of P vivax malaria (Gogtay 2013).
A previous Cochrane Review showed that primaquine regimens of
five days or fewer had similar recurrence rates to placebo or no pri-
maquine. Of the comparisons included in the review, a regimen of
0.25 mg/kg/day (15 mg) a day of primaquine for 14 days had the
lowest recurrence rates of P vivax infection (Galappaththy 2013).
There were no trials at that time that compared higher doses of pri-
maquine at 14 or 7 days.
Primaquine was first made available to North American soldiers
in the 1950s (Baird 2004). Its mechanism and metabolism are not
widely understood, but it has a broad spectrum of activity against
the Plasmodium parasite. As well as preventing relapse of P vivax
malaria by targeting the latent and developing hypnozoites in the
liver, it is also used in malaria prophylaxis (Baird 2003). It is ab-
sorbed from the gastrointestinal tract, has a half-life of about four
to nine hours, and crosses the placenta in pregnancy (Baird 2004).
New advancements in studying P vivax in humanized mice may lead
to a greater understanding of the mechanism of action of the drug
(Mikolajczak 2015).
Adverse effects of primaquine include production of methaemo-
globin, an oxidated state of haemoglobin that cannot transport
oxygen to tissues. Methaemoglobinaemia (an abnormal buildup of
methaemoglobin) can result in cyanosis when levels exceed 10% of
the usual haemoglobin level (Vale 2009). As described above, pri-
maquine causes haemolysis in people with G6PD deficiency, which
leads to anaemia (Ashley 2014). When taken on an empty stom-
ach it can cause abdominal pain and gastrointestinal upset (Vale
2009). Safe use of primaquine during pregnancy has not been es-
tablished. The radical cure with primaquine can be delayed until af-
ter pregnancy. With regard to breastfeeding patients, a recent study
showed that the levels of primaquine in breast milk may not be suf-
ficient to cause haemolysis even in a G6PD-deficient baby (Gilder
2018), but it is not recommended at this time.
How the intervention might work
The WHO advises that 0.25 mg to 0.5 mg/kg/day of primaquine for
14 days should be used for radical cure of P vivax malaria in patients
over six months old, excluding people with G6PD deficiency and
those who are pregnant or breastfeeding (WHO 2015).
There has been suggestion of failure of the regimen of 0.25 mg/kg/
day for 14 days (hereafter referred to as the 'standard 14-day reg-
imen') of primaquine for the Chesson strain of P vivax, which was
behind the suggestion of the increased dosing of 0.5 mg/kg/day in
East Asia and Oceania (hereafter referred to as the 'high-standard
14-day regimen'). However, evidence for the choice of the high-
standard regimen is not presented in the WHO treatment guide-
lines (WHO 2015). The previous Cochrane Review, Galappaththy
2013, found no trials that compared the high-standard 14-day reg-
imen to the standard 14-day regimen. The WHO recommends a
weekly dose of 0.75 mg/kg for eight weeks for patients with G6PD
deficiency, but the evidence for this is of low quality, as there are
few high-quality trials (WHO 2015).
The 14-day course of primaquine can lead to treatment adherence
issues, as well as to safety concerns about haemolysis in places
where G6PD testing is not available, meaning that shorter courses
of primaquine are desirable. Failure to treat the hypnozoite stage of
P vivax malaria leads to repeated relapses, morbidity, and persis-
tent infection. The logic framework for developing efficacious and
safe treatment regimens for P vivax is illustrated in Figure 1.
 
Figure 1.   Logic framework: treatment outcome pathways in Plasmodium vivax liver hypnozoite activation.
 
It has long been suggested that it may be the total dose of pri-
maquine that is important in the treatment of the hypnozoite stage
rather than the length of the course (Schmidt 1977). If a higher dose
of primaquine could be administered safely over a shorter peri-
od of time, it may improve adherence rates, thus reducing relapse
rates and morbidity and mortality resulting from P vivax infection.
There are small trials from the 1970s that suggest that shorter, high-
er-dose regimens were as efficacious as the 14-day courses (Clyde
1977; Saint-Yves 1977). At the time of the previous Cochrane Review
(Galappaththy 2013), there were no recent large high-quality trials
that had investigated the use of higher doses given over seven days.
We planned to include any such trials in this Cochrane Review.
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Why it is important to do this review
The use of primaquine for radical cure of P vivax malaria contin-
ues to pose a therapeutic dilemma for healthcare providers in ar-
eas without adequate screening for G6PD status. Clinicians must ei-
ther choose to give primaquine and risk haemolysis if the patient
is G6PD-deficient, or withhold treatment and accept the complica-
tions of ongoing parasite infection and relapses. This is why when
clinicians choose to treat with primaquine they prefer a lower dose
over a more prolonged period, which then risks difficulties with ad-
herence and thus reduced effectiveness.
We know from the previous Cochrane Review on primaquine with
chloroquine for radical cure that the standard 14-day regimen of
0.25 mg/kg/day (15 mg per day or 210 mg total dose) is better
than shorter regimens of similar daily doses and placebo (Galap-
paththy 2013). In fact, the regimen of 0.25 mg/kg/day for 5 days of
primaquine did not reduce recurrences compared to treating with
chloroquine alone.
A major problem with the radical cure of P vivax is difficulty with
the adherence of the 14-day course of primaquine, which has led to
many countries shortening the regimen. Peru was one such exam-
ple, although a study revealed that patients often still discontinued
the therapy after around three days, when they started to feel bet-
ter (Grietens 2010). A study that compared directly observed ther-
apy (DOT) for 14 days of primaquine versus non-DOT primaquine
found that the P vivax recurrence rate was significantly lower in the
DOT group (Takeuchi 2010). These problems have led to a more ur-
gent call for shorter treatment regimens. Various trials are inves-
tigating regimens that revise dosing and duration of treatment in
order to improve adherence and reduce the potential for incom-
plete treatment and development of resistance. As mentioned pre-
viously, the significance of the total cumulative primaquine dose
given, rather than the length of the course, is one avenue of investi-
gation. In areas where G6PD screening is present, using higher dos-
ing regimens over shorter time periods, if at least similarly effica-
cious, could improve adherence and reduce morbidity associated
with P vivax parasitaemia.
World Health Organization guidelines suggest a higher dosing reg-
imen of primaquine for the tropical, frequent-relapsing strain of P
vivax in East Asia and Oceania (WHO 2015), although the previous
Cochrane Review, Galappaththy 2013, did not find any trials assess-
ing this. Investigating the evidence base for this is therefore impor-
tant. The 2015 WHO guidelines also suggest an alternate dosing
regimen of weekly primaquine, which may be safer in patients with
G6PD deficiency. As the previous Cochrane Review included data
from only one trial assessing this, it is useful to investigate whether
there is further evidence to substantiate this guidance.
In this Cochrane Review, we have excluded comparisons between
blood-stage drug (chloroquine/ACT) with and without primaquine,
as the rationale for primaquine use has been sufficiently demon-
strated in a previous Cochrane Review (Galappaththy 2013). Simi-
larly, we have not included comparisons between different blood-
stage drugs in which the same dose of primaquine was used; an up-
date to an existing Cochrane Review, Gogtay 2013, is in progress
and will address this. However, we planned to stratify our results
according to partner drug, as there is increasing evidence that pri-
maquine is metabolized via the cytochrome P450 2D6 (CYP2D6)
pathway (Bennett 2013), and efficacy may thus be affected if the
blood-stage antimalarial drug is a CYP2D6 inhibitor (Baird 2018).
This review excluded comparisons of regimens that do not use the
control of the standard or high-standard regimen of 14 days of pri-
maquine. Also, it did not include comparisons of primaquine reg-
imens of 0.25 mg/kg/day for less than 14 days, as Galappaththy
2013 has already assessed these shorter regimens of the same daily
dose.
There is currently a lack of consensus among studies as to what
the minimum time frame for follow-up of relapse in P vivax malar-
ia should be. The WHO guidance on clinical trials in malaria sets
out standard follow-up for blood (or schizontal) stage infection as
28 days after treatment commencement, but has no clear defini-
tion on the follow-up period for radical cure in primaquine studies.
It states that "follow up varies from three months to a year in the
literature, and should be adapted to regional parasite characteris-
tics" (WHO 2009). In a recent review, John 2012 described relapse of
the tropical frequently relapsing strain of P vivax as typically three
weeks, but this varies according to blood-stage treatment: "three
weeks following quinine therapy" and "six to eight weeks follow-
ing chloroquine" (White 2011). With exposure to primaquine - even
if radical cure is not achieved - relapses may occur at longer inter-
vals (Sutanto 2013). In the Cochrane Review (Galappaththy 2013),
the follow-up period started 30 days after completing primaquine
treatment. Relapse is frequently defined as the presence of P vivax
parasites more than 28 to 30 days after the full course of primaquine
in people living in a non-endemic area (Looareesuwan 1997). Due to
the varying lengths of treatment and relapse time in P vivax malar-
ia, 28 days from treatment completion may not allow true assess-
ment of radical cure. It also makes assessment of the weekly pri-
maquine regimen difficult, as the follow-up time should start be-
fore the eight-week treatment course has finished. In this Cochrane
Review we planned to assess parasitaemia at 3, 6, and 12 months'
follow-up, in keeping with WHO guidance. We intended to describe
the length of follow-up across studies, and then group them into
meaningful lengths of follow-up, depending on the regimen.
We intended to answer the following questions by comparing the
new regimens to the standard 14-day regimen of primaquine (0.25
mg/kg/day; 15 mg adult dose) or the high-standard 14-day regimen
(0.5 mg/kg/day; 30 mg adult dose) recommended for East Asia/
Oceania.
• Is the high-standard 14-day regimen more efficacious and safer
compared to the standard 14-day course in all areas, or only in
areas where it is recommended (East Asia and Oceania)?• Are shorter, higher-dose regimens (0.5 mg/kg/day for 7 days) as
efficacious and safe as the standard 14-day regimen?• Are weekly dosing regimens (0.75 mg/kg or 45 mg adult dose/
week for 8 weeks) as efficacious and safe as the standard or high-
standard 14-day regimen?
O B J E C T I V E S
To assess the efficacy and safety of alternative primaquine regi-
mens for radical cure of P vivax malaria compared to the standard
or high-standard 14 days of primaquine (0.25 or 0.5 mg/kg/day), as
well as comparison of these two WHO-recommended regimens.
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M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomized controlled trials (RCTs). We excluded quasi-RCTs.
Types of participants
Adults and children with confirmed clinical and parasitological
(light microscopy or PCR, or both) diagnosis of P vivax malaria. We
included trials that excluded people with G6PD deficiency and tri-
als that included populations that had or had not been screened
for G6PD deficiency. People with mixed malaria infections were ex-
cluded.
Types of interventions
Intervention
Any regimen of either chloroquine or an artemisinin-based combi-
nation therapy (ACT) plus primaquine with any of the following.
• Daily doses higher than 0.25 mg/kg/day for 14 days.• Shorter regimens with the same total dose.• Weekly dosing regimens.
Control
WHO-defined standard regimen of 14 days of primaquine at 0.25
mg/kg/day (15 mg adult dose) in most areas, or high-standard reg-
imen of 0.5 mg/kg/day (30 mg adult dose) in East Asia and Oceania,
plus either chloroquine or an ACT.
We included comparisons between the two WHO recommended 14
day regimes (0.25mg/kg/day and 0.5mg/kg/day). We included tri-
als that used chloroquine or ACT as the treatment for blood-borne
infection, and we planned to stratify by the blood schizonticidal
agent.
Types of outcome measures
Primary outcomes• P vivax parasitaemia (detected by light microscopy or PCR, or
both) at 3, 6, and 12 months' follow-up. We planned to describe
this as recurrences of P vivax malaria due to the previously men-
tioned difficulties in distinguishing between relapse and re-in-
fection.
Secondary outcomes• P vivax parasitaemia (detected by light microscopy or PCR, or
both) at one to three months' follow-up.
Adverse events• Serious adverse events (fatal, life-threatening, or requiring hos-
pitalization).• Adverse events that result in discontinuation of treatment.• Events known to occur with primaquine (cyanosis, leucopenia,
methaemoglobinaemia, hypertension, cardiac arrhythmia, ab-
dominal pain, nausea, vomiting, or haemolysis) or those due to
a comparator drug used along with primaquine.• Anaemia or change in haemoglobin status.• Other adverse events.
Search methods for identification of studies
We attempted to identify all relevant studies regardless of lan-
guage or publication status (published, unpublished, in press, or in
progress).
Electronic searches
We searched the following databases using the search terms and
strategy described in Appendix 1: the Cochrane Infectious Diseases
Group Specialized Register (17 December 2018); the Cochrane Cen-
tral Register of Controlled Trials (CENTRAL, 2018, Issue 12, pub-
lished in the Cochrane Library); MEDLINE (PubMed, 1946 to 17 De-
cember 2018); Embase (Ovid, 1947 to 17 December 2018); and
LILACS (Bireme, 1982 to 17 December 2018). We also searched the
World Health Organization (WHO) International Clinical Trials Reg-
istry Platform (ICTRP; www.who.int/ictrp/), and ClinicalTrials.gov
(clinicaltrials.gov/ct2/home), for trials in progress, on 17 December
2018, using "primaquine" and "vivax" as search terms.
Searching other resources
We checked the reference lists of all studies identified by the above
methods for additional potentially relevant studies. We contacted
researchers working in the field and the WHO for unpublished and
ongoing trials. We also searched the reference lists and included
studies of the Cochrane Review by Galappaththy 2013.
Data collection and analysis
Selection of studies
Two review authors independently screened the titles and ab-
stracts of the search results to identify potentially eligible trials,
coding the articles as either 'retrieve' or 'do not retrieve'. We ob-
tained the full-text reports of potentially eligible trials and assessed
them for inclusion in the review using a predesigned eligibility form
based on the inclusion criteria. Any discrepancies were resolved
through discussion or by consulting a third review author if neces-
sary. Where necessary, we contacted the trial authors for clarifica-
tion of trial methods. We listed the excluded trials and the reasons
for their exclusion in a 'Characteristics of excluded studies' table.
Where there were multiple reports relating to the same trial, we
planned to include all reports and collate data. We detailed the trial
selection process in a PRISMA diagram.
Data extraction and management
Two review authors independently extracted data from the includ-
ed trials using a data extraction form designed specifically for this
review, in keeping with Cochrane guidance (Higgins 2011).
For each included trial we extracted a minimum of the following
data where available.
• Study design.• Endemicity/population demographics.• G6PD status of participants (known/unknown).• CYP2D6 status (if available).• Blood-stage antimalarial drug choice.• Dose/duration/timing of treatment arms.• Supervised or non-supervised therapy.• Duration of follow-up.• Adverse events.
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• Reported outcomes.
Any differences in data extraction were resolved through discus-
sion or by consulting a third review author if necessary. We entered
the extracted data into Review Manager 5 (RevMan 2014). Where
necessary, we contacted the authors of primary trials regarding
missing data or methodological details of the trial. We noted any
limitations in the included studies.
We grouped comparisons as illustrated in Table 1.
Assessment of risk of bias in included studies
Two review authors independently assessed the risk of bias of each
included trial using the Cochrane 'Risk of bias' assessment tool,
discussing any differences of opinion. In the case of missing or un-
clear information, we contacted the trial authors for clarification.
We summarized the results in the 'Risk of bias' tables in the 'Char-
acteristics of included studies' tables (Higgins 2011).
Measures of treatment eBect
For dichotomous data, we compared interventions using risk ratios
(RRs) to measure treatment effect. Where trial authors presented
data as odds ratios, we recalculated the effect. We defined statis-
tical significance as P < 0.05 and calculated 95% confidence inter-
vals (CIs) for all results. For comparable trials, we performed meta-
analyses if there were sufficient data.
Unit of analysis issues
We split trials that included more than two comparison groups and
analysed them as individual pair-wise comparisons. If there was
a shared control group, we split the control group so that partici-
pants were only counted once in the overall meta-analysis.
Dealing with missing data
We analysed missing data using available-case analysis if we judged
the trial to be at low risk of bias for incomplete outcome data. We at-
tempted to contact trial authors to obtain missing or unclear data.
If the missing data rendered the result uninterpretable, we exclud-
ed the data from meta-analyses and clearly stated the reason for
exclusion. If the missing data meant that results were interpretable
but likely to be at high risk of bias, we used imputation methods
to investigate the impact of the missing data. We analysed extract-
ed data on an intention-to-treat basis where there were no missing
data.
Assessment of heterogeneity
We inspected forest plots for overlapping CIs. We also applied the
Chi2 test as a statistical test for the presence of heterogeneity, with
a P value of 0.10 used to indicate statistical significance, and we
computed the I2 statistic to quantify the percentage of the variabil-
ity in effect estimates that was due to heterogeneity rather than
sampling error (chance). We investigated possible causes of hetero-
geneity by subgroup analysis. If substantive heterogeneity persist-
ed, defined as an I2 statistic value of greater than 50%, we used a
random-effects meta-analysis.
Assessment of reporting biases
We planned to examine the likelihood of reporting bias using fun-
nel plots, however the number of included trials was insufficient to
permit this.
Data synthesis
We analysed the data using Review Manager 5 (RevMan 2014).
We assessed the certainty of the evidence for each outcome mea-
sure using the GRADE approach, and we constructed 'Summary
of findings' tables using GRADEpro GDT (GRADEpro GDT 2015). We
stratified results according to blood-stage partner drug (if differ-
ent blood-stage antimalarials were used, which only occurred for
one comparison). Length of follow-up varied with regimens and be-
tween studies. We described regimens and follow-up periods and
defined sensible groupings for follow-up. We also performed sub-
group analyses according to geographical region/endemicity and
directly observed therapy (DOT) or non-DOT. We stratified results by
length of follow-up. We had planned to perform a subgroup analy-
sis according to CYP2D6 status, however data were insufficient to
permit this.
Subgroup analysis and investigation of heterogeneity
We grouped the analysis by drug regimen. We described the inter-
ventions and outcomes in all included trials. We conducted an in-
ventory of length of follow-up against each drug regimen and then
grouped P vivax parasitaemia recurrence by appropriate groupings
for length of follow-up.
Sensitivity analysis
We planned to assess the risk of bias of studies that contributed da-
ta to the meta-analyses for the prespecified outcomes with sensi-
tivity analyses against concealment of allocation.
R E S U L T S
Description of studies
Results of the search
Our database search, conducted up to 17 December 2018, identi-
fied 251 studies (after removal of 3 duplicates). We excluded 214
articles during abstract screening, and selected 37 studies for full-
text review. We excluded 25 studies with reasons provided; identi-
fied two trials as ongoing; and included 10 studies in the review.
The search results are presented in a PRISMA diagram in Figure 2.
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Figure 2.   Study flow diagram.
 
Included studies
Although 10 studies (of 10 trials) met our inclusion criteria, one
study was deemed ineligible for data extraction and analysis. There
were only partially available results available in a conference ab-
stract for Chu 2016 THA, meaning that we could not assess risk of
bias or analyse results. We contacted the author for the full results
but this was declined pending future publication. We included nine
studies (of nine trials) in our quantitative analysis.
Four trials were conducted in South America: one in Colombia (Car-
mona-Fonseca 2009 COL), one in Brazil (Abdon 2001 BRA), and two
in Peru (Solari-Soto 2002 PER; Durand 2014 PER). Five trials were
conducted in Asia: one in Pakistan (Leslie 2008 PAK), one in Thai-
land (Bunnag 1994 THA), and three in India (Rajgor 2014 IND; Pareek
2015 IND; Saravu 2018 IND). All nine trials included data for adults,
and four trials included children under the age of 10 years (So-
lari-Soto 2002 PER; Leslie 2008 PAK; Carmona-Fonseca 2009 COL;
Durand 2014 PER). No trials had information on children under one
year old.
Seven trials excluded pregnant women, and two trials did not
specify whether or not pregnant women were included (Bunnag
1994 THA; Solari-Soto 2002 PER). Six trials specified that lactating
women were excluded, while the remaining three trials did not pro-
vide details regarding this (Bunnag 1994 THA; Solari-Soto 2002 PER;
Carmona-Fonseca 2009 COL). Only one trial included people with
G6PD deficiency (Leslie 2008 PAK). Six trials excluded people with
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G6PD deficiency (Bunnag 1994 THA; Carmona-Fonseca 2009 COL;
Durand 2014 PER; Rajgor 2014 IND; Pareek 2015 IND; Saravu 2018
IND), and two trials did not specify whether or not people with G6PD
deficiency were included (Abdon 2001 BRA; Solari-Soto 2002 PER).
All of the trials used microscopy for diagnosis of parasitaemia. Four
trials carried out PCR genotyping of vivax parasitaemia as well (Du-
rand 2014 PER; Rajgor 2014 IND; Pareek 2015 IND; Saravu 2018 IND).
Two trials used different doses or regimens of chloroquine within
trial arms, but as both confirmed that parasitaemia had resolved
following treatment, we still included them in the review (see Char-
acteristics of included studies) (Bunnag 1994 THA; Abdon 2001
BRA). None of the included trials described the CYP2D6 status of
participants.
Excluded studies
We excluded 25 studies during full-text screening; see details in
Characteristics of excluded studies.
Risk of bias in included studies
A summary of the 'Risk of bias' assessments is presented in Figure
3. Full details are shown in the Characteristics of included studies
tables.
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Figure 3.   ‘Risk of bias' summary: review authors' judgements about each ‘Risk of bias' item for each included
study.
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Allocation
Four trials described adequate methods of treatment randomiza-
tion and were judged to be at low risk of selection bias (Durand 2014
PER; Rajgor 2014 IND; Pareek 2015 IND; Saravu 2018 IND). We as-
sessed one trial as being at high risk of bias as it used two differ-
ent methods of randomization depending on location, using house
numbers or sequential patient numbers (Leslie 2008 PAK). Four tri-
als did not detail the randomization process (Bunnag 1994 THA; Ab-
don 2001 BRA; Solari-Soto 2002 PER; Carmona-Fonseca 2009 COL).
Two trials used sealed envelopes to conceal allocation and so were
assessed as being at low risk of bias (Durand 2014 PER; Pareek 2015
IND). We assessed two trials with no concealment of treatment al-
location as at high risk of bias (Leslie 2008 PAK; Rajgor 2014 IND),
while five trials provided no information on whether or not alloca-
tion concealment was used(Bunnag 1994 THA; Abdon 2001 BRA; So-
lari-Soto 2002 PER; Carmona-Fonseca 2009 COL; Saravu 2018 IND).
Blinding
Seven trials were open-label and were assessed as at high risk of
performance bias (Abdon 2001 BRA; Solari-Soto 2002 PER; Leslie
2008 PAK; Carmona-Fonseca 2009 COL; Durand 2014 PER; Rajgor
2014 IND; Saravu 2018 IND); two of these trials reported blinding of
the microscopists who analysed the blood work (Leslie 2008 PAK;
Rajgor 2014 IND). Two trials reported blinding of participants and
personnel and were classified as being at low risk of bias (Bunnag
1994 THA; Pareek 2015 IND).
Incomplete outcome data
Five trials had low rates of attrition with losses accounted for and
so were judged as at low risk of attrition bias (Abdon 2001 BRA;
Solari-Soto 2002 PER; Carmona-Fonseca 2009 COL; Durand 2014
PER; Pareek 2015 IND). We assessed four trials as at high risk of at-
trition bias. Bunnag 1994 THA had unexplained, significant loss to
follow-up (more than three-quarters of participants by the end of
the trial), making the results uninterpretable. Leslie 2008 PAK had a
higher loss to follow-up in the intervention group compared to the
control group (6% loss versus 1% loss). Rajgor 2014 IND had a high
percentage of missing results at six months. Saravu 2018 IND had a
high percentage of loss to follow-up in both arms by six months.
Selective reporting
We judged four trials to have adequately reported on either pre-
specified or expected outcomes (Abdon 2001 BRA; Leslie 2008 PAK;
Durand 2014 PER; Saravu 2018 IND). Risk of reporting bias was un-
clear for five trials as no protocols were available (Bunnag 1994
THA; Solari-Soto 2002 PER; Carmona-Fonseca 2009 COL; Rajgor
2014 IND; Chu 2016 THA). We assessed Pareek 2015 IND as being
at high risk of reporting bias because compliance was added as an
outcome, primaquine levels were not reported as planned, and PCR
results were not well-detailed.
Other potential sources of bias
We judged Pareek 2015 IND to be at high risk of other bias as it was
funded by the drug company that manufactured the primaquine
preparations, and the authors were employees of the company. We
assessed six trials as at low risk of other bias (Solari-Soto 2002 PER;
Leslie 2008 PAK; Carmona-Fonseca 2009 COL; Durand 2014 PER; Ra-
jgor 2014 IND; Saravu 2018 IND). We assessed two trials for which
funding was not detailed as at unclear risk of other bias (Bunnag
1994 THA; Abdon 2001 BRA).
EBects of interventions
See: Summary of findings for the main comparison ‘Summary of
findings' (main comparison); Summary of findings 2 ‘Summary of
findings' table 2; Summary of findings 3 ‘Summary of findings' ta-
ble 3
High-standard 14-day regimen versus standard 14-day
regimen
The WHO recommends higher doses of primaquine (0.5 mg/kg/
day) for 14 days in East Asia and Oceania. We intended to examine
whether this high-standard regimen was more efficacious in areas
where it is currently recommended (because of assumed resistance
- East Asia, Oceania) as well as in all other areas where resistance
is not thought to occur.
Two trials compared the high-standard 14-day course with the
standard (0.25 mg/kg/day) 14-day course, both carried out in
adults in India (Rajgor 2014 IND; Saravu 2018 IND). Both trials ex-
cluded pregnant/lactating and G6PD-deficient patients. In Rajgor
2014 IND, participants were treated with chloroquine, with the
primaquine regimen (which was supervised) given after comple-
tion of the chloroquine course. In Saravu 2018 IND, participants
were treated with either chloroquine or an ACT (artesunate with
doxycycline or artemether-lumefantrine), and (unsupervised) pri-
maquine was given after completion of the blood-stage treatment.
We planned to stratify results according to blood-stage treatment;
however, Saravu 2018 IND combined the results for both blood-
stage treatments, so we were unable to separate results according
to partner drug. Only the blood-stage drugs given to participants
who had recurrences were described. For this reason, results from
the two studies are not combined and are presented separately.
Eicacy
In Rajgor 2014 IND, 21 participants out of 317 in the high-standard
14-day group had a recurrence of vivax malaria compared with 26
out of 322 in the standard 14-day group at 6 months' follow-up,
giving an 18% reduction in recurrence of parasitaemia in the high-
standard group (risk ratio (RR) 0.82, 95% confidence intervals (CI)
0.47 to 1.43; 639 participants; very low-certainty evidence; Analy-
sis 1.1). Vivax malaria recurrences were also investigated by PCR to
determine whether they were true relapses or new infections. Af-
ter this adjustment, results showed an 83% increase in vivax malar-
ia cases in the high-standard group (RR 1.83, 95% CI 0.62 to 5.40;
Analysis 1.2).
Rajgor 2014 IND was at high risk of bias for allocation concealment.
However, as we chose not to combine the data with Saravu 2018
IND for this analysis, a sensitivity analysis could not be done.
In Saravu 2018 IND, 2 out of 18 participants in the high-standard
14-day group had a recurrence of P vivax malaria compared to 2
out of 20 in the standard 14-day group at 6 months' follow-up (RR
1.11, 95% CI 0.17 to 7.09; Analysis 1.1). Both of the recurrences in
the high-standard 14-day group were given chloroquine. Of the re-
currences in the standard 14-day group, one participant received
chloroquine and one participant received artesunate and doxycy-
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cline. Polymerase chain reaction genotyping suggested that all four
participants had true relapses of infection.
It should be noted that because Saravu 2018 IND was a small pilot
trial, if we had not stratified according to blood-stage treatment,
results would have been largely the same as for Rajgor 2014 IND
alone.
Adverse eects
In Rajgor 2014 IND there were no serious adverse events were re-
ported in either study arm (778 participants). In the high-standard
14-day group, 8 out of 380 participants discontinued treatment due
to adverse events, compared to 2 out of 398 in the standard 14-day
group (RR 4.19, 95% CI 0.90 to 19.60; 778 participants; very low-cer-
tainty evidence; Analysis 1.4). In the high-standard arm, 13 out of
380 participants experienced adverse events known to occur with
primaquine, compared to 5 out of 398 in the standard arm (RR 2.72,
95% CI 0.98 to 7.57; 778 participants; very low-certainty evidence;
Analysis 1.5). In the high-standard arm, 4 out of 380 participants
experienced adverse events known to occur with the blood-stage
antimalarial chloroquine, compared to 0 out of 398 in the stan-
dard group (RR 9.43, 95% CI 0.51 to 174.47; 778 participants; very
low-certainty evidence; Analysis 1.6). This could suggest a trend to-
wards a higher occurrence of adverse events in the high-standard
14-day regimen.
No significant adverse events were noted in either group in Saravu
2018 IND.
0.5 mg/kg/day for 7 days versus standard 14-day regimen
This comparison aimed to investigate whether shorter, higher-dose
regimens of primaquine over 7 days are as efficacious as standard
treatment over 14 days to determine whether the total dose rather
than the length of treatment is an important factor (total dose 210
mg).
Five trials in India and South America compared 0.5 mg/kg/day of
primaquine for 7 days versus the standard (0.25 mg/kg/day) 14-day
regimen (same total dose 210 mg) (Abdon 2001 BRA; Solari-Soto
2002 PER; Durand 2014 PER; Rajgor 2014 IND; Pareek 2015 IND). Pa-
reek 2015 IND used a sustained-release preparation of primaquine
in two of the study arms (0.5 mg/kg/day sustained release and 0.25
mg/kg/day sustained release) and standard primaquine at 0.25mg/
kg/day in a third arm. We included the 0.5 mg/kg/day sustained re-
lease in the analysis and combined the results with the standard
preparation at the same dose used for the other trials, but used on-
ly the standard-preparation group of 0.25 mg/kg/day in the study
as the control group and did not include the arm of 0.25mg/kg/day
sustained release preparation.
Three trials excluded people with G6PD deficiency, while two tri-
als did not provide this information (Bunnag 1994 THA; Solari-So-
to 2002 PER). All but one trial excluded women who were pregnant
or lactating (Solari-Soto 2002 PER did not provide details). Partici-
pants were a mixture of adults and children over one year old. All
trials used microscopy for diagnosis, and only Pareek 2015 IND did
not use supervised treatment. Two trials gave chloroquine and pri-
maquine courses simultaneously (Abdon 2001 BRA; Durand 2014
PER), while the other three trials administered primaquine follow-
ing the chloroquine course. No trials stratified by age, so results
were combined.
Eicacy
There was minimal difference in the number of malaria recurrences
between groups at 6 to 7 months' follow-up (RR 0.96, 95% CI 0.66 to
1.39; 1211 participants; low-certainty evidence; Analysis 2.1). One
trial only followed participants for two months (Solari-Soto 2002
PER), and so was not part of the main analysis.
We had planned to perform a sensitivity analysis based on risk of
bias for allocation concealment (which would have involved re-
moving Rajgor 2014 IND from the meta-analysis), but we decided
that as the remaining trials were all at high risk of bias for blinding
and thus quality was generally low, we would not conduct a sensi-
tivity analysis but address these issues in our GRADE assessment.
Two trials PCR-adjusted their results to differentiate between re-
lapses and new infections at 6 to 7 months' follow-up. In Durand
2014 PER, PCR-adjusted results showed a 31% reduction in re-
currence (24% reduction with light microscopy) with the regimen
of 0.5 mg/kg/day for 7 days compared with the standard 14-day
course, while in Rajgor 2014 IND, PCR-adjusted results showed a
159% increase in recurrence (25% increase in recurrence with light
microscopy) with the regimen of 0.5 mg/kg/day for 7 days com-
pared to the standard 14-day regimen (Analysis 2.2). We decided
that these results could not be combined in a meta-analysis, as PCR
techniques can differ, and there were high levels of heterogeneity.
We performed a subgroup analysis according to geographic region
(Analysis 2.3). For trials in South America, the regimen of 0.5 mg/kg/
day for 7 days led to a 30% reduction in P vivax recurrences com-
pared to a 19% increase in recurrences for trials in Asia, although
confidence intervals were wide and included no effect for both sub-
groups (South America: RR 0.70, 95% CI 0.39 to 1.26; Asia: RR 1.19,
95% CI 0.73 to 1.94). Only one trial did not use directly observed
therapy (DOT) (Pareek 2015 IND). Subgroup analysis (Analysis 2.4)
showed that with DOT there was minimal difference in recurrences
at 6 to 7 months between treatment regimens (RR 0.98, 95% CI 0.67
to 1.43) compared to a reduction of about half of recurrences with
the regimen of 0.5 mg/kg/day for 7 days when treatment was not
supervised (RR 0.48, 95% CI 0.04 to 5.20).
Adverse eects
No serious adverse events were reported in either group (1427 par-
ticipants). The number of participants experiencing adverse events
leading to discontinuation of treatment was similar in both groups
(RR 1.04, 95% CI 0.15 to 7.38; 1154 participants; Analysis 2.6), as
were adverse events known to occur with primaquine (RR 1.06, 95%
CI 0.64 to 1.76; 1154 participants; Analysis 2.7). One trial reported on
change in haemoglobin status (Pareek 2015 IND), with 1 participant
out of 120 in the group receiving 0.5 mg/kg/day for 7 days becoming
anaemic, versus no participants out of 120 in the standard 14-day
regimen group (RR 3.0, 95% CI 0.51 to 174.01; 240 participants; very
low-certainty evidence; Analysis 2.8). Only one study reported on
adverse events known to occur with chloroquine (Rajgor 2014 IND),
with more occurring in the group receiving 0.5 mg/kg/day for 7 days
than the standard 14-day group (RR 9.40, 95% CI 0.51 to 174.01; 779
participants; very low-certainty evidence; Analysis 2.9).
0.75 mg/kg primaquine/week for 8 weeks versus high-
standard 14-day regimen
This comparison aimed to investigate whether a higher once-week-
ly dosing regimen, which may be more beneficial for people with
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G6PD deficiency, was as efficacious as the high-standard 14-day
regimen.
One trial compared weekly 0.75 mg/kg primaquine (45 mg adult
dose) for 8 weeks with the high-standard 14-day regimen (0.5 mg/
kg/day) (Leslie 2008 PAK). G6PD-deficient participants were not
randomized but were included in the weekly group, although there
only was one G6PD-deficient person included. Pregnant and lactat-
ing women were excluded. Treatment was supervised. It was not
specified whether chloroquine and primaquine were given concur-
rently.
Eicacy
Recurrences were more common in the weekly group at 8 months'
follow-up (RR 7.0, 95% CI 0.38 to 127.32; 126 participants; Analysis
3.1). Recurrences remained more common in the weekly group at
11 months' follow-up (RR 3.18, 95% CI 0.37 to 27.6; 122 participants;
Analysis 3.1). Leslie 2008 PAK was at high risk of bias for allocation
concealment, but a sensitivity analysis could not be done as it was
the only trial found for this comparison.
Adverse eects
No serious adverse events were reported in either study arm (Analy-
sis 3.2). No participants had anaemia defined as haemoglobin less
than 7 g/dL (Analysis 3.3).
Other regimens
0.375 mg/kg/day for 14 days versus standard 14-day regimen
Bunnag 1994 THA compared 0.375 mg/kg/day (adult dose 22.5 mg)
primaquine daily for 14 days with the standard regimen of 0.25 mg/
kg/day for 14 days. There was a high loss to follow-up, with 167 par-
ticipants enrolled and only 38 completing 18 months' follow-up, al-
though the loss was equal in both groups at the end of follow-up. At
6 months' follow-up there were no episodes of P vivax in the exper-
imental group (0/40) and two recurrences in the standard-regimen
group (2/33) (RR 0.17, 95% CI 0.01 to 3.34; 73 participants; Analy-
sis 4.1), although only about half of enrolled participants were fol-
lowed up at this time point. No further recurrences were described
in either group up to the end of follow-up at 18 months, but as de-
scribed, the high level of unexplained dropout makes interpreta-
tion difficult.
No formal assessment of adverse events was reported, but it is
mentioned in the study narrative that there was no drop in haema-
tocrit or haemoglobinuria in either group.
1.17 mg/kg/day for 3 days versus standard 14-day regimen
One trial delivered the total dose of primaquine (1.17 mg/kg/day or
70 mg adult dose, total dose 210 mg) over 3 days versus the stan-
dard (0.25 mg/kg/day) 14-day regimen (Carmona-Fonseca 2009
COL). Recurrences of P vivax malaria were more common in the
group receiving 1.17 mg/kg/day for 3 days than in the standard 14-
day group at 4 months' follow-up (RR 3.88, 95% CI 2.11 to 7.11; 129
participants; Analysis 5.1).
Adverse events were not reported, although it was noted that there
were no serious adverse events from co-administering primaquine
and chloroquine.
1 mg/kg/day for 7 days versus high-standard 14-day regimen
This comparison aimed to investigate whether shorter, higher dos-
es of primaquine over 7 days are as effective as the high-standard
14-day regimen to determine whether the total dose rather than the
length of treatment is the important factor for East Asia and Ocea-
nia regimen (total dose 420 mg primaquine). Only one included trial
compared 1 mg/kg/day (adult dose 60 mg) of primaquine for 7 days
with the high-standard 14-day course (0.5 mg/kg/day) (Chu 2016
THA), administering the regimen with either chloroquine or an ACT
(4 arms). Results are still awaited, but a conference report of the tri-
al reports that out of 680 participants there was no difference be-
tween the two regimens. No further details are currently available.
D I S C U S S I O N
Summary of main results
High-standard 14-day regimen versus standard 14-day
regimen
See Summary of findings 2
We included 2 RCTs that compared 0.5 mg/kg/day primaquine (dai-
ly adult dose 30 mg) for 14 days with 0.25 mg/kg/day (daily adult
dose 15 mg) for 14 days, both conducted in India. People with G6PD
deficiency and pregnant or lactating women were excluded. One
trial did not account for whether participants were given chloro-
quine or an ACT for blood-stage treatment. We do not know if there
is any difference in P vivax recurrences at 6 months with the high-
standard 14-day course compared to the standard 14-day course
when given with chloroquine (very low-certainty evidence). We do
not know if there is any difference in P vivax relapses at 6 months
with the high-standard 14-day course compared to the standard 14-
day course when given with chloroquine or an ACT (very low-cer-
tainty evidence).
No serious events were reported in either trial. We do not know
whether there is a difference in adverse events between the high-
standard 14-day course and the standard 14-day course (very low-
certainty evidence).
0.5 mg/kg/day for 7 days versus standard 14-day regimen
See Summary of findings for the main comparison
We included 5 RCTs that compared 0.5 mg/kg/day (adult dose 30
mg) primaquine for 7 days with the standard 14-day regimen (0.25
mg/kg/day). There may be little or no difference in P vivax recur-
rences at 6 to 7 months when using the same total dose (210 mg)
over 7 days as compared to 14 days (low-certainty evidence). No
serious adverse events were reported. There may be little or no
difference in the number of adverse events known to occur with
primaquine when using the shorter regimen as compared to the
longer regimen (low-certainty evidence).
We do not know whether there is any difference in the frequency
of anaemia or discontinuation of treatment between groups (very
low-certainty evidence). Three trials excluded people with G6PD
deficiency, and two did not provide this information, so we do not
know the effect of the higher daily dose regimen in this group. Preg-
nant and lactating women were either excluded or this information
was not provided.
Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
19
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
0.75 mg/kg primaquine/week for 8 weeks versus high-
standard 14-day regimen
See Summary of findings 3
We included 1 RCT that compared 0.75 mg/kg (daily adult dose 45
mg) weekly primaquine for 8 weeks with the high-standard 14-day
regimen (0.5 mg/kg/day, daily adult dose 30 mg). G6PD-deficient
participants were not randomized but were included in the week-
ly primaquine group. Only one G6PD-deficient participant was de-
tected during the trial and was included in the weekly group. We do
not know whether weekly primaquine reduces recurrence of P vivax
compared to the high-standard 14-day regimen at 8 to 11 months'
follow-up (very low-certainty evidence).
No serious adverse events and no episodes of anaemia were report-
ed.
Some other included trials evaluated alternative regimens and dos-
es of primaquine, but these regimens have not been widely used,
and the evidence available from stand-alone trials was of very low
certainty.
Overall completeness and applicability of evidence
We initially thought we could evaluate whether the high-standard
14-day regimen (0.5 mg/kg/day) was more effective in all areas
rather than just areas where recommended by the WHO due to
reported resistance or strain differences (East Asia and Oceania)
(WHO 2015). However, we only found two trials that compared
the high standard 14-day regimen to the standard 14-day regimen,
both of which were conducted in India. A recent retrospective case
review in French Guiana (also an area where the high-standard
regimen is not currently recommended) found that recurrences
were similar in both standard and high-standard 14-day regimens
(Valdes 2018). We did not find any RCTs that evaluated whether
the high-standard 14-day regimen was more effective compared to
the standard 14-day regimen for the tropical, frequently relapsing
strain of P vivax in East Asia and Oceania, so we are unable to com-
ment on its efficacy.
A difficulty encountered in including and comparing studies was
the variation in dosing and length of follow-up in studies.
In general, there were few well-conducted RCTs that used an evi-
dence-based standard primaquine regimen (15 mg/kg/day for 14
days) as a comparator. Some trials used the high-standard 0.5 mg/
kg/day for 14 days regimen as a comparator, which is recommend-
ed by the WHO in East Asia and Oceania, which is why we included
these trials. However, there is limited clear evidence in this review
for the increased high-standard 14-day regimen. We found two ran-
domized clinical trials that compared its efficacy to the standard
regimen, both of which were conducted in India (Rajgor 2014 IND;
Saravu 2018 IND), where the regimen is not recommended.
We also found that trials continue to be conducted where place-
bo is used instead of an alternative primaquine regimen, which is
contrary to the evidence available demonstrating its superiority for
reducing recurrences (Galappaththy 2013). This may be because
there is continued reluctance to use primaquine in some national
programmes.
We excluded studies where individuals had mixed malaria infec-
tions so as to assess the efficacy of treatment on P vivax malaria
alone. Areas endemic for P vivax malaria may also be co-endemic
for P falciparum or Plasmodium ovale infection, or both. However,
it should be noted that as part of our screening process we did not
identify any studies where participants with mixed malaria were in-
cluded, so we do not think that narrowing our search criteria im-
pacted the directness of our results.
Although the evidence is currently of low certainty, it does appear
that using 0.5 mg/kg/day with the same total dose (210 mg) over 7
days may be non-inferior to the regimen of 0.25 mg/kg/day for 14
days. It may be that these shorter regimens promote course com-
pletion. Although no serious adverse events were reported due to
few reported events for any other adverse effects, it is difficult to
draw conclusions as to whether there may be increased adverse
events for this higher dosing until more data are available. This
higher-dose regimen was not tested in G6PD-deficient patients in
any of the RCTs meeting our inclusion criteria. This remains a con-
cern in settings where testing is not available.
There was a general lack of detailed safety data for trials, which
is interesting given that safety is a particular concern with pri-
maquine use. Only one included RCT investigated the weekly pri-
maquine regimen that is currently recommended by WHO for
G6PD-deficient individuals, and only one G6PD-deficient partici-
pant was actually included in the treatment group.
Certainty of the evidence
The overall certainty of evidence for all of the outcomes was either
low or very low. All results were downgraded for imprecision due to
wide CIs for all of the meta-analyses performed.
The efficacy comparison for the high-standard 14-day regimen ver-
sus the standard 14-day regimen was also downgraded for indirect-
ness. Results were based on two trials in adults in India (Rajgor 2014
IND; Saravu 2018 IND). Rajgor 2014 IND was at risk of bias as there
was no allocation concealment and unexplained loss to follow-up;
this study also contributed most to the meta-analysis for the com-
parison of 0.5 mg/kg/day for 7 days versus standard 14-day regi-
men, so this study was also downgraded. Saravu 2018 IND was a
small pilot study where participants were given either chloroquine
or an ACT for the blood stage, and which blood-stage treatment
they were given was not stated. Saravu 2018 IND was downgraded
for imprecision, indirectness, and risk of bias (not blinded and high
rate of loss to follow-up).
We downgraded the comparison of 0.75 mg/kg weekly primaquine
versus high-standard 14-day regimen for indirectness as it was
based on just one study conducted in Pakistan (Leslie 2008 PAK),
with only one G6PD-deficient patient participating. Leslie 2008 PAK
was at risk of bias due to the randomization process used, lack of
allocation concealment, and incomplete outcome data. We down-
graded efficacy outcomes for this comparison for serious impreci-
sion due to few events and very wide CIs.
Potential biases in the review process
The strictness of our inclusion criteria to not include trials where
the total dose was less than the total dose of the standard regimen
and the necessity of having the comparison arm be one of the WHO-
recommended regimens may have meant that some relevant com-
parisons were excluded.
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We changed the protocol to include the high-standard 14-day regi-
men that WHO recommends in East Asia and Oceania as a control
regimen, as we realized that some trials had used this as the com-
parator, and we felt that these comparisons were useful. However,
this may have introduced bias, as per our results the evidence base
for RCTs showing the efficacy of this regimen is limited.
The difficulty in determining between relapse and re-infection with
P vivax remains a recognized challenge for assessing the efficacy of
drugs for radical cure.
Agreements and disagreements with other studies or
reviews
Our findings that 210 mg over 7 days may be as efficacious as 210
mg over 14 days are similar to the findings of other systematic re-
views that examined both randomized and non-randomized stud-
ies (Carmona-Fonseca 2015; Zuluaga-Idarraga 2015). Other reviews
also commented on the difficulty of comparing results due to the
varying treatment regimens and length of follow-up used in clinical
trials (John 2012; Carmona-Fonseca 2015; Zuluaga-Idarraga 2015).
A U T H O R S '   C O N C L U S I O N S
Implications for practice
Although limited data were available, no difference was detected
for efficacy between the regimen of 0.5 mg/kg/day for 7 days and
the standard (0.25 mg/kg/day) 14-day regimen in G6PD-normal pa-
tients.
No serious adverse events were reported in G6PD-normal patients
taking 0.5 mg/kg/day of primaquine.
Implications for research
Further high-quality randomized controlled trials are needed with
more standardized comparison regimens and length of follow-up,
in particular investigating the use of the high-standard 14-day reg-
imen, same total dose over 7 days, and weekly regimens in G6PD-
deficient patients. Trials such as IMPROV will help resolve some of
the uncertainties.
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Characteristics of included studies [ordered by study ID]
 
Methods RCT
July 1994 to June 1995
Participants 120 participants enrolled.
Inclusion criteria:
• Confirmed parasitological diagnosis for P vivax malaria.• Age older than 12 years.• Staying in Belém (study area) until the end of the follow-up period (180 days).
Exclusion criteria
• Pregnant and nursing mothers were excluded.• Patients who used antimalarials at least 2 weeks prior to the start of current treatment.• Carriers of mixed malaria.
Diagnosis: microscopy
G6PD status not stated
No details CYP2D6 status.
Interventions • Chloroquine 10 mg/kg single dose + primaquine 0.5 mg/kg/day for 7 days.• Chloroquine 150 mg (25 mg/kg total dose) over 3 days, 10 mg/kg day 1, 7.5 mg/kg days 2 and 3 +
primaquine 15 mg/day 14 days.
(Additional arm chloroquine 10 mg/kg + primaquine 0.5 mg/kg for 5 days not included as total dose
(150 mg) less than standard treatment (210 mg))
Although different doses of chloroquine in the 2 arms, all participants had negative parasitaemia with-
in 72 hours.
Primaquine and chloroquine given concurrently.
Supervised treatment.
Outcomes • Relapse.• Safety.
Abdon 2001 BRA 
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Follow-up 180 days
Notes Location: Belém, state of Pará, Brazil
Setting: not stated
Source of funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No details supplied on randomization process.
Allocation concealment
(selection bias)
Unclear risk No details supplied on allocation.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Open-label.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk One loss to follow-up as moved out of area.
Selective reporting (re-
porting bias)
Low risk Unable to find protocol but relapse and standard errors (SEs) reported as
would be expected.
Other bias Unclear risk Funding not stated.
Abdon 2001 BRA  (Continued)
 
 
Methods RCT
Dates not provided.
Participants 167 participants enrolled.
Inclusion criteria:
• 15 to 60 years.
Exclusion criteria:
• History of previous treatment.• G6PD deficiency.• Mixed infections.
Diagnosis: microscopy
No details on pregnant/breastfeeding women.
Bunnag 1994 THA 
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No details CYP2D6 status.
Interventions • Chloroquine + 22.5 mg/day primaquine for 14 days.• Chloroquine + 15 mg/day primaquine for 14 days.
Open randomization to chloroquine treatment – either 300 mg or 450 mg on day 1 of admission. Re-al-
located after recovery of acute symptoms (double-blind RCT). Chloroquine course completed and para-
sitological clearance confirmed prior to randomization to primaquine group (exact time between treat-
ment courses not specified).
Supervised treatment in hospital.
Outcomes • Relapse.• Safety.
Follow-up 6 months
Notes Location: Thailand
Setting: not stated
Funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk 1st step chloroquine is open randomization, then PQ stage randomized. No de-
tails on randomization process.
Allocation concealment
(selection bias)
Unclear risk No details.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Reported as double-blind.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Reported as double-blind.
Incomplete outcome data
(attrition bias) 
All outcomes
High risk Unexplained high loss to follow-up.
Selective reporting (re-
porting bias)
Unclear risk No protocol.
Other bias Unclear risk Funding not disclosed.
Bunnag 1994 THA  (Continued)
 
 
Methods RCT
September 2003 to September 2006
Carmona-Fonseca 2009 COL 
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Participants 133 patients enrolled across 2 arms (total 188 counting arms not included in review)
Inclusion criteria:
• Age > 2 years.• P vivax parasitaemia of > 1000 asexual forms/L.• Willingness to participate.• A normal quantitative G6PD screening test was required for those administered > 0.25 mg/kg/day pri-
maquine base, and only individuals with normal G6PD levels were included in the study.
Exclusion criteria:
• Pregnant women.• Those with associated acute infectious diseases.• A history of antimalarials intake during the previous 2 weeks.• Presence of diarrhoea or vomiting (> 5 episodes in 24 hours).• Symptoms or signs of severe malaria (according to WHO 2006).• Hypersensitivity to antimalarials or severe undernutrition.• Exclusion from the study also followed intake of any antimalarial different from those provided by the
researchers.• Failure to attend follow-up appointments.• Treatment failure during the primary episode (first 28 days of follow-up).• Consent withdrawal.
Diagnosis: microscopy
No details CYP2D6 status or breastfeeding mothers.
Interventions • Chloroquine (10 mg/kg day 1, 7.5 mg/kg days 2 and 3) + primaquine 1.17 mg/kg/day for 3 days (total
210 mg).• Chloroquine (10 mg/kg day 1, 7.5 mg/kg days 2 and 3) + primaquine 0.25 mg/kg/day for 14 days.
(Additional arms: 0.83 mg/kg day for 3 days (total dose 149.4 mg) and 0.58 mg/kg day for 3 days (total
dose 104.4 mg) not included as total dose less than standard treatment)
Primaquine given simultaneously with chloroquine.
Supervised treatment.
Outcomes • Recurrence of P vivax malaria (parasitaemia after day 28).
Follow-up 120 days
Notes Location: Colombia
Setting: patients that attended the local health clinics in Turbo and El Bagre
Funding: not stated
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk Details of randomization not given.
Allocation concealment
(selection bias)
Unclear risk No details supplied.
Carmona-Fonseca 2009 COL  (Continued)
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Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Not blinded.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk No mention on blinding in blood smear assessment.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 2 lost per group, no explanations given, but less than 5% of total across
groups.
Selective reporting (re-
porting bias)
Unclear risk Protocol not found. No safety data were provided (which might have been ex-
pected to have been provided).
Other bias Low risk Looks like government funding.
Carmona-Fonseca 2009 COL  (Continued)
 
 
Methods RCT
Participants 680 enrolled.
G6PD normal.
No further details
Interventions • Chloroquine + primaquine 7 days (1 mg/kg/day).• Chloroquine + primaquine 14 days (0.5 mg/kg/day).• Dihydroartemisinin-piperaquine + primaquine 7 days (1 mg/kg/day).• Dihydroartemisinin-piperaquine + primaquine 14 days (0.5 mg/kg/day).
No further details
Outcomes • Relapse.
Follow-up: 1 year
Notes Location: Thailand
Setting: no details
Funding: no details
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No details.
Allocation concealment
(selection bias)
Unclear risk No details.
Chu 2016 THA 
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Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Unclear risk No details.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk No details.
Incomplete outcome data
(attrition bias) 
All outcomes
Unclear risk No details.
Selective reporting (re-
porting bias)
Unclear risk No details.
Other bias Unclear risk No details.
Chu 2016 THA  (Continued)
 
 
Methods RCT
March 2006 to August 2008
Participants 360 participants
Inclusion criteria:
• Microscopy-confirmed diagnosis of monoinfection with P vivax between 250 and 100,000 asexual par-
asites/mL (determined by microscopic examination of thick and thin peripheral blood smears).• Fever defined as axillary temperature 37.5 °C or history of fever, or both.• > 1 year old.
Exclusion criteria:
• Pregnant and lactating women.• Patients with chronic illnesses.• Patients with symptoms of severe malaria.• Patients with G6PD deficiency.
Diagnosis: light microscopy
Parasite genotyping with PCR also performed - 5 microsatellite loci used to determine whether homol-
ogous relapse.
Interventions • Chloroquine (10 mg/kg day 1 and 2, 5 mg/kg day 3) + primaquine 0.5 mg/kg/day 7 days.• Chloroquine (10 mg/kg day 1 and 2, 5 mg/kg day 3) + primaquine 0.25 mg/kg/day for 14 days.
(Additional arm of chloroquine + primaquine 0.5 mg/kg/day for 5 days excluded as total dose 150 mg,
which was less than standard treatment.)
Supervised.
Primaquine administered concurrently with chloroquine.
Outcomes • Relapse between days 35 and 210.• Relapses (homologous only).
Durand 2014 PER 
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Follow-up: 210 days
Notes Location: Peru
Setting: Padre Cocha and the San Juan Health Centers and Santa Clara Health Center The periphery of
the city of Iquitos, which is located on the river bank of the Amazon River and is the largest city in the
Peruvian rainforest
Funding: the US Department of Defense Global Emerging Infections Surveillance and Response Sys-
tem (DoD-GEIS), the National Institute of Health of Peru, and the Pan-American Health Organization/US
Agency for International Development (PAHO-USAID) Americas Malaria Initiative/Amazonic Network of
Antimalarial Drug Resistance, AMI/RAVREDA project
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Computer-generated block randomization table.
Allocation concealment
(selection bias)
Low risk The treatment allocation for each participant was placed in a sealed envelope,
kept in an orderly manner, and opened only at the time of enrolment of a new
participant to prevent selection bias by study physicians.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Open-label – no mention of blood smear blinding.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk 8% to 10% loss following randomization, but all accounted for.
Selective reporting (re-
porting bias)
Low risk Study protocol registered. Unable to find outcomes in protocol, but expected
outcomes were reported on.
Other bias Low risk We did not detect any other sources of bias.
Durand 2014 PER  (Continued)
 
 
Methods RCT
September 2004 to July 2006
Participants 129 Afgan refugees
Inclusion criteria:
• Patients diagnosed with P vivax parasitaemia at study basic health units (BHUs).• Patients over 3 years of age.• Patient permanently resident in the village.
Exclusion criteria:
Leslie 2008 PAK 
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• Pregnancy or lactation.• Severe clinical anaemia (7 g/dL).• P falciparum or P vivax (mixed infections), or both.• Intake of any antimalarial drug in the 2 weeks prior to consultation.• Patients unavailable for the duration of follow-up (11 months).• Patients with concomitant infections or disease likely to mask treatment response.
Diagnosis: microscopy
Interventions • Chloroquine (25 mg/kg in divided doses over 3 days) + primaquine 0.75 mg/kg once weekly for 8
weeks.• Chloroquine (25 mg/kg in divided doses over 3 days) + primaquine 0.5 mg/kg/day for 14 days.
(Additional arm chloroquine + weekly placebo not included)
Supervised.
Not specified whether primaquine given concurrently with chloroquine.
Outcomes • P vivax malaria relapse.• The number of subsequent episodes and anaemia rates during and up to 2 weeks post-treatment as
well as any notable adverse events.
Follow-up: 9 months (11 months participation: 8 weeks treatment + 9 months follow-up)
Notes Location: Pakistan
Setting: Adizai, Baghicha, and Khagan villages, close to Peshawar, Northwest Frontier Province, Pak-
istan where Afghan refugees have been resident for more than 20 years
Funding: UNDP/World Bank/WHO Special Program for Research in Tropical Diseases; Gates Malaria
Partnership)
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
High risk Two randomization methods were used. In Baghicha and Khagan villages, par-
ticipants were randomized by household, whereas in Adizai, randomization
was at the individual level. Randomization lists for each village were generat-
ed using a random number list (MS Excel, Microsoft Corp, Seattle, USA) by staE
not involved in patient recruitment. Participants were randomized on enrol-
ment by study staE in the BHUs based on house number or sequential patient
numbers, depending on the study site.
Allocation concealment
(selection bias)
High risk Participants were randomized on enrolment by study staE in the BHUs based
on house number or sequential patient numbers, depending on the study site.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Blood slides were double-read by 2 microscopists working independently, who
were blinded to the other's result.
Incomplete outcome data
(attrition bias) 
High risk Higher loss to follow-up in intervention group (6% to 8% versus 1% to 1.8%).
Leslie 2008 PAK  (Continued)
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All outcomes
Selective reporting (re-
porting bias)
Low risk Trial protocol available, all planned outcomes reported on.
Other bias Low risk We did not detect any other sources of bias.
Leslie 2008 PAK  (Continued)
 
 
Methods RCT
Participants 358 participants
Inclusion criteria:
• Patients of either sex.• Aged between 18 and 65 years.• Body weight > 40 kg.• Microscopically confirmed P vivax malaria with ≥ 1000 asexual parasites/µL of blood.• Axillary temperature ≥ 37.5°C (≥ 99.5°F).• Presence of at least 5 of the following signs and symptoms of uncomplicated malaria: chills, nausea,
vomiting, headache, malaise, diarrhoea, anorexia, abdominal cramps, myalgia, and arthralgia.
Exclusion criteria:
• Mixed malarial infections.• Severe or complicated malaria (as defined by the WHO).• G6PD deficiency.• Any other significant concomitant illness.• Patients with history of dark urine or significant haemoglobinuria related to previous primaquine
treatment or those with history of methaemoglobinaemia.• Patients with protracted vomiting and oliguria.• Those with underlying condition compromising bone marrow function or having a tendency to gran-
ulocytopenia.• Patients taking cardioactive drug or potentially haemolytic drugs or drugs that could interact with
study drugs.• Patients having history of hypersensitivity to any of the study-related drugs.• Those on another investigational drug.• History/presence of substance abuse.• Pregnant or lactating women or women of childbearing potential not using medically accepted means
of birth control.
Diagnosis: microscopy
Interventions • Chloroquine (3-day course, dose not specified) + primaquine 30 mg sustained release 7 days.• Chloroquine (3-day course, dose not specified) + primaquine 15 mg 14 days.
(Additional arm of chloroquine + primaquine 15 mg sustained release for 14 days not included in re-
view)
Primaquine given following completion of chloroquine course.
Not supervised.
Outcomes • Relapse.• Compliance.
Pareek 2015 IND 
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• Safety.
PCR genotyping done to see if true relapse (no details on genotyping method).
Follow-up: 5 months (6 months participation)
Notes Location: India
Setting: multicentre, no details as to centres involved
Funding: funded by drug manufacturer Ipca Laboratories Ltd. Anil Pareek and Nitin Chandurkar are the
employees of Ipca Laboratories Ltd who sponsored this trial.
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Randomization codes were generated using computer-generated block ran-
domization method.
Allocation concealment
(selection bias)
Low risk Patient-specific sealed boxes of medicine were provided to each study site.
(Sequentially numbered, sealed, opaque envelopes (from protocol)).
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
Low risk Double-blind, double-dummy.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk No details as to whether microscopy was blinded or whether there was double
reading of smears.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Loss to follow-up equal between groups. Relapses counted as discontinued
patients, but numbers provided so can be assessed.
Selective reporting (re-
porting bias)
High risk Compliance added as an outcome, but original outcomes also reported on.
Not clear why they have concluded that compliance increased with SR, as par-
ticipants had to take 3 sets of pills as did those who took dummy versions, so
all participants took 3 sets of drugs.
No measurement of levels of PQ (pharmacokinetics), although states that PQ
SR should have therapeutic concentration over 24 hours as part of the con-
cept.
PCR results are not well-detailed.
Other bias High risk The study was sponsored by Ipca Laboratories Ltd, who manufactures the
drugs, and the principal investigators are employees of the company.
Pareek 2015 IND  (Continued)
 
 
Methods RCT
August 2001 to February 2004
Participants 1159 participants enrolled.
Rajgor 2014 IND 
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Inclusion criteria:
• Adult patients, male and female (18 years of age or older).• Peripheral blood smear diagnosis of P vivax.• Willing to undergo hospitalization for the entire duration of primaquine treatment.• Willing to provide informed consent.• Willing to undergo investigations and come for regular follow-up.• Normal G6PD.• Haemoglobin ≥ 10 g/dL.
Exclusion criteria:
• Mixed infection with P falciparum.• Pregnancy and lactation.• Evidence of significant hepatic, renal, or cardiac disease as diagnosed by history, clinical examination,
and laboratory tests whenever necessary.• Any other condition that would interfere with patient’s participation in the study or compliance with
the treatment.
Diagnosis: microscopy
Interventions • Chloroquine (10 mg/kg day 1 and 2, 5 mg/kg day 3) + primaquine 30 mg/day 7 days.• Chloroquine (10 mg/kg day 1 and 2, 5 mg/kg day 3) + primaquine 30 mg/day 14 days.• Chloroquine (10 mg/kg day 1 and 2, 5 mg/kg day 3) + primaquine 15 mg/day 14 days.
(Additional no-primaquine arm not included in analysis)
Supervised treatment.
Primquine treatment commenced after chloroquine treatment (day 4).
Outcomes • Recurrence of vivax malaria.• Safety.
Follow-up: 6 months
The secondary outcome also included comparison of number of participants classified as relapse and
re-infection by the 3 methods to determine the concordance between the methods used and the genet-
ic diversity observed based on PCR sequencing method. The cases of recurrence were classified as re-
lapse or re-infection based on the 3 methods, the month of recurrence, and the 2 genotyping methods:
PCR-RFLP and PCR sequencing.
Notes Location: Mumbai, India
Setting: inpatient assessment in Mumbai
Funding: Indian Council of Medical Research
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk A simple, computer-generated randomization scheme was used for the ran-
domization of participants into the 3 PQ regimen groups.
Allocation concealment
(selection bias)
High risk This was an open-label study, and no concealment of treatment allocation was
followed.
Rajgor 2014 IND  (Continued)
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Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Low risk Although the study was not blinded in terms of treatment administration, the
person seeing the slides and carrying out other outcome assessments was
blinded to the treatment group by coding of the samples.
Incomplete outcome data
(attrition bias) 
All outcomes
High risk High percentage of participants not completing 6 months' follow-up across all
groups. Minimal explanation for discontinuation of participants.
Selective reporting (re-
porting bias)
Unclear risk No registered protocol found - reported on expected outcomes of efficacy and
adverse effects. Trial carried out 2001 to 2004 but not published until 2014.
Other bias Low risk We did not detect any other sources of bias.
Rajgor 2014 IND  (Continued)
 
 
Methods RCT, open-label, pilot study
March 2017 to August 2017
Participants 50 participants enrolled.
Patients presenting to Kasturba Hospital, Manipal and Dr TMA Pai Hospital, Udupi, India
Inclusion criteria:
• P vivax malaria monoinfection.• Age 18 years and over.• Fever > 37.5°C tympanic or oral, or a history of fever within previous 3 days.• Willing to give informed consent.
Exclusion criteria:
• Pregnant or lactating, or both.• Patients with G6PD deficiency.• Mixed infection with P vivax and P falciparum.
Primaquine given after blood-stage treatment.
Diagnosis: microscopy, but PCR also performed to genotype recurrences
No details CYP2D6
Interventions Blood-stage treatment: either CQ or ACT (artesunate with doxycycline or artemether-lumefantrine as
per the treating clinician’s judgement of severity)
• Primaquine 0.5 mg/kg/day for 14 days• Primaquine 0.25 mg/kg/day for 14 days
Drug therapy not supervised.
Outcomes 1. Recurrence
(2. Primaquine levels in the blood at 7 days)
Saravu 2018 IND 
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Follow-up 6 months
Notes Location: Udupi district of Karnataka State, India
Setting: typical tropical climatic conditions. Malaria incidence throughout the year with peaks around
June to July. Urban and rural settings in catchment area.
Source of funding: seed Grant Award from Manipal McGill Center for Infectious Diseases
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Low risk Block randomization – 5 blocks of 10, randomization within each block done
by a lottery method.
Allocation concealment
(selection bias)
Unclear risk No details.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
High risk Open-label.
Incomplete outcome data
(attrition bias) 
All outcomes
High risk High percentage of loss to follow-up by 6 months in both arms – results diffi-
cult to interpret.
Selective reporting (re-
porting bias)
Low risk Outcomes reported as per protocol.
Other bias Low risk Supported by a seed Grant Award from Manipal McGill Center for Infectious
Diseases, MAHE, Manipal.
Saravu 2018 IND  (Continued)
 
 
Methods RCT
October 1998 to January 1999
Participants 60 participants enrolled.
Inclusion criteria:
• Confirmed diagnosis of P vivax malaria (febrile and positive P vivax blood smear).
Exclusion criteria:
• Patients who had received antimalarial medication in the 4 weeks prior to diagnosis.• Children under 5 years.• Patients with severe concomitant diseases.
No details about inclusion/exclusion of G6PD-deficient/pregnant/breastfeeding patients.
Solari-Soto 2002 PER 
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Diagnosis: microscopy
Interventions • Chloroquine (10 mg/kg day 1 and 2, 5 mg/kg day 3) + primaquine 0.25 mg/kg/day for 14 days.• Chloroquine (10 mg/kg day 1 and 2, 5 mg/kg day 3) + primaquine 0.5 mg/kg/day for 7 days.
Directly observed therapy.
Primaquine given after chloroquine course.
Outcomes • Relapse.• Adverse events.
Follow-up: 60 days (total enrolment 60 days)
Notes Location: Peru
Setting: patients treated at San Martín de Pangoa Hospital, Junín
Funding: US Naval Medical Research Institute Detachment
Risk of bias
Bias Authors' judgement Support for judgement
Random sequence genera-
tion (selection bias)
Unclear risk No details on randomization process.
Allocation concealment
(selection bias)
Unclear risk No details on allocation process.
Blinding of participants
and personnel (perfor-
mance bias) 
All outcomes
High risk Open-label.
Blinding of outcome as-
sessment (detection bias) 
All outcomes
Unclear risk Samples double-checked, but no details as to whether blinded.
Incomplete outcome data
(attrition bias) 
All outcomes
Low risk Missing data accounted for, similar in each group.
Selective reporting (re-
porting bias)
Unclear risk No details.
Other bias Low risk We did not detect any other sources of bias.
Solari-Soto 2002 PER  (Continued)
Abbreviations: ACT: artemisinin-based combination therapy; CQ: chloroquine; CYP2D6: cytochrome P450 2D6; G6PD: glucose-6-phosphate
dehydrogenase; PCR: polymerase chain reaction; PCR-RFLP: polymerase chain reaction-restriction fragment length polymorphism; PQ:
primaquine; RCT: randomized controlled trial; SE: standard error; SR: sustained release; WHO: World Health Organization.
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
Adak 2001 No PQ comparison group.
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Study Reason for exclusion
Alvarez 2006 Comparison regimens are of a lower total dose than the control (15 mg/day for 3 days or 7 days) –
shown to be inferior in Galappaththy 2013.
Alvarez Sanchez 2007 Low-dose, shorter regimens of PQ.
Betuela 2012 Only one treatment group received primaquine.
Chu 2017 Wrong outcomes: primary outcome of this analysis was the fractional haematocrit reduction up to
day 14 after enrolment.
Chu 2018 No primaquine comparison arm.
Clyde 1977 Not an RCT, observational single-arm trial.
Contacos 1974 Not an RCT.
da Silva 1984 Not properly randomized (randomized according to whether the end of the notes code is odd or
even), low-dose comparison PQ group.
Gogtay 1999 Low-dose 15 mg for shorter time period (5 days) – shown to be ineffective in Galappaththy 2013.
Goller 2007 Not an RCT – logistic regression using already-published RCTs and observational studies (not pri-
mary trial).
Kim 2012 Wrong comparator: low-dose for 5 days - shown to be ineffective in Galappaththy 2013.
Kimura 1996 Not an RCT.
Krudsood 2008 Artesunate only as blood-stage treatment (does not meet inclusion criteria) and follow-up only 28
days.
Leslie 2004 No PQ comparison group: supervised versus unsupervised therapy.
Leslie 2008b Duplicate of Leslie 2008 PAK; conference abstract title only for session at ASTMH 57th Annual Meet-
ing.
Maneeboonyang 2011 Not randomized, participants were sequentially allocated into either the directly observed thera-
py (DOT) group or the self-administered therapy (SAT) group. No PQ comparison group, supervised
versus non-supervised therapy.
Miller 1974 Not an RCT.
Pasaribu 2013 No PQ comparison group.
Pukrittayakamee 2000 No PQ comparison group.
Sabchareon 1981 No blood-stage antimalarial treatment used in primaquine comparison group according to inclu-
sion criteria.
Saint-Yves IF 1977 Presumptive treatment of 45 mg PQ given to all participants before randomization.
Takeuchi 2010 No PQ comparison group: supervised versus non-supervised therapy.
Villalobos-Salcedo 2000 Wrong comparator: lower dose of PQ in comparison group (total dose 150 mg) - shown to be inef-
fective in Galappaththy 2013.
Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
41
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Study Reason for exclusion
Warrasak 2018 No primaquine comparison arm, ophthalmological outcomes.
Abbreviations: PQ: primaquine; RCT: randomized controlled trial.
 
Characteristics of ongoing studies [ordered by study ID]
 
Trial name or title Improving the radical cure of vivax malaria: a multicentre randomised comparison of short and
long course primaquine regimens
Methods RCT, multicentre
Participant, care provider, and investigator blinding
Participants Aged 6 months and older.
Inclusion criteria:
• Participant (or parent/guardian of children below age of consent) is willing and able to give written
informed consent to participate in the trial; verbal consent in the presence of a literate witness
is required for illiterate patients. In addition, written assent (or verbal assent in the presence of a
literate witness for illiterates) from children 12 to 17 years as per local practice.• Monoinfection with P vivax of any parasitaemia in countries that use chloroquine as blood sch-
izonticidal therapy. Mixed infections with P vivax and P falciparum can be enrolled in countries
that use an artemisinin combination therapy.• Diagnosis based on rapid diagnostic tests.• Over 6 months of age.• Weight 5 kg or greater.• Fever (axillary temperature 37.5°C) or history of fever in the last 48 hours.• Able (in the investigator's opinion) and willing to comply with the study requirements and fol-
low-up.
Exclusion criteria:
• Female participant who is pregnant, lactating, or planning pregnancy during the course of the
study.• Inability to tolerate oral treatment.• Previous episode of haemolysis or severe haemoglobinuria following primaquine.• Signs/symptoms indicative of severe/complicated malaria or warning signs requiring parenteral
treatment - haemoglobin concentration less than 9 g/dL.• Known hypersensitivity or allergy to the study drugs.• Blood transfusion in last 90 days, since this can mask G6PD-deficient status.• A febrile condition due to diseases other than malaria (for example, measles, acute lower respira-
tory tract infection, severe diarrhoea with dehydration).• Presence of any condition which in the judgement of the investigator would place the participant
at undue risk or interfere with the results of the study (for example, serious underlying cardiac,
renal, or hepatic disease; severe malnutrition; HIV/AIDS; or severe febrile condition other than
malaria); co-administration of other medication known to cause haemolysis or that could inter-
fere with the assessment of antimalarial regimens.• Currently taking medication known to interfere significantly with the pharmacokinetics of pri-
maquine and the schizonticidal study drugs.• Prior antimalarial medications in the previous 7 days.
Locations: Afghanistan, Ethiopia, Indonesia, Vietnam
NCT01814683 
Primaquine at alternative dosing schedules for preventing relapse in people with Plasmodium vivax malaria (Review)
Copyright © 2019 The Authors. Cochrane Database of Systematic Reviews published by John Wiley & Sons, Ltd. on behalf of The Cochrane
Collaboration.
42
Cochrane
Library
Trusted evidence.
Informed decisions.
Better health.
 
 
Cochrane Database of Systematic Reviews
Estimated enrolment: 3150 participants
Interventions 1. Standard blood schizonticidal therapy plus 7 days of supervised primaquine (7 mg/kg total dose)
administered once per day (1.0 mg/kg once daily) followed by 7 days of placebo
2. Standard blood schizonticidal therapy plus 14 days of supervised primaquine (7 mg/kg total
dose) administered once per day (0.5 mg/kg)
(3. Standard blood schizonticidal therapy plus 14 days placebo)
Outcomes • Incidence rate (per person-year) and risk of symptomatic recurrent P vivax [Time Frame: 12
months]. The incidence rate (that is, per person-year) of symptomatic recurrent P vivax para-
sitaemia (detected by microscopy) over 12 months of follow-up in the 7- versus 14-day primaquine
groups for all sites combined and stratified by site• Incidence rate (per person-year) of recurrent P vivax parasitaemia; haematological recovery; seri-
ous adverse drug reaction, primaquine tolerability, risk of severe anaemia in G6PD-deficient arm,
cost-effective analysis with respect to the use of G6PD tests
Starting date July 2014
Contact information Ric Price, University of Oxford; ric.price@ndm.ox.ac.uk
Notes Esimated completion date: December 2019
Protocol published (see IMPROV Study Group 2015; listed under NCT01814683)
clinicaltrials.gov/ct2/show/NCT01814683
NCT01814683  (Continued)
 
 
Trial name or title Evaluation of safety and efficacy of two primaquine dosing regimens for the radical treatment of
Plasmodium vivax malaria in Vanuatu and Solomon Islands
Methods RCT, open-label
Participants Children and adults aged 12 months to 60 years. Solomon Islands and Vanuatu.
Inclusion criteria:
• Age 12 months to 60 years.• Melanesian background and living in local area.• Microscopically (based on field microscopy) or RDT-confirmed P vivax regardless of parasite den-
sity. Mixed infections (P falciparum-P vivax and P malariae-P vivax) can be included.
Exclusion criteria:
• Any signs of severe malaria (see WHO definitions) including: impaired consciousness, respirato-
ry distress, severe anaemia (haemoglobin < 5), multiple seizures, frequent vomiting/inability to
swallow tablets, prostration, jaundice, hypotension, abnormal bleeding, or hypoglycaemia.• Clinical evidence of non-malarial illness (such as pneumonia or otitis media).• Severe malnutrition (weight-for-age nutritional Z score < 60th percentile).• Permanent disability that prevents or impedes study participation.• Treatment with primaquine in the previous 14 days.• Residence or planned travel outside the study area during the follow-up period (precluding su-
pervised treatment and follow-up procedures).• Known or suspected pregnancy.• Currently breastfeeding.
NCT01837992 
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• A positive rapid test for G6PD deficiency (Binax or Carestart RDT).
Interventions 1. Primaquine dose of 0.5 mg/kg/day for 14 consecutive days and standard age-based dosage 3-
day course of artemether-lumefantrine
2. Primaquine dose of 0.25 mg/kg for 14 consecutive days and standard age-based dosage 3-day
course of artemether-lumefantrine
(3. Participants will receive a standard 3-day treatment course of artemether-lumefantrine at the
standard age-based dosage, but will not receive primaquine until the time of confirmed recurrent
parasitaemia or completion of 3 months follow-up)
Outcomes • Efficacy: numbers of P vivax relapses per person-years of follow-up [Time Frame: 12 months].
Total number of microscopically diagnosed (including both symptomatic and asymptomatic in-
fections), PCR-confirmed relapses with P vivax in participants in each treatment arm over the 3-
month follow-up period, expressed as number of relapses per person-years of follow-up.• Safety and toxicity: mild, moderate, and severe adverse events, haemolysis, methaemoglobi-
naemia.
Starting date May 2013
Contact information Dr Ivo Mueller; mueller@wehi.edu.au
Notes Estimated completion date May 2015. Contacted for results - no response.
Protocol available at clinicaltrials.gov/ct2/show/NCT01837992
NCT01837992  (Continued)
Abbreviations: G6PD: glucose-6-phosphate dehydrogenase; RCT: randomized controlled trial; RDT: rapid diagnostic test; WHO: World
Health Organization.
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   High-standard 14-day regimen versus standard 14-day regimen
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Recurrence at 6 months' follow-up 2   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 6 months (chloroquine blood-
stage treatment)
1 639 Risk Ratio (M-H, Fixed, 95% CI) 0.82 [0.47, 1.43]
1.2 6 months (chloroquine or ACT
blood-stage treatment)
1 38 Risk Ratio (M-H, Fixed, 95% CI) 1.11 [0.17, 7.09]
2 Recurrence (PCR-adjusted) 1   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1 6 to 7 months 1 639 Risk Ratio (M-H, Fixed, 95% CI) 1.83 [0.62, 5.40]
3 Serious adverse effects 1 778 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
4 Adverse events that result in dis-
continuation of treatment
1 778 Risk Ratio (M-H, Fixed, 95% CI) 4.19 [0.90, 19.60]
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Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
5 Adverse effects known to occur
with primaquine
1 778 Risk Ratio (M-H, Fixed, 95% CI) 2.72 [0.98, 7.57]
6 Adverse events known to occur
with chloroquine
1 778 Risk Ratio (M-H, Fixed, 95% CI) 9.43 [0.51, 174.47]
 
 
Analysis 1.1.   Comparison 1 High-standard 14-day regimen versus
standard 14-day regimen, Outcome 1 Recurrence at 6 months' follow-up.
Study or subgroup 0.5mg/kg/
day PQ 14 days
0.25mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
1.1.1 6 months (chloroquine blood-stage treatment)  
Rajgor 2014 IND 21/317 26/322 100% 0.82[0.47,1.43]
Subtotal (95% CI) 317 322 100% 0.82[0.47,1.43]
Total events: 21 (0.5mg/kg/day PQ 14 days), 26 (0.25mg/kg/day PQ 14
days)
 
Heterogeneity: Not applicable  
Test for overall effect: Z=0.7(P=0.48)  
   
1.1.2 6 months (chloroquine or ACT blood-stage treatment)  
Saravu 2018 IND 2/18 2/20 100% 1.11[0.17,7.09]
Subtotal (95% CI) 18 20 100% 1.11[0.17,7.09]
Total events: 2 (0.5mg/kg/day PQ 14 days), 2 (0.25mg/kg/day PQ 14 days)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.11(P=0.91)  
Test for subgroup differences: Chi2=0.09, df=1 (P=0.76), I2=0%  
Favours 0.5mg/kg/day PQ 14 days 1000.01 100.1 1 Favours 0.25mg/kg/day PQ 14 days
 
 
Analysis 1.2.   Comparison 1 High-standard 14-day regimen versus
standard 14-day regimen, Outcome 2 Recurrence (PCR-adjusted).
Study or subgroup 0.5mg/kg/
day PQ 14 days
0.25mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
1.2.1 6 to 7 months  
Rajgor 2014 IND 9/317 5/322 100% 1.83[0.62,5.4]
Subtotal (95% CI) 317 322 100% 1.83[0.62,5.4]
Total events: 9 (0.5mg/kg/day PQ 14 days), 5 (0.25mg/kg/day PQ 14 days)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.09(P=0.27)  
Favours 0.5mg/kg/day PQ 14 days 1000.01 100.1 1 Favours 0.25mg/kg/day PQ 14 days
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Analysis 1.3.   Comparison 1 High-standard 14-day regimen versus
standard 14-day regimen, Outcome 3 Serious adverse eBects.
Study or subgroup 0.5mg/kg/
day PQ 14 days
0.25mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Rajgor 2014 IND 0/380 0/398   Not estimable
   
Total (95% CI) 380 398 Not estimable
Total events: 0 (0.5mg/kg/day PQ 14 days), 0 (0.25mg/kg/day PQ 14 days)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours 0.5mg/kg/day PQ 14 days 1000.01 100.1 1 Favours 0.25mg/kg/day PQ 14 days
 
 
Analysis 1.4.   Comparison 1 High-standard 14-day regimen versus standard 14-
day regimen, Outcome 4 Adverse events that result in discontinuation of treatment.
Study or subgroup 0.5mg/kg/
day PQ 14 days
0.25mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Rajgor 2014 IND 8/380 2/398 100% 4.19[0.9,19.6]
   
Total (95% CI) 380 398 100% 4.19[0.9,19.6]
Total events: 8 (0.5mg/kg/day PQ 14 days), 2 (0.25mg/kg/day PQ 14 days)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.82(P=0.07)  
Favours 0.5mg/kg/day PQ 14 days 1000.01 100.1 1 Favours 0.25mg/kg/day PQ 14 days
 
 
Analysis 1.5.   Comparison 1 High-standard 14-day regimen versus standard 14-
day regimen, Outcome 5 Adverse eBects known to occur with primaquine.
Study or subgroup 0.5mg/kg/
day PQ 14 days
0.25mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Rajgor 2014 IND 13/380 5/398 100% 2.72[0.98,7.57]
   
Total (95% CI) 380 398 100% 2.72[0.98,7.57]
Total events: 13 (0.5mg/kg/day PQ 14 days), 5 (0.25mg/kg/day PQ 14 days)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.92(P=0.05)  
Favours 0.5mg/kg/day PQ 14 days 1000.01 100.1 1 Favours 0.25mg/kg/day PQ 14 days
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Analysis 1.6.   Comparison 1 High-standard 14-day regimen versus standard 14-
day regimen, Outcome 6 Adverse events known to occur with chloroquine.
Study or subgroup 0.5mg/kg/
day PQ 14 days
0.25mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Rajgor 2014 IND 4/380 0/398 100% 9.43[0.51,174.47]
   
Total (95% CI) 380 398 100% 9.43[0.51,174.47]
Total events: 4 (0.5mg/kg/day PQ 14 days), 0 (0.25mg/kg/day PQ 14 days)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.51(P=0.13)  
Favours 0.5mg/kg/day PQ 14 days 1000.01 100.1 1 Favours 0.25mg/kg/day PQ 14 days
 
 
Comparison 2.   0.5 mg/kg/day for 7 days versus standard 14-day regimen
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Recurrence by 6 to 7 months' fol-
low-up
4 1211 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.66, 1.39]
2 Recurrence by 6 to 7 months' fol-
low-up (PCR-adjusted)
2   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
3 Recurrence by 6 to 7 months sub-
grouped by geographical region
4 1211 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.66, 1.39]
3.1 South America 2 397 Risk Ratio (M-H, Fixed, 95% CI) 0.70 [0.39, 1.26]
3.2 Asia 2 814 Risk Ratio (M-H, Fixed, 95% CI) 1.19 [0.73, 1.94]
4 Recurrence by 6 to 7 months sub-
grouped by directly observed thera-
py (DOT) versus non-DOT
4 1211 Risk Ratio (M-H, Fixed, 95% CI) 0.96 [0.66, 1.39]
4.1 DOT 3 1017 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.67, 1.43]
4.2 Non-DOT 1 194 Risk Ratio (M-H, Fixed, 95% CI) 0.48 [0.04, 5.20]
5 Serious adverse effects 5 1427 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
6 Adverse events that result in dis-
continuation of treatment
5 1427 Risk Ratio (M-H, Fixed, 95% CI) 1.04 [0.15, 7.38]
7 Adverse effects known to occur
with primaquine
4 1154 Risk Ratio (M-H, Fixed, 95% CI) 1.06 [0.64, 1.76]
8 Anaemia or change in haemoglo-
bin status
1 240 Risk Ratio (M-H, Fixed, 95% CI) 3.0 [0.12, 72.91]
9 Adverse events known to occur
with chloroquine
1 779 Risk Ratio (M-H, Fixed, 95% CI) 9.40 [0.51, 174.01]
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Analysis 2.1.   Comparison 2 0.5 mg/kg/day for 7 days versus standard
14-day regimen, Outcome 1 Recurrence by 6 to 7 months' follow-up.
Study or subgroup 0.5mg/kg/
day PQ 7 days
0.25mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Abdon 2001 BRA 0/39 2/40 4.83% 0.21[0.01,4.14]
Durand 2014 PER 16/156 22/162 42.25% 0.76[0.41,1.38]
Pareek 2015 IND 1/99 2/95 4% 0.48[0.04,5.2]
Rajgor 2014 IND 30/298 26/322 48.92% 1.25[0.76,2.06]
   
Total (95% CI) 592 619 100% 0.96[0.66,1.39]
Total events: 47 (0.5mg/kg/day PQ 7 days), 52 (0.25mg/kg/day PQ 14 days)  
Heterogeneity: Tau2=0; Chi2=2.99, df=3(P=0.39); I2=0%  
Test for overall effect: Z=0.23(P=0.82)  
Favours 0.5mg/kg/day PQ 7 days 1000.01 100.1 1 Favours 0.25mg/kg/day PQ 14 days
 
 
Analysis 2.2.   Comparison 2 0.5 mg/kg/day for 7 days versus standard 14-day
regimen, Outcome 2 Recurrence by 6 to 7 months' follow-up (PCR-adjusted).
Study or subgroup 0.5mg/kg/
day PQ 7 days
0.25mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Durand 2014 PER 8/156 12/162 0% 0.69[0.29,1.65]
Rajgor 2014 IND 12/298 5/322 0% 2.59[0.92,7.27]
Favours 0.5mg/kg/day PQ 7 days 1000.01 100.1 1 Favours 0.25mg/kg/day PQ 14 days
 
 
Analysis 2.3.   Comparison 2 0.5 mg/kg/day for 7 days versus standard 14-day
regimen, Outcome 3 Recurrence by 6 to 7 months subgrouped by geographical region.
Study or subgroup 0.5mg/kg/
day PQ 7 days
0.25mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
2.3.1 South America  
Abdon 2001 BRA 0/39 2/40 4.83% 0.21[0.01,4.14]
Durand 2014 PER 16/156 22/162 42.25% 0.76[0.41,1.38]
Subtotal (95% CI) 195 202 47.08% 0.7[0.39,1.26]
Total events: 16 (0.5mg/kg/day PQ 7 days), 24 (0.25mg/kg/day PQ 14 days)  
Heterogeneity: Tau2=0; Chi2=0.7, df=1(P=0.4); I2=0%  
Test for overall effect: Z=1.19(P=0.23)  
   
2.3.2 Asia  
Pareek 2015 IND 1/99 2/95 4% 0.48[0.04,5.2]
Rajgor 2014 IND 30/298 26/322 48.92% 1.25[0.76,2.06]
Subtotal (95% CI) 397 417 52.92% 1.19[0.73,1.94]
Total events: 31 (0.5mg/kg/day PQ 7 days), 28 (0.25mg/kg/day PQ 14 days)  
Heterogeneity: Tau2=0; Chi2=0.59, df=1(P=0.44); I2=0%  
Test for overall effect: Z=0.69(P=0.49)  
Favours 0.5mg/kg/day PQ 1000.01 100.1 1 Favours 0.25mg/kg/day PQ
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Study or subgroup 0.5mg/kg/
day PQ 7 days
0.25mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
   
Total (95% CI) 592 619 100% 0.96[0.66,1.39]
Total events: 47 (0.5mg/kg/day PQ 7 days), 52 (0.25mg/kg/day PQ 14 days)  
Heterogeneity: Tau2=0; Chi2=2.99, df=3(P=0.39); I2=0%  
Test for overall effect: Z=0.23(P=0.82)  
Test for subgroup differences: Chi2=1.86, df=1 (P=0.17), I2=46.1%  
Favours 0.5mg/kg/day PQ 1000.01 100.1 1 Favours 0.25mg/kg/day PQ
 
 
Analysis 2.4.   Comparison 2 0.5 mg/kg/day for 7 days versus standard 14-day regimen, Outcome
4 Recurrence by 6 to 7 months subgrouped by directly observed therapy (DOT) versus non-DOT.
Study or subgroup 0.5 mg/kg/
day PQ 7 days
0.25 mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
2.4.1 DOT  
Abdon 2001 BRA 0/39 2/40 4.83% 0.21[0.01,4.14]
Durand 2014 PER 16/156 22/162 42.25% 0.76[0.41,1.38]
Rajgor 2014 IND 30/298 26/322 48.92% 1.25[0.76,2.06]
Subtotal (95% CI) 493 524 96% 0.98[0.67,1.43]
Total events: 46 (0.5 mg/kg/day PQ 7 days), 50 (0.25 mg/kg/day PQ 14
days)
 
Heterogeneity: Tau2=0; Chi2=2.64, df=2(P=0.27); I2=24.28%  
Test for overall effect: Z=0.12(P=0.91)  
   
2.4.2 Non-DOT  
Pareek 2015 IND 1/99 2/95 4% 0.48[0.04,5.2]
Subtotal (95% CI) 99 95 4% 0.48[0.04,5.2]
Total events: 1 (0.5 mg/kg/day PQ 7 days), 2 (0.25 mg/kg/day PQ 14 days)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.6(P=0.55)  
   
Total (95% CI) 592 619 100% 0.96[0.66,1.39]
Total events: 47 (0.5 mg/kg/day PQ 7 days), 52 (0.25 mg/kg/day PQ 14
days)
 
Heterogeneity: Tau2=0; Chi2=2.99, df=3(P=0.39); I2=0%  
Test for overall effect: Z=0.23(P=0.82)  
Test for subgroup differences: Chi2=0.33, df=1 (P=0.56), I2=0%  
Favours 0.5mg/kg/day PQ 1000.01 100.1 1 Favours 0.25mg/kg/day PQ
 
 
Analysis 2.5.   Comparison 2 0.5 mg/kg/day for 7 days versus
standard 14-day regimen, Outcome 5 Serious adverse eBects.
Study or subgroup 0.5mg/kg/
day PQ 7 days
0.25mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Abdon 2001 BRA 0/40 0/40   Not estimable
Durand 2014 PER 0/156 0/162   Not estimable
Favours 0.5mg/kg/day PQ 7 days 1000.01 100.1 1 Favours 0.25mg/kg/day PQ 14 days
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Study or subgroup 0.5mg/kg/
day PQ 7 days
0.25mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Pareek 2015 IND 0/99 0/95   Not estimable
Rajgor 2014 IND 0/381 0/398   Not estimable
Solari-Soto 2002 PER 0/28 0/28   Not estimable
   
Total (95% CI) 704 723 Not estimable
Total events: 0 (0.5mg/kg/day PQ 7 days), 0 (0.25mg/kg/day PQ 14 days)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours 0.5mg/kg/day PQ 7 days 1000.01 100.1 1 Favours 0.25mg/kg/day PQ 14 days
 
 
Analysis 2.6.   Comparison 2 0.5 mg/kg/day for 7 days versus standard 14-day
regimen, Outcome 6 Adverse events that result in discontinuation of treatment.
Study or subgroup 0.5mg/kg/
day PQ 7 days
0.25mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Abdon 2001 BRA 0/40 0/40   Not estimable
Durand 2014 PER 0/156 0/162   Not estimable
Pareek 2015 IND 0/99 0/95   Not estimable
Rajgor 2014 IND 2/381 2/398 100% 1.04[0.15,7.38]
Solari-Soto 2002 PER 0/28 0/28   Not estimable
   
Total (95% CI) 704 723 100% 1.04[0.15,7.38]
Total events: 2 (0.5mg/kg/day PQ 7 days), 2 (0.25mg/kg/day PQ 14 days)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.04(P=0.97)  
Favours 0.5mg/kg/day PQ 7 days 1000.01 100.1 1 Favours 0.25mg/kg/day PQ 14 days
 
 
Analysis 2.7.   Comparison 2 0.5 mg/kg/day for 7 days versus standard 14-
day regimen, Outcome 7 Adverse eBects known to occur with primaquine.
Study or subgroup 0.5mg/kg/
day PQ 7 days
0.25mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Abdon 2001 BRA 6/39 11/40 42.18% 0.56[0.23,1.36]
Pareek 2015 IND 11/120 10/120 38.83% 1.1[0.49,2.49]
Rajgor 2014 IND 10/381 5/398 18.99% 2.09[0.72,6.06]
Solari-Soto 2002 PER 0/28 0/28   Not estimable
   
Total (95% CI) 568 586 100% 1.06[0.64,1.76]
Total events: 27 (0.5mg/kg/day PQ 7 days), 26 (0.25mg/kg/day PQ 14 days)  
Heterogeneity: Tau2=0; Chi2=3.54, df=2(P=0.17); I2=43.55%  
Test for overall effect: Z=0.22(P=0.82)  
Favours 0.5mg/kg/day PQ 7 days 1000.01 100.1 1 Favours 0.25mg/kg/day PQ 14 days
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Analysis 2.8.   Comparison 2 0.5 mg/kg/day for 7 days versus standard 14-
day regimen, Outcome 8 Anaemia or change in haemoglobin status.
Study or subgroup 0.5mg/kg/
day PQ 7 days
0.25mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Pareek 2015 IND 1/120 0/120 100% 3[0.12,72.91]
   
Total (95% CI) 120 120 100% 3[0.12,72.91]
Total events: 1 (0.5mg/kg/day PQ 7 days), 0 (0.25mg/kg/day PQ 14 days)  
Heterogeneity: Not applicable  
Test for overall effect: Z=0.67(P=0.5)  
Favours 0.5mg/kg/day PQ 7 days 1000.01 100.1 1 Favours 0.25mg/kg/day PQ 14 days
 
 
Analysis 2.9.   Comparison 2 0.5 mg/kg/day for 7 days versus standard 14-
day regimen, Outcome 9 Adverse events known to occur with chloroquine.
Study or subgroup 0.5mg/kg/
day PQ 7 days
0.25mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Rajgor 2014 IND 4/381 0/398 100% 9.4[0.51,174.01]
   
Total (95% CI) 381 398 100% 9.4[0.51,174.01]
Total events: 4 (0.5mg/kg/day PQ 7 days), 0 (0.25mg/kg/day PQ 14 days)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.5(P=0.13)  
Favours 0.5mg/kg/day PQ 7 days 1000.01 100.1 1 Favours 0.25mg/kg/day PQ 14 days
 
 
Comparison 3.   0.75 mg/kg primaquine/week for 8 weeks versus high-standard 14-day regimen
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Recurrence 1   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 5 months 1 129 Risk Ratio (M-H, Fixed, 95% CI) 5.23 [0.28, 99.15]
1.2 8 months 1 126 Risk Ratio (M-H, Fixed, 95% CI) 7.0 [0.38, 127.32]
1.3 11 months 1 122 Risk Ratio (M-H, Fixed, 95% CI) 3.18 [0.37, 27.60]
2 Serious adverse effects 1 129 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
3 Anaemia (haemoglobin < 7 g/
dL)
1 129 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
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Analysis 3.1.   Comparison 3 0.75 mg/kg primaquine/week for 8
weeks versus high-standard 14-day regimen, Outcome 1 Recurrence.
Study or subgroup 0.75mg/kg PQ
weekly 8wks
0.5mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
3.1.1 5 months  
Leslie 2008 PAK 3/74 0/55 100% 5.23[0.28,99.15]
Subtotal (95% CI) 74 55 100% 5.23[0.28,99.15]
Total events: 3 (0.75mg/kg PQ weekly 8wks), 0 (0.5mg/kg/day PQ 14 days)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.1(P=0.27)  
   
3.1.2 8 months  
Leslie 2008 PAK 4/71 0/55 100% 7[0.38,127.32]
Subtotal (95% CI) 71 55 100% 7[0.38,127.32]
Total events: 4 (0.75mg/kg PQ weekly 8wks), 0 (0.5mg/kg/day PQ 14 days)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.31(P=0.19)  
   
3.1.3 11 months  
Leslie 2008 PAK 4/68 1/54 100% 3.18[0.37,27.6]
Subtotal (95% CI) 68 54 100% 3.18[0.37,27.6]
Total events: 4 (0.75mg/kg PQ weekly 8wks), 1 (0.5mg/kg/day PQ 14 days)  
Heterogeneity: Not applicable  
Test for overall effect: Z=1.05(P=0.29)  
Test for subgroup differences: Chi2=0.2, df=1 (P=0.91), I2=0%  
Favours 0.75mg/kg PQ weekly 8wks 1000.01 100.1 1 Favours 0.5mg/kg/day PQ 14 days
 
 
Analysis 3.2.   Comparison 3 0.75 mg/kg primaquine/week for 8 weeks
versus high-standard 14-day regimen, Outcome 2 Serious adverse eBects.
Study or subgroup 0.75mg/kg PQ
weekly 8wks
0.5mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Leslie 2008 PAK 0/74 0/55   Not estimable
   
Total (95% CI) 74 55 Not estimable
Total events: 0 (0.75mg/kg PQ weekly 8wks), 0 (0.5mg/kg/day PQ 14 days)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours 0.75mg/kg PQ weekly 8wks 1000.01 100.1 1 Favours 0.5mg/kg/day PQ 14 days
 
 
Analysis 3.3.   Comparison 3 0.75 mg/kg primaquine/week for 8 weeks versus
high-standard 14-day regimen, Outcome 3 Anaemia (haemoglobin < 7 g/dL).
Study or subgroup 0.75mg/kg PQ
weekly 8wks
0.5mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Leslie 2008 PAK 0/74 0/55   Not estimable
Favours 0.75mg/kg PQ weekly 8wks 1000.01 100.1 1 Favours 0.5mg/kg/day PQ 14 days
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Study or subgroup 0.75mg/kg PQ
weekly 8wks
0.5mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
   
Total (95% CI) 74 55 Not estimable
Total events: 0 (0.75mg/kg PQ weekly 8wks), 0 (0.5mg/kg/day PQ 14 days)  
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Favours 0.75mg/kg PQ weekly 8wks 1000.01 100.1 1 Favours 0.5mg/kg/day PQ 14 days
 
 
Comparison 4.   0.375 mg/kg/day primaquine for 14 days versus standard 14-day regimen
Outcome or subgroup title No. of
studies
No. of
partici-
pants
Statistical method Effect size
1 Recurrence 1   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
1.1 6 months' follow-up 1 73 Risk Ratio (M-H, Fixed, 95% CI) 0.17 [0.01, 3.34]
1.2 12 months' follow-up 1 49 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
1.3 18 months' follow-up 1 38 Risk Ratio (M-H, Fixed, 95% CI) 0.0 [0.0, 0.0]
 
 
Analysis 4.1.   Comparison 4 0.375 mg/kg/day primaquine for 14
days versus standard 14-day regimen, Outcome 1 Recurrence.
Study or subgroup 0.375mg/kg/
day PQ 14 days
0.25mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
4.1.1 6 months' follow-up  
Bunnag 1994 THA 0/40 2/33 100% 0.17[0.01,3.34]
Subtotal (95% CI) 40 33 100% 0.17[0.01,3.34]
Total events: 0 (0.375mg/kg/day PQ 14 days), 2 (0.25mg/kg/day PQ 14
days)
 
Heterogeneity: Not applicable  
Test for overall effect: Z=1.17(P=0.24)  
   
4.1.2 12 months' follow-up  
Bunnag 1994 THA 0/24 0/25   Not estimable
Subtotal (95% CI) 24 25 Not estimable
Total events: 0 (0.375mg/kg/day PQ 14 days), 0 (0.25mg/kg/day PQ 14
days)
 
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
   
4.1.3 18 months' follow-up  
Bunnag 1994 THA 0/19 0/19   Not estimable
Subtotal (95% CI) 19 19 Not estimable
Total events: 0 (0.375mg/kg/day PQ 14 days), 0 (0.25mg/kg/day PQ 14
days)
 
Favours 0.375mg/kg/day PQ 14 days 1000.01 100.1 1 Favours 0.25mg/kg/day PQ 14 days
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Study or subgroup 0.375mg/kg/
day PQ 14 days
0.25mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Heterogeneity: Not applicable  
Test for overall effect: Not applicable  
Test for subgroup differences: Not applicable  
Favours 0.375mg/kg/day PQ 14 days 1000.01 100.1 1 Favours 0.25mg/kg/day PQ 14 days
 
 
Comparison 5.   1.17 mg/kg/day primaquine for 3 days versus standard 14-day regimen; follow-up 4 months
Outcome or subgroup title No. of
studies
No. of partici-
pants
Statistical method Effect size
1 Recurrence 1 129 Risk Ratio (M-H, Fixed, 95% CI) 3.88 [2.11, 7.11]
 
 
Analysis 5.1.   Comparison 5 1.17 mg/kg/day primaquine for 3 days versus
standard 14-day regimen; follow-up 4 months, Outcome 1 Recurrence.
Study or subgroup 1.17mg/kg/
day PQ 3 days
0.25mg/kg/
day PQ 14 days
Risk Ratio Weight Risk Ratio
  n/N n/N M-H, Fixed, 95% CI   M-H, Fixed, 95% CI
Carmona-Fonseca 2009 COL 37/63 10/66 100% 3.88[2.11,7.11]
   
Total (95% CI) 63 66 100% 3.88[2.11,7.11]
Total events: 37 (1.17mg/kg/day PQ 3 days), 10 (0.25mg/kg/day PQ 14
days)
 
Heterogeneity: Not applicable  
Test for overall effect: Z=4.37(P<0.0001)  
Favours 1.17mg/kg/day PQ 3 days 1000.01 100.1 1 Favours 0.25mg/kg/day PQ 14 days
 
 
A D D I T I O N A L   T A B L E S
 
Objective Intervention Control
Are higher doses (0.5
mg/kg/day or 30 mg/
day primaquine for 14
days) more effective in
all areas, or only in areas
where they are standard
treatment (East Asia and
Oceania)?
Blood-stage antimalarial drug with pri-
maquine 0.5 mg/kg/day (adult dose 30
mg) for 14 days (total dose 420 mg).
Both intervention and control groups
must have received the same treatment
for the blood-borne stage of infection,
that is, either CQ or ACT.
Blood-stage antimalarial drug with standard 14-day course
primaquine (0.25 mg/kg/day, adult dose 15 mg, total dose
210 mg).
Both intervention and control groups must have received the
same treatment for the blood-borne stage of infection, that
is, either CQ or ACT.
Are shorter, higher-dose
regimens of primaquine
over 7 days as effective
as treatment over 14
days (is the total dose
Blood-stage antimalarial drug with pri-
maquine 0.5 mg/kg/day (adult dose 30
mg) for 7 days (total dose 210 mg) or 1
mg/kg/day (adult dose 60 mg) for 7 days
(total dose 420 mg).
Blood-stage antimalarial drug with standard 14-day course
primaquine (0.25 mg/kg/day, adult dose 15 mg, total dose
210 mg) or high-standard 14-day course primaquine (0.5 mg/
kg/day, adult dose 30 mg, total dose 420 mg).
Table 1.   Data extraction: grouping of comparisons to address the review's objectives 
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rather than the length of
treatment the important
factor)?
Both intervention and control groups
must have received the same treatment
for the blood-borne stage of infection,
that is, either CQ or ACT.
Both intervention and control groups must have received the
same treatment for the blood-borne stage of infection, that
is, either CQ or ACT.
Are weekly dosing regi-
mens (0.75 mg/kg/week
or 45 mg/week for 8
weeks) as effective?
Blood-stage antimalarial drug with pri-
maquine 0.75/kg (45 mg) per week for 8
weeks (total dose 360 mg)
Blood-stage antimalarial drug with standard 14-day course
primaquine (0.25 mg/kg/day, adult dose 15 mg, total dose
210 mg) or high-standard 14-day course primaquine (0.5 mg/
kg/day, adult dose 30 mg, total dose 420 mg).
Both intervention and control groups must have received the
same treatment for the blood-borne stage of infection, that
is, either CQ or ACT.
Table 1.   Data extraction: grouping of comparisons to address the review's objectives  (Continued)
Abbreviations: ACT = artemisinin-based combination therapy; CQ = chloroquine.
 
 
A P P E N D I C E S
Appendix 1. Detailed search strategies
 
PubMed MEDLINE
1 primaquine [Title/Abstract]
2 "Primaquine"[Mesh]
3 1 or 2
4 "plasmodium vivax" [Title/Abstract]
5 "Plasmodium vivax"[Mesh]
6 "vivax malaria " [Title/Abstract]
7 "Malaria, Vivax"[Mesh]
8 4 or 5 or 6
9 3 and 8
10 "Randomized Controlled Trial" [Publication Type] OR "Controlled Clinical Trial" [Publication Type]
11 randomized or placebo [Title/Abstract]
12 randomly or trial or groups [Title/Abstract]
13 "drug therapy" [Subheading]
14 10 or 11 or 12 or 13
15 9 and 14
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Cochrane Library
Issue 12 2018
ID Search
#1 primaquine: ti,ab,kw: (Word variations have been searched)
#2 MeSH descriptor: [Primaquine] explode all trees
#3 #1 or #2
#4 "plasmodium vivax": ti, ab,kw (Word variations have been searched)
#5 MeSH descriptor : [Malaria, Vivax] explode all trees
#6 MeSH descriptor: [Plasmodium vivax ] explode all trees
#7 #4 or #5 or #6
#8 #3 and #7
Embase
1947-Present, updated daily
--------------------------------------------------------------------------------
1 "primaquine".mp.
2 primaquine/
3 1 or 2
4 plasmodium vivax.mp. or Plasmodium vivax/
5 malaria vivax.mp. or Plasmodium vivax malaria/
6 4 or 5 or 6
7 controlled clinical trial.mp. or Controlled Clinical Trial/
8 randomized controlled trial.mp. or Randomized Controlled Trial/
9 (randomized or placebo or double-blind* or single-blind*).mp.
10 randomization/
11 crossover procedure/
12 7 or 8 or 9 or 10 or 11
13 3 and 6 and 12
LILACS
Search on : primaquine [Words] and malaria vivax or plasmodium vivax [Words]
ClinicalTrials.gov and WHO ICTRP
primaquine and vivax
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Introduction Chapter III 
 
The use of routine health information systems 
 
The gold standard to evaluate the efficacy of medical interventions is the randomized 
clinical trial (RCT); these usually assess an efficacy outcome in a controlled scenario. 
RCT designs minimize bias and confounding factors, and provide robust causal 
inferences comparing two interventions (Friedman et al., 2010). Although there is a clear 
need to produce this sort of evidence for regulatory purposes before any large-scale use 
of a medical intervention, these results may lack external validity, meaning that the same 
results may not be reproduced in other conditions than the ideal scenario.   
 
As renewed interest of evaluating the impact of large scale interventions in public health 
develops, methodologies for broader assessment are needed. Public health policies need 
to consider outcomes in the real-world setting, i.e. the effectiveness of the intervention 
(Thriemer et al., 2018). Effectiveness evaluations have tended to use intermittent surveys, 
but there are compelling arguments to expand the use of routine health information 
systems to enable assessment of the outcomes of programmatic interventions or policy 
changes (Wagenaar et al., 2015). 
 
Routine health information systems tend to generate numerous observations over an 
extended period, and a wide range of health facilities, in real time. On the other hand, 
intermittent surveys are expensive, can only be undertaken intermittently and mostly rely 
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on external research teams, preventing local capacity building and sustainability of 
surveillance.  Certain features of routine health information systems may allow research 
designs that demonstrate causal inferences of a programme intervention or policy change 
that surveys might have  less  power to demonstrate, especially in low endemicity settings 
(Ashton et al., 2017).  
 
Concerns about the  use of routine health information systems focus on potential 
measurement  error; incomplete or inaccurate collected data may bias estimations of the 
intervention’s impact (Wagenaar et al., 2015, Ashton et al., 2017).  This was particularly 
illustrated in malaria studies in Africa, where case definitions were based on clinical 
examination without parasitological confirmation and treatment provided by the private 
sector was not captured in the routine health system. Widespread use of the malaria rapid 
diagnosis test and the implementation of electronic capturing data systems have changed 
this (AbouZahr and Boerma, 2005). The Global Technical Strategy for Malaria 2016-
2030 emphasizes the need urges to transform malaria surveillance into a core intervention 
(World Health Organization., 2015b).   
 
The Brazilian Ministry of Health has recorded all notified cases of malaria since 2003 in 
an online surveillance system (Sistema de Vigilância Epidemiológica em malária- 
SIVEP-mal) (Braz et al., 2016). This surveillance system was designed to track outbreaks 
and assess the effectiveness of local malaria control activity, and eventually, prospective 
interventions (Santelli et al., 2012). It is estimated that 99.6% of malaria cases notified in 
Brazil were captured by the system in 2014 (Secretaria de Vigilância em Saúde, 2015). 
High rates of completeness are driven by the compulsory notification of malaria in Brazil 
and because notification is necessary to access free of charge malaria treatment, which is 
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provided exclusively by the National Health System (Sistema Único de Saúde-SUS) 
(Braz et al., 2016) for each microscopy or rapid diagnostic test confirmed case of malaria.  
Although, SIVEP provide a unique source of rich data, there is a fundamental limitation 
to its use to evaluate interventions. Successive observations of the same patient over a 
period of time are not linked by a personal unique identifier, making the evaluation of 
individual outcomes challenging. We have explored how computational tools can address 
this issue.   
 
Record linkage 
Assembling information from difference sources is routine in almost all research settings. 
Drawing conclusions based on information recorded in two distinct logbooks is easy and 
feasible, but only if there is a link between the two records, using a unique identifier. 
Linking pairs of records based on  agreement using a specific identifier is called 
deterministic record linkage (Machado, 2004).   
 
Deterministic record linkage relies on unique identifiers (ID), limiting its use when they 
are absent. It may also miss the link if there is an ID error, meaning that this approach 
does not necessarily adequately reflect the uncertainty that exist due to inherent quality 
assurance problems. 
 
In contrast, probabilistic record linkage is based on the similarity of the records, and does 
not require a unique identifier. The underlying assumption is that if there is enough 
information on a record as name, date of birth, and address, these items of information 
may be as suitable to link records as a unique ID.  This approach in public health dates 
backs to the 40’s (Dunn, 1946). Its use as a way of recording follow up of the patients 
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based on hospital records appeared for the first time in the medical literature in the end 
of the 50’s (Newcombe et al., 1959). 
 
Since then, many approaches have been developed: calculating an edit distance; name 
phonetic algorithms; the q-gram approach, which divides strings into chunks of size q; 
other distance metrics such as the Jaro or Jaro–Winkler (Sayers et al., 2016), and finally 
the bloom filters. All of these methods have certain principles in common, the need to 
use a score and a definition on what is an acceptable threshold of similarity, in other 
words, criteria to classify the records either as unmatched or matches (Fellegi and Sunter, 
1969).  
 
The Dice score was described in 1945 as a measure of ecological association between 
species (Dice, 1945). It is consistently used in computational science to define the 
acceptance threshold in probabilistic record linkage, or a measure of association between 
records. The Dice score is the simple formula 2h/A+B, where h is the number of 
coincidences, A = number of “0s” and B = number of  “1s”.    
 
In this work, we used Dice scores and Bloom filters. The latter  were initially designed in 
the 70’s as a spell correcting tool, but  currently are used to screen vast amounts of data 
with applications in many fields of computational science (Broder A., 2005). Bloom filter 
uses the array of bit underlying the data, i.e. a sequence of 0 and 1, and compares with 
the array of bit in another group. The Figure 7 illustrate a hypothetical pair of arrays of 
10 bits, each one corresponding to one record, and its Dice score.  
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Figure 7. Illustration of two hypothetical arrays of 10 bits each.  
0 1 0 0 0 1 1 0 1 1 
 
1 0 0 0 1 1 0 0 0 1 
The coincident bits are grey. Dice score = 2*5/11+9 = 0.5 
The study evaluation of malaria recurrence rate in Brazil 
The data matching in the study evaluation of malaria recurrence rate in Brazil, an 
observational retrospective cohort was done using bloom filters to exclude duplicate 
records of the same patient in the National System of Malaria Surveillance (SIVEP 
malaria) data set from 1st July 2014 till 31st May 2015.  As we were looking for 
recurrences, we compared this data set with itself, and therefore, each record was 
duplicate. This process is called deduplication.  
 
The procedure used in this study included the filter of 240 bites (Figure 8). The results 
are converted into a threshold score using the Dice index. The designing of the data 
matching strategy was a critical methodological step to define the relevant probabilistic 
record linkage threshold within this dataset.  
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Figure 8.  Division of the 240 bites array. 
 
The data used in this study record linkage is schematically presented in  Figure 9. The 
final match was based the area surrounded by the black line.  
Figure 9. Schematically presented record linkage 
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Evaluating the data matching strategy 
After a record linkage procedure, each record is classified either as a match or an 
unmatched record. The match result can be either a false match or a true match, excessive 
false matches mean lack of specificity. On the other hand, unmatched records that are 
“missed true matches” denote lack of sensitivity. 
 
Using current computational processors, a deterministic record linkage (based on unique 
ID) can only miss a true match or provide a false match due to an error in the unique ID. 
Dealing with routine health information systems and probabilistic record linkage is more 
challenging. The underlying assumption is that other information rather than a unique ID 
can be compared to produce a match, and the highest score (100% similarity) is a true 
match. However, if we rely only on the highest score, many true matches will be missed 
(low sensitivity) due to the inherent quality of the routine health information systems, that 
includes misspelling and other errors. In this scenario, setting the threshold score is a 
critical point.    
 
 A dataset that has a subset of records with a unique ID is the ideal situation to test and 
set the probabilistic record linkage threshold score. A deterministic record linkage based 
on the unique ID is the gold standard that allows defining the accuracy of the procedure 
(Silveira and Artmann, 2009). This ideal setting is very unlikely to happen, and other 
strategies have been put in place, none of them are universally useful or accepted, 
although many produce satisfactory results (Blakely and Salmond, 2002, Oliveira et al., 
2016, Fonseca et al., 2010).    
 
 
103 
The National System of Malaria Surveillance (SIVEP malaria) data set does not has a 
subset of records with a unique ID and a data matching strategy was defined prior to the 
procedure.  
 
The national guidelines require the health agent to record all vivax positive slide with in 
a 60 days’ period as a follow up slides. This data does not allow the matching of the 
records, but it provides an estimate of the recurrences in Brazil. The objective of the data 
matching strategy was to be more sensitive than the health agent reports in the field 
(number of follow up slides- LVC- SIVEP).  Match counts lower than reported cases in 
the field were considered to be inadequate sensitivity, or regarded as not able to identify 
all true matches. The specificity of the record matching was confirmed by visual 
inspection, in order to quantify the false matches. 
 
Similarly to a drug dose range study, threshold scores were chosen from a wide range that 
included a low specificity (low scores and vast number of matches) to a low sensitivity 
(higher scores and smaller number of matches than the health agent reports in the field). 
Each intersection of figure 2 (ABCD; ABD; ABC) was tested as shown in  Table 1. 
Table 1. Threshold scores tested to define the  data matching strategy. 
 
 
Dice score 
(x 10000) 
 Probabilistic record linkage fields 
Strategy ABCD ABD ABC 
I 8000 8500 8500 
II 8000 9500 9500 
III 9500 9500 9500 
IV 9500 10000 10000 
 A= Name; B= mother’s name; C= Date of Birth; D = Municipality of residence 
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Results of data matching 
The main limitation to Strategy IV (higher scores in the ABC) was the very low 
completeness of the field date of birth in the state of Acre. This was one of states with the 
highest malaria incidence in Brazil during the year studied, however this strategy resulted 
in a very low number of matches. The strategy III, II and I were selected as these were 
more sensitive than the health agent reports in the field.  
 
These were then individually inspected to see whether the pairs were true matches. Both 
I and II had too many false matches. Complete visual inspection was performed in the 
dataset that was processed according to the strategy III, namely Matches ABCD 
(threshold score 9.500) and ABD and ABC (threshold score 9.500).  
 
In this dataset, 241 matches (out of 17983) were identified as false matches (1.3%), 
denoting good specificity. Some of these false matches had more than one patient grouped 
as the same match. These matches were reorganized and they generated 493 new matched 
records. The replacement and manual matching procedures are recorded in the 
investigator file. After the replacement of the false matches the dataset was locked and 
analysis performed. Herein, the results are presented and discussed (Daher et al., 2019).  
 
In conclusion, during the current era, computational data analysis capabilities are growing 
exponentially. It makes the use of the routine health information methodologically easier 
and more valuable, as it increases the external validity of the results and the feasibility of 
the studies in low endemic areas, as Brazil. Besides the methodological and financial 
advantages of the use of routine health information, its widespread use in operational 
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research promotes improvement in data collection quality and strengthens the local health 
care organization. 
 
Many methods are available to link the records of these health information systems, 
including bloom filters that process the data in its minimal unit, an array of bits. Despite 
the use of technology proving the sensitivity and specificity of the method is challenging. 
The linkage strategy is a crucial methodological point to appraise these features of the 
evaluation. In this study, the selected strategy had an acceptable sensitivity according to 
the threshold defined. There were not excessive false matches denoting good specificity. 
However, as each data set presents dissimilarities in the completeness and accuracy of 
the data, there is not a universally useful methodology, and the most suitable one must be 
appraised on a case-by-case basis.  
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Abstract 
Background: Control of vivax malaria in endemic areas requires management of recurrence. The Brazilian National 
Malaria Surveillance System (SIVEP-Malária) records every case of malaria in Brazil, but is not designed to differentiate 
between primary and recurrent infections. The aim of this study was to explore whether the information provided by 
SIVEP-Malária could be used to identify Plasmodium vivax recurrences, its risk factors and evaluate the effectiveness of 
short course primaquine (7–9 days: total dose 3–4.2 mg/kg) in preventing relapses.
Methods: In this observational retrospective cohort study, data matching of SIVEP-Malária records was undertaken 
using bloom filters to identify potential recurrences defined as microscopically-confirmed P. vivax episodes from the 
same individual occurring within a year. Generalized Estimation Equation (GEE) models were used to determine pre-
dictors of recurrence. Extended Cox-based conditional Prentice–Williams–Peterson models (PWP) models were used 
to evaluate time to recurrence.
Results: Between June 1, 2014 and May 31, 2015, 26,295 episodes fulfilled the criteria of potential recurrence among 
154,970 reported malaria episodes. Age ≤ 3 years, being male, literate, not-indigenous and having domestic working 
activities were identified as risk factors for recurrence. There was no difference in time to recurrence or recurrence 
frequency between patients treated with 14-day or 7–9 day primaquine regimens (HR = 1.02, 0.96–1.09) and RR = 0.97 
(0.90–1.04), respectively. The use of chloroquine alone was associated with a 1.43 (1.29–1.58, p < 0.0001) increased 
risk of P. vivax recurrence compared to patients who used chloroquine combined with short-course primaquine, the 
Brazilian standard of care. This was RR = 2.06 (1.48–2.86, p < 0.0001), RR = 1.90 (1.60–2.25, p = 0.0001) and RR = 1.14 
(1.00–1.29, p = 0.05) for recurrences occurring between 3–28, 29–60 and > 60 days, respectively. PWP models showed 
that the time to recurrence was longer in recipients of both primaquine and artemisinin-based combination therapy 
(ACT) compared to patients treated with chloroquine alone or with concomitant primaquine, HR = 2.2 (1.62–2.99, 
p < 0.0001), HR = 1.27 (0.97–1.66, p = 0.08), respectively.
Conclusion: Short course primaquine was as effective as 14-day regimens and associated with a halving of the risk 
and delay in time to recurrence of P. vivax infections in comparison to chloroquine alone. The study demonstrates the 
feasibility of using record linkage on routine surveillance data to identify potential P. vivax recurrences, associated risk 
factors and impact of treatment.
Keywords: Malaria, Recurrences, Plasmodium, Vivax, Falciparum, Primaquine, Chloroquine, Artemisinin-based 
combination therapy, ACT , Record link
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Background
Malaria control was first implemented in Brazil in 1905. 
Initial success led to the eradication campaign in 1965 
[1], which lasted until the late 60s. The lowest number 
of annual cases, 36,900, was recorded in 1961 [2]. Dur-
ing the 90s, partly because of a growing population in the 
Amazon Region, over half a million cases per year were 
recorded, peaking in 1999 with 637,470 cases [3]. Since 
then, following the introduction of renewed malaria con-
trol efforts, including vector control and early diagnos-
tics and treatment with artemisinin-based combination 
therapy (ACT) [4, 5], a drop in malaria cases has been 
observed with a nadir of 143,552 malaria cases in 2014. 
Plasmodium vivax infections accounted for 84% of all 
cases, highlighting the growing importance of this specie.
Brazil is currently focusing on the elimination of both 
Plasmodium falciparum and P. vivax [6, 7]. Understand-
ing P. vivax recurrences is critical for malaria control in 
endemic areas. In Brazil, cases of malaria are recorded 
in the National System of Malaria Surveillance (SIVEP 
Malária). Although it is believed that over 99% of cases 
are recorded in this system, it is not designed to differ-
entiate between primary and recurrent malaria episodes. 
This study aimed to explore if and how routinely col-
lected data from the Health Surveillance System can be 
used to describe epidemiological patterns such as the 
event rate, the time interval between repeated episodes 
of vivax malaria, and risk factors of P. vivax recurrence, 
such as age or P. falciparum triggering a P. vivax episode.
The study also investigated the effectiveness of a 
7–9 days primaquine and its comparison with a 14 days 
primaquine regimen, the synergic effects of concomitant 
use of primaquine with chloroquine and the influence of 
the use of ACT on the time to P. vivax recurrence.
Methods
National malaria treatment guidelines Brazil
The current first-line treatment for vivax infection is 
3 days of chloroquine (600 mg on day 1, and 450 mg on 
days 2 and 3) with concomitant use of a short course of 
primaquine (7–9 days: total dose 3–4.2 mg/kg). The pre-
scription of 14-day regimens of primaquine is indicated 
only if the health care provider can monitor the adher-
ence. Pregnant women standardly receive the 3-day 
treatment course of chloroquine but do not receive pri-
maquine. Only if they experience more than one episode 
of clinical malaria during a single pregnancy, they receive 
weekly chloroquine chemoprophylaxis for 12  weeks or 
until delivery. The current first-line treatment for uncom-
plicated falciparum malaria is artemether-lumefantrine 
[8] combined with a single dose of primaquine (maxi-
mum total dose 45 mg).
Population and study design
This observational retrospective cohort study used 
records of the National System of Malaria Surveillance 
(SIVEP Malária) from nine States in the Brazilian Legal 
Amazon Region between 1st June 2014 and 31st May 
2015 inclusive. The SIVEP Malaria is an online surveil-
lance system from the Ministry of Health that records all 
notified cases of malaria in Brazil since 2003 [9]. This sur-
veillance system was designed to identify outbreaks and 
track the effectiveness of malaria control.
It is estimated that 99.6% of malaria cases notified in 
Brazil were captured by the system in 2014 [5]. High rates 
of notification are driven by the compulsory notification 
of malaria in Brazil and because notification is neces-
sary to access free malaria treatment, which is provided 
exclusively by the National Health System (Sistema Único 
de Saúde-SUS) [9] for each microscopy or rapid diagnos-
tic tests (RDT) confirmed case of malaria. Only malaria 
cases in specific populations, such as illegal gold miners 
working in border areas, may be under represented in the 
National System of Malaria Surveillance.
Recurrences and data matching
National guidelines state that any malaria positive smears 
conducted within 60 days of previous P. vivax infections 
and within 40 days for P. falciparum should be recorded 
as ‘follow up’ smears [8]. This information relies upon 
the reports provided by the patient to the health worker 
because the SIVEP Malaria system does not include a 
unique individual patient identifier, making it difficult to 
easily identify recurrent events.
Bloom filters matching strategies [10] were used to link 
records of different clinic visits made by the same patient 
to determine the interval in days between visits. A filter 
of 240 bites was defined, using a combination of patient’s 
name (A), patient’s mother’s name (B), date of birth 
(C), and municipality of residency (D) (Venn diagram 
presented in Additional file  1). Absent identifiers were 
replaced with random values to avoid unwanted simi-
larity. The degree of similarity between two filters was 
assessed using the Dice Coefficient calculated on the two 
binary vectors [11]. The score was scaled to a maximum 
of 10,000. Different combinations of identifiers were used 
in separate reduplication runs: (a) ABCD, (b) ABD and 
(c) ABC. These were then individually inspected to see 
whether the pairs were coherent. This procedure allowed 
the exclusion of false matches.
Evaluation of the population and recurrences
Baseline characteristics available from the SIVEP form 
(see Additional file  2) were evaluated. Age catego-
ries were matched to the primaquine dose bands of the 
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Brazilian treatment guidelines. A map of the incidence 
rate of vivax recurrences (cases per 1000) at the local 
governmental level of the Federative Republic of Bra-
zil (municipalities) was obtained using Tableau Desktop 
(version 10.3).
The effect of baseline variables on recurrent events was 
expressed as relative risks (RR) obtained from log-bino-
mial regression models with random effect for patients 
using Generalized Estimation Equation (GEE). Time 
between recurrent events was stratified as 3–28, 29–60 
and > 60  days based on the chloroquine half-life and 
per national definitions of recurrence. The same model 
was used to estimate the synergic effect of the concom-
itant use of primaquine and chloroquine on P. vivax 
recurrence.
Extended Cox-based conditional Prentice–Williams–
Peterson (PWP) survival models for repeated ordered 
events were used for the analysis of time to vivax recur-
rence [12]. The time interval between sequential malaria 
episodes were graphically displayed using Kaplan–Meier 
curves and results presented as median (95% CI) time to 
recurrence. Two-sided p-values were used and statistical 
significance defined as < 0.05. Analysis was conducted 
using R (version 3.2.5) and IBM SPSS statistics (version 
24.0).
Ethics statement
The study protocol was reviewed and approved by the 
Ethics Committee at National Institute of Infectious Dis-
ease, Oswaldo Cruz Foundation (No. 1.591.434 CAAE 
56245716.1.0000.5262) and complied with procedures 
of the Health Surveillance Secretary (SVS)—Ministry of 
Health of Brazil to access datasets containing personal 
information. The investigators ensured confidentiality of 
all records. The study is registered at the Brazilian Regis-
ter of Clinical Trials (RBR-3n947j), a primary repository 
of WHO.
Results
Data matching results
Between June 1, 2014 and May 31, 2015 inclusive, 26,295 
recurrences involving 18,185 patients were identi-
fied among 154,970 reported malaria episodes involv-
ing 128,675 patients using the Bloom Filter matching 
strategy. The strategy selected had ABCD, ABD and 
ABC Dice threshold scores of 9500. Individual record 
inspection identified 241 out of 17,983 matches as false 
matches. Some of these involved multiple potential 
matches between episodes from multiple patients (i.e. 
one visit matching to more than one patient). These 241 
potential false matches were manually inspected and cor-
rected, which resulted in 493 additional matches.
The original SIVEP Malaria dataset had 28,062 recur-
rent malaria episodes, however 1767 episodes were 
recurrences occurring within 2  days from the initial 
report and were excluded from the analysis giving a total 
of 26,295 recurrences that were used in the model (Addi-
tional file 3). The baseline characteristics are presented in 
Table 1.
Plasmodium vivax malaria recurrence
The final combination of parameters of the strategy 
selected resulted in more matches than the number of 
recurrences reported by the health agents. The incidence 
rates of P. vivax recurrence varied considerably at the 
municipality level, reflecting the widespread area over 
which malaria transmission occurs in Brazil [13] (Fig. 1).
Risk factors for Plasmodium vivax recurrences
Among those who took primaquine, the risk of recur-
rence decreased with increasing age. Compared to 
children aged ≤ 3  years, children aged 4–8  years and 
older adults had a 20% and 38% lower risk (4–8  years: 
RR = 0.80, 95% CI 0.75–0.86, p < 0.0001; adults RR = 0.62, 
0.57–0.67, p < 0.0001, respectively). Being male increased 
the risk of P. vivax recurrence (RR = 1.11, 1.07–1.14, 
p < 0.0001). The native indigenous population were at 
lower risk compared to other groups. The risk of vivax 
recurrence was higher in all education levels compared to 
those who were illiterate. Individual with domestic work-
ing activities were at the highest risk of recurrence com-
pared to other occupations.
Similar risk factors were identified for time to recur-
rence. This reduced with each successive episode of P. 
vivax malaria (Table  2 and Fig.  2). Other factors asso-
ciated with shorter time to recurrence included age 
≤ 3  years, male gender, no hypnozoite treatment, and 
domestic occupation (Table  3). Previous P. falciparum 
infection was not associated with a shorter time to recur-
rence HR = 1.04, 0.93; 1.16, p = 0.50.
Effectiveness of 7 days versus 14 days primaquine on P. 
vivax recurrence incidence
Overall, 6226 (4.9%) patients were prescribed a 14-day 
course of primaquine and 120,608 (95.1%) a 7-day course 
(total dose 3–4.2  mg/kg). All received 3-days of chloro-
quine for P. vivax malaria. The risk of P. vivax recurrence 
was similar between the two regimens: 14-day: 887/6226 
(14.3%) vs 7–9  day: 17,610/12,0608 (14.6%), RR = 0.97 
(0.90–1.04), p = 0.96. Similar conclusions could be drawn 
from the PWP survival model which also showed no dif-
ference in the time to recurrence (HR = 1.02, 0.96–1.09, 
p = 0.52).
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Effectiveness of the concomitant use of primaquine on P. 
vivax recurrence incidence
As stated previously, primaquine treatment is not recom-
mended in Brazil for pregnant women and chloroquine 
chemoprophylaxis for pregnant women is only given 
after the second malaria episode. This enabled the use of 
the pregnant population with a single vivax recurrence as 
a comparator to assess the effect of hypnozoite treatment.
Pregnant patients who did not take short-course pri-
maquine had a 1.43 (95% CI [1.29–1.58]) risk of P. vivax 
recurrence compared to non-pregnant patients who took 
primaquine. This was RR = 2.06 (1.48–2.86, p < 0.0001), 
RR = 1.90 (1.60–2.25, p = 0.0001) and RR = 1.14 (1.00–
1.29, p = 0.05) for recurrences occurring between 3–28, 
28–60 and > 60  days. The time to a P. vivax recurrence 
was also shorter in pregnant women (HR = 1.53, 1.39–
1.69, p < 0.0001).
Overall, 399 patients received ACT with a primaquine 
total dose of 3–4.2 mg/kg starting after the third day of 
ACT to treat mixed P. vivax and P. falciparum infec-
tions. There was a reduced risk of P. vivax recurrence 
in those taking ACT and sequential primaquine com-
pared to pregnant patients treated with chloroquine only 
(RR = 0.70, 0.52–0.93, p = 0.015). Plasmodium vivax 
recurrence also took longer in patients taking ACT and 
sequential primaquine than chloroquine alone treated 
patients HR = 2.2 (1.62–2.99, p < 0.0001), and those 
treated with chloroquine and with concomitant pri-
maquine, HR = 1.27 (0.97–1.66, p = 0.08), but this differ-
ence was of borderline statistical significance.
Discussion
This study demonstrated the potential for the use of 
routinely collected public health surveillance records to 
evaluate the epidemiology and risk factors of recurrent 
P. vivax malaria in Brazil. The computational tools avail-
able allowed the processing and successful automated 
matching of over 150,000 case records to identify poten-
tial recurrent infections. This provided access to unique 
data that allowed us to identify associated risk factors 
and impact of treatment using routine surveillance data. 
The analysis showed that short 7–9  day courses of pri-
maquine with concomitant use of chloroquine was more 
effective than chloroquine alone, and equally as effective 
as the 14-day regimen in preventing P. vivax recurrences. 
ACT-primaquine combinations were also more effective 
Fig. 1 Incidence of Plasmodium vivax recurrence (cases per 1000)
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than chloroquine alone or chloroquine–primaquine 
combinations in delaying recurrence, although the latter 
was not statistically significant.
An important part of this analysis included matching 
of case records in the absence of a unique patient identi-
fier to link different episodes that occurred in the same 
individual during a 1-year period. Although there are 
limitations in the quality of the routine data in many sur-
veillance systems in resource poor settings, using com-
putational approaches to explore the large datasets may 
help generate evidence to support public health policies 
[14]. Bloom filters are designed to screen vast amounts 
of data with applications in many fields of computational 
science [15] and are aimed at detecting duplicate entries. 
The quality of data entry is a major factor in defining the 
best matching strategy and, therefore, there is no stand-
ard strategy suitable for all datasets. This meant that, 
depending on the completeness of the dataset using high 
Dice’s coefficients in the matching strategy led to a low 
number of matches (low sensitivity). However, the visual 
inspection of the lower thresholds had too many false 
matches (low specificity). The current strategy identified 
a greater frequency of recurrences than the one reported 
by the health agents based on patient’s recall.
Brazil recommends a short 7–9 days courses (total dose 
3–4.2  mg/kg). Fourteen days of primaquine is only rec-
ommended in Brazil either when patients are considered 
likely to be compliant or can undergo supervised treat-
ment. The similar effectiveness between these two regi-
mens is encouraging, reinforcing the idea that cure rate is 
a function of the total primaquine dose rather than treat-
ment length [16, 17].
The importance of addressing the effectiveness of pri-
maquine in real life for radical cure of P. vivax infections 
was highlighted recently [18]. This equal effectiveness of 
the short-course regimen has important practical impli-
cations because a patient friendly primaquine regimen 
is desirable and regimens of shorter duration are more 
likely to be adhered to [19]. The evidences on which 
this short-course primaquine regimen in Brazil is based 
Table 2 Median time to  sequential episodes of  vivax 
malaria
Recurrences Number of vivax 
recurrences
Median time (95% CI) 
to recurrence (days)
1st 17,460 71 (70.19–71.81)
2nd 4967 65 (63.83–66.17)
3rd 1429 60 (58.33–61.67)
4th 452 56 (52.08–59.92)
5th 150 54 (46.41–61.59)
6th 49 41 (31.47–50.53)
7th 15 38 (29.51–46.49)
8th 6 46 (34.24–57.76)
Overall 69 (68.37–69.63)
Fig. 2 Kaplan Meier graph sequential episodes of vivax malaria
Page 8 of 10Daher et al. Malar J           (2019) 18:18 
on are a limited number of clinical trials [20, 21], pro-
grammatic experience, and historical evidence suggest-
ing that the efficacy of primaquine is more a function of 
the cumulative dose than the duration of treatment [17]. 
However, the evidence has been deemed insufficient to 
support international guidelines. An ongoing systematic 
review [22] and the results of this current analysis may 
increase this body of evidence.
Children under 3  years old had an increased risk of 
recurrence compared to all other age categories, with a 
trend towards increasingly lower risk with increasing 
age. There are several potential explanations for this in 
addition to differences in acquired immunity: The doses 
of chloroquine and primaquine may be inadequate at this 
young age [23] or the absence of child-friendly formula-
tions may result in poor adherence and reduced effec-
tiveness. Herein it was demonstrated a reduced risk of 
recurrence in the native indigenous population. Similarly, 
it was also showed that the risk was lowest in the illiterate 
population. Both may reflect higher exposure rates early 
in life and a more rapid acquisition of protective immu-
nity in these groups [24].
Previous falciparum infection was not found to 
caused more rapid recurrence of P. vivax, in contrast to 
Table 3 Factors related to P. vivax recurrence
REF reference group
Predictor factor Categories Generalized Estimation Equation (GEE) model Prentice, Williams 
and Peterson (PWP) 
survival model
N (%)
N = 151,784
RR (95% CI), p value HR (95% CI), p value
Age categorical Older than 36 years 68,173 (44.9) 0.62 (0.57–0.67), p < 0.0001 0.75 (0.70; 0.81), p < 0.0001
15–35 years 46,380 (30.6) 0.71 (0.65–0.77), p < 0.0001 0.78 (0.72;0.84), p < 0.0001
12–14 years 8337 (5.5) 0.77 (0.7–0.85), p < 0.0001 0.81 (0.74;0.88), p < 0.0001
9–11 years 7604 (5) 0.82 (0.75–0.91), p < 0.0001 0.87 (0.80;0.96), p = 0.003
4–8 years 11,982 (7.9) 0.8 (0.75–0.86), p < 0.0001 0.83 (0.78;0.88), p < 0.0001
≤ 3 9308 (6.1) REF REF
Hypnozoite treatment No primaquine 2667 (1.8) 1.43 (1.29–1.58), p < 0.0001 1.53 (1.39;1.69), p < 0.0001
Primaquine 3–4.2 mg/kg 149,117 (98.2) REF REF
Gender Male 90,914 (59.9) 1.11 (1.07–1.14), p < 0.0001 1.08 (1.05;1.11), p < 0.0001
Female 60,870 (40.1) REF REF
Ethnic background Not informed 1377 (0.9) 1.60 (1.4–1.82), p < 0.0001 1.19 (1.02;1.38), p = 0.03
Native indigenous 25,705 (16.9) 0.78 (0.73–0.84), p < 0.0001 0.89 (0.84;0.95), p < 0.0001
Mixed background 106,819 (70.4) 1.03 (0.97–1.09), p = 0.34 0.95 (0.87;1.04), p = 0.25
Asian background 1527 (1) 0.96 (0.8–1.15), p = 0.68 0.94 (0.80;1.11), p = 0.49
African background 5908 (3.9) 0.94 (0.86–1.04), p = 0.23 0.95 (0.87;1.04), p = 0.25
White 10,448 (6.9) REF REF
Economic activity Road dam construction 467 (0.3) 1.01 (0.8–1.27), p = 0.94 0.92 (0.74;1.13), p = 0.42
Fishing hunting 3106 (2) 0.72 (0.63–0.82), p < 0.0001 0.73 (0.65;0.82), p < 0.0001
Vegetal extraction 1191 (0.8) 0.59 (0.48–0.73), p < 0.0001 0.70 (0.58;0.85), p < 0.0001
Mining 7046 (4.6) 0.81 (0.74–0.89), p < 0.0001 0.86 (0.79;0.93), p < 0.0001
Tourism 3182 (2.1) 0.79 (0.71–0.89), p < 0.0001 0.76 (0.68;0.84), p < 0.0001
Agriculture livestock 32,919 (21.7) 0.77 (0.73–0.82), p < 0.0001 0.79 (0.75;0.83), p < 0.0001
Others 89,132 (58.7) 0.85 (0.81–0.9), p < 0.0001 0.91 (0.87;0.95), p < 0.0001
Domestic 14,741 (9.7) REF REF
Years in school Complete graduation 1341 (0.9) 1.14 (0.97–1.35), p = 0.12 1.04 (0.89;1.22), p = 0.63
Complete high school 13,647 (9) 1.14 (1.06–1.23), p < 0.0001 1.07 (1.00;1.15), p = 0.04
Incomplete high school 12,070 (8) 1.15 (1.07–1.24), p < 0.0001 1.09 (1.02;1.17), p = 0.02
Complete fundamental studies 9745 (6.4) 1.11 (1.03–1.2), p = 0.01 1.05 (0.97;1.13), p = 0.24
Not informed 17,596 (11.6) 1.33 (1.22–1.44), p < 0.0001 1.27 (1.17;1.37), p < 0.0001
Incomplete fundamental studies 81,190 (53.5) 1.12 (1.06–1.18), p < 0.0001 1.06 (1.01;1.12), p = 0.02
Illiterate 16,195 (10.7) REF REF
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suggestions from others in the literature [24]. It is not 
clear if this is a function of a long duration of post-treat-
ment prophylactic effect of ACT to suppress P. falcipa-
rum infections.
It was found that the time to recurrence appears to 
reduce with each subsequent episode of vivax recurrence. 
Although these observations are in contrast with the 
current understanding of hypnozoite activation which 
implies a gradual lengthening, rather than shortening 
with each successive relapse, these results are consistent 
with previous observations in Brazil [25]. The underlying 
assumption related to the gradual lengthening hypoth-
esis is that with multiclonal infections the earliest active 
and more rapidly multiplying parasite became patent first 
[24]. These observations relied on artificial infection and 
animal models. Although this study cannot differenti-
ate with relapse, reinfections and recrudescence, it does 
not provide strong support for a gradual lengthening of 
relapse intervals. Further research to address the issue is 
needed.
The observation that the addition of primaquine was 
already effective in preventing recurrence in the first 
28 days is interesting. It implies that the addition of pri-
maquine to chloroquine either reduced recrudescence 
or early relapses and may support the synergic effect of 
primaquine and chloroquine in the blood stage [26–29]. 
This trend is also seen in the following period until the 
60th day. A small (RR = 1.14) effect was also seen beyond 
60  days, but it is not clear if this reflects a long-lasting 
anti-relapse effect of primaquine [4] or a higher exposure 
risk in the non-primaquine recipients resulting in more 
new infections and thus a higher rate of recurrence.
The study design is an important limitation. This is a 
1-year retrospective open cohort, meaning that patients 
infected before the study start yet recurring during the 
study were considered as initial events. Second, the only 
way that the effectiveness of short course of primaquine 
could be evaluated was to use the pregnant popula-
tion as the reference group because this group does not 
receive primaquine during pregnancy. However, this is 
a biased population and the results must be interpreted 
with this in mind. Potential confounders include changes 
in mosquito biting frequency during pregnancy, altered 
personal protection and healthcare-seeking behaviour, 
altered immunological responses, and changes in dis-
tribution of drugs, although chloroquine pharmacoki-
netics parameters in pregnant women does not appear 
to be very different from the rest of the population [30]. 
Despite these limitations, our results do suggest that the 
current national treatment guidelines in Brazil are effec-
tive in reducing relapse.
Additionally, every data matching strategy has its 
limitations and they can result in different number of 
recurrences depending on the reliability of the data entry. 
A unique identifier for the patients would allow a better 
evaluation of the sensitivity and specificity of the strategy 
and increase the use of the database as routine. Besides 
the data quality concerns, microscopy does not allow 
differentiation between relapse, recrudescence and rein-
fection of the P. vivax episodes and the aggregate recur-
rence was used in the analysis. Routine genotyping to 
differentiate these is currently not feasible at scale under 
programmatic conditions. Efforts to differentiate relapse 
and reinfection in this study by restringing the analysis to 
infants born during the study and, therefore, free of hyp-
nozoites, was not successful as the sample of newborns 
was too small. Multi-year cohorts may address this issue.
Conclusions
Overall, this study confirmed that under real-life condi-
tions, short-course primaquine was equally as effective as 
the 14-day regimen, which is the standard in many other 
countries. ACT-primaquine combinations were also 
more effective than chloroquine alone or chloroquine-
primaquine combinations in delaying recurrence. The 
concomitant use of primaquine and chloroquine either 
reduced recrudescence or very early relapse and may 
support their synergic effect in the blood stage. Finally, 
the study demonstrates the feasibility of using record 
linkage to identify potential P. vivax recurrences, associ-
ated risk factors and impact of treatment using routine 
surveillance data. These routine data could also poten-
tially provide a baseline for evaluation of further malaria 
control interventions that address the malaria control in 
Brazil.
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Introduction Chapter IV 
The importance of the vivax ACT trial to Brazil 
 
The study Efficacy and safety of Artemisinin-based Combination Therapy and 
chloroquine with concomitant primaquine to treat Plasmodium vivax malaria in Brazil: 
an open label randomized clinical trial (Daher et al., 2018a)  was conducted to evaluate 
potential new treatment regimens that could be used to replace the current chloroquine 
based regimen recommended as public health policy in Brazil. 
 
The study was designed with the support of the National Malaria Control Programme in 
an effort to improve the efficacy, tolerability and adherence of vivax treatment. This effort 
included: (i) the development of a new coated formulation of chloroquine to mask the 
bitter taste of the drug, potentially improving the tolerability (Pereira et al., 2016b), (ii) a 
new formulation of primaquine that lead to drug exposure comparable to the FDA 
reference product (FDA, 2019), (iii) a co-blisters of chloroquine and primaquine (7 days 
regimen) according to four weight bands, as co-packaging may improve treatment 
compliance (Orton and Barnish, 2005)  and improve  effectiveness (malERA, 2017b), 
and finally (iv) Artemisinin-based Combination Therapies (ACTs) + primaquine to treat 
vivax. 
 
There is a convincing rationale for a simpler drug treatment for both P. falciparum and 
P. vivax malarias, and ACTs are the most obvious candidates for this purpose. The 
benefits of a unified treatment for both malaria species have been discussed for almost 
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ten years  (Douglas et al., 2010) including in our paper (Daher et al., 2018a), namely: (i) 
efficacious treatment in co-endemic areas with unreliable diagnosis per species (Douglas 
et al., 2010); (ii) or high incidence of mixed infections; (iii) prevention of P. vivax relapse 
following P. falciparum infections (White, 2011, Commons et al., 2019); (iv) simplified 
drug stock and supply management; (v) maintenance of ACT production in industrial 
scale if falciparum treatment purchases fade out; (vi) availability of more than one vivax 
treatment avoiding selective pressure; (vii)  a child friendly formulation where liquid 
chloroquine is not available.  
 
However, although it is the development of chloroquine-resistant P. vivax that has been 
the final rationale for adoption of this approach (World Health Organization., 2010a), 
these others advantages ought to be taken in account. They may justify update of 
treatment guidelines before the end of the drug lifespan, sparing the emergence of 
chloroquine resistance. Here, we present the efficacy and safety results of three vivax 
treatment regimens using either an ACT or chloroquine with concomitant use of 
primaquine in Brazil. 
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Efficacy and safety of Artemisinin-based Combination 
Therapy and chloroquine with concomitant primaquine to 
treat Plasmodium vivax malaria in Brazil: An open label 
randomized clinical trial. Malaria Journal, 2017 
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Efficacy and safety of artemisinin-based 
combination therapy and chloroquine 
with concomitant primaquine to treat 
Plasmodium vivax malaria in Brazil: an open 
label randomized clinical trial
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Abstract 
Background: There is general international agreement that the importance of vivax malaria has been neglected, 
and there is a need for new treatment approaches in an effort to progress towards control and elimination in Latin 
America. This open label randomized clinical trial evaluated the efficacy and safety of three treatment regimens using 
either one of two fixed dose artemisinin-based combinations or chloroquine in combination with a short course of 
primaquine (7–9 days: total dose 3–4.2 mg/kg) in Brazil. The primary objective was establishing whether cure rates 
above 90% could be achieved in each arm.
Results: A total of 264 patients were followed up to day 63. The cure rate of all three treatment arms was greater than 
90% at 28 and 42 days. Cure rates were below 90% in all three treatment groups at day 63, although the 95% confi-
dence interval included 90% for all three treatments. Most of the adverse events were mild in all treatment arms. Only 
one of the three serious adverse events was related to the treatment and significant drops in haemoglobin were rare.
Conclusion: This study demonstrated the efficacy and safety of all three regimens that were tested with 42-day cure 
rates that meet World Health Organization criteria. The efficacy and safety of artemisinin-based combination therapy 
regimens in this population offers the opportunity to treat all species of malaria with the same regimen, simplifying pro-
tocols for malaria control programmes and potentially contributing to elimination of both vivax and falciparum malaria.
Trial registration RBR-79s56s
Keywords: Malaria, Plasmodium vivax, Antimalarial treatment, Chloroquine, Mefloquine, Artesunate, Lumefantrine, 
Artemether, Primaquine, Artemisinin-based combination therapy, ACT, Clinical trial
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Background
Malaria control and elimination activities have mainly 
focused upon Plasmodium falciparum as the leading 
cause of malaria mortality and morbidity worldwide. 
Nevertheless, Plasmodium vivax remains a major public 
health problem [1]. In 2010, 2.48 billion people world-
wide were living in areas at risk for vivax infection. Bra-
zil is the largest endemic area in the Americas; where 
stable transmission and a dispersed population [2, 3] 
pose major challenges for malaria control [4, 5]. In 2014, 
143,552 malaria cases were reported [6].
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Over the last 30 years, the proportion of malaria cases 
due to vivax in Brazil has increased from 50%, in 1988 
to 84% in 2014. Plasmodium vivax now causes 65% of 
hospitalizations due to malaria in the Brazilian Ama-
zon region, and 13 out of 38 malaria deaths in Brazil in 
2014 were due to P. vivax [6]. Control and management 
of this disease is therefore important, particularly in light 
of the increasing recognition that vivax infection is not 
as benign as first thought and that vivax can both cause 
severe disease [7–9], and have negative impacts on pros-
perity, longevity, school performance, pregnancy and the 
economy [10–12]. Optimizing the treatment of vivax 
malaria is critical to improve vivax control.
In Brazil, the current treatment recommended to treat 
vivax is chloroquine with concomitant use of 7 days of 
primaquine. The primaquine total dose ranges from 3 
to 4.2 mg/kg [13]. Recent trials have not demonstrated 
chloroquine resistant vivax in Brazil [14–16], although 
there are still concerns about chloroquine resistance 
emergence [17]. The availability of other options, par-
ticularly ones that may be useful for the treatment of 
both vivax and falciparum malaria, would help to avoid 
selective pressure over a single therapeutic regimen. 
This study was designed to evaluate new approaches 
for the acute treatment of vivax in preparation for 
plans for both vivax elimination and updated treatment 
guidelines.
This randomized clinical trial evaluated the efficacy and 
safety of three vivax treatment regimens using either an 
ACT or chloroquine with concomitant use of primaquine 
in Brazil. The primary objective was to establish whether 
cure rates above 90% could be achieved in each arm [18].
Methods
Study population
Patients with uncomplicated vivax malaria were included 
in the study, after giving informed consent, if they met the 
following inclusion criteria: age between 18 and 70 years; 
weight between 50 and 90  kg, P. vivax mono-infection 
confirmed by microscopy, asexual parasite count > 250/
μL, axillary temperature ≥  37.5  °C or a history of fever 
during the past 48 h, and haemoglobin > 7.0 g/dL. Exclu-
sion criteria were: malaria treatment in the previous 
63 days; signs of severe malaria; concurrent other febrile 
conditions or chronic disease (such as severe cardiac, 
hepatic or renal disorders or HIV); the use of any medi-
cation known to interfere with anti-malarial pharmacoki-
netics; previous history of intolerance to any study drug; 
known glucose-6-phosphate deficiency; pregnancy con-
firmed by urinary human chorionic gonadotropin (hCG) 
testing; and breastfeeding.
Study design and drug administration procedures
This prospective, randomized, open label, three-arm 
efficacy study of uncomplicated vivax malaria was con-
ducted according to World Health Organization (WHO) 
methods for surveillance of anti-malarial drug efficacy 
[18] at two centres in the Amazon Region of Brazil: the 
Tropical Medicine Research Centre (CEPEM) in Ron-
dônia and Tropical Medicine Foundation Dr Heitor 
Vieira Dourado (FMT-HVD) in Manaus.
A 90% cure rate or greater is considered by the WHO 
to be sufficient evidence of efficacy to support the choice 
of a specific regimen by National Malaria Control Pro-
grammes in their treatment guidelines [18]. The sample 
size was calculated with an expected failure rate of 5%. 
88 patients were included in each study arm to achieve 
a precision of 5% and allowing for 20% loss to follow-up, 
leading to a total of 264 patients.
A randomization list using blocks of six and alloca-
tion rate 1:1:1 was generated by software (Etcetera, ver-
sion 2.72). Sequentially numbered (0–176 CEPEM and 
177–264 FMT) opaque sealed envelopes were provided 
to the local clinical coordinators and used to randomize 
patients. Differences in dosing schedules and the diffi-
culty of dummy blinding meant that neither patients nor 
healthcare workers were blinded, but microscopists were 
not aware of treatment allocation. The statistician was 
blind to the treatment allocation until the database had 
been locked.
Eligible patients were allocated to one of the follow-
ing three treatment groups: (a) chloroquine (CQ); (b) 
fixed dose combination of artesunate and mefloquine 
(ASMQ) and; (c) fixed dose combination of artemether 
and lumefantrine (AL). All three arms received the same 
primaquine regimen.
Group A received chloroquine (Farmanguinhos—
Fiocruz, Batch Numbers 12080940 and 14060467) 
600 mg on day 1, and 450 mg on days 2 and 3. This is the 
Brazilian Ministry of Health current recommendation for 
uncomplicated malaria vivax treatment [13].
Group B received two tablets daily for 3 days of a fixed 
dose combination of 100  mg  +  200  mg artesunate and 
mefloquine (ASMQ) tablets (Farmanguinhos—Fiocruz 
Batch Numbers 11100680 and 13040348) in a total of six 
tablets.
Group C received four tablets twice a day for 3 days of 
a fixed dose combination of 20 mg + 120 mg artemether 
and lumefantrine (AL) tablets  (Coartem®—Novartis, 
Batch Numbers F2618 and K30711) in a total of 24 AL 
tablets.
All groups also received two tablets of 15  mg pri-
maquine (Pq) (Farmanguinhos—Fiocruz, Batch numbers 
12010038 and 13030282) for 7, 8 or 9  days (accord-
ing to three weight ranges;  ≥  50–69; 70–79; 80–90  kg, 
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respectively), as recommended by National Malaria 
Control Programme treatment guidelines [13]. Patients 
received a total primaquine dose between 3.0 and 4.2 mg/
kg.
The first 3 days’ treatment were supervised for Group 
A and B. For Group C, only the first daily AL dose was 
directly observed. Patients in the AL arm were asked 
about their adherence to the previous second daily dose 
after the morning supervised dose. For all groups, the 
first dose was administered after diagnosis, and all sub-
sequent supervised doses were taken between 8 and 
10 a.m. If the patient vomited within 30 min after a dose, 
the same dose was administered again. At D7 follow-up 
visit, patients were inquired about their treatment adher-
ence to unsupervised primaquine on days 4 through 7. 
The use of other treatments was recorded at every visit.
Glucose-6-phosphate dehydrogenase (G6PD) defi-
ciency screening was not performed: this is not routinely 
performed in Brazil and it is not required by the national 
treatment guidelines. At enrolment, patients were asked 
about adverse events during previous primaquine use.
Ethics statement
The clinical study protocol and informed consent form 
were reviewed and approved by the Ethics Committee 
at CEPEM (No. 31/11 CEP/CEPEM 0018.0.046.000-
11 CAAE—SISNEP and Plataforma Brasil No. 74869 
CEP/CEPEM No. 05462612.7.0000.0011 CAAE). In 
April 2014, an amendment (No. 644.709 CEP/CEPEM) 
approved the inclusion of the second study site FMT-
HVD, in Manaus. The Brazilian National Council on Eth-
ics in Research (CONEP), Ministry of Health, accredits 
the CEPEM Ethics Committee. The study is registered 
at the Brazilian Register of Clinical Trials (RBR-79s56  s 
U1111-1132-8050), a primary repository of WHO. The 
clinical study was conducted in accordance with the Hel-
sinki Declaration (Edinburgh, 2000), Good Clinical Prac-
tice [19, 20] and the Brazilian National Health Council 
(CNS) resolution 466/2011. During the study, monitoring 
visits were conducted to ensure GCP adherence. Written 
informed consent was obtained for every subject prior to 
enrolment. If the study subject was illiterate, an impartial 
third party witnessed the informed consent process. All 
subjects were informed of the nature and possible associ-
ated risks of the trial and that they were free to withdraw 
their consent to participate at any time. The investigators 
and study staff ensured confidentiality of all records.
Efficacy and safety evaluations
Patients were assessed on the day of enrolment and on 
days 1, 2, 3, 7, 14, 21, 28, 42 and 63 days after study inclu-
sion. The scheduled study procedures comprised a full 
history, physical examination, and urinalysis at enrolment 
and assessment for clinical signs and adverse events (AE) 
at every follow-up visit. Blood samples were collected for 
parasite counts at 0, 3, 7, 14, 21, 28, 42 and 63 days, and 
haemoglobin was measured at 0, 14, 28, 42 and 63 days. 
An additional blood smear was also collected whenever 
treatment failed. Data was double entered using an elec-
tronic clinical record form (OpenClinica Community, 
version 3.1.3.1). Analysis was performed using R (version 
3.2.5).
The primary efficacy endpoint was the proportion of 
the population with an adequate clinical and parasito-
logical response (ACPR) at 63 days. Early treatment fail-
ure or late treatment failure were classified in line with 
standard WHO methodology [18]. The primary analysis 
was per protocol (PP); an intention-to-treat (ITT) anal-
ysis was also performed. The PP population excluded 
any participant with a protocol violation. Patients who 
missed the 28 or 42-day visit, but who had an ACPR at 
the subsequent follow visit was considered as a success at 
the previous visit. In the ITT population, protocol viola-
tions or losses to follow-up were considered as parasito-
logical and clinical failure.
The secondary efficacy endpoints included the success 
rate at day 3 (72 h after first drug administration) as well 
as gametocyte clearance, fever clearance, and the cumu-
lative success rate at days 28, 42 and 63.
The cumulative success rate by day 63, i.e. the probabil-
ity of remaining parasite-free at day 63, was calculated 
using a Kaplan–Meier survival curve. Categorical vari-
ables were summarized using frequencies and percent-
ages, while for quantitative variables, means, standard 
deviations (SD) and maximum–minimum values were 
used. Parasite counts were presented using geometric 
means.
The study was not designed to compare outcomes 
between treatment arms. However, exploratory analyses 
were conducted to explore the impact of the treatment 
arm on the safety and efficacy outcomes. The proportions 
of categorical variables were compared using Pearson’s 
Chi squared test with Yates’ continuity correction at sig-
nificance level of 5%. Nonparametric tests of Wilcoxon 
and Kruskal–Wallis were used for continuous variables. 
Additionally, generalized linear models (binominal and 
Poisson distribution, respectively) were used to estimate 
the effect of predictors (baseline characteristics and the 
use of other medications) on treatment success at day 63 
and the numbers of AEs that were possibly, probably or 
highly probably related to the treatment.
A safety analysis was conducted in the ITT population 
describing frequency, causality, and severity of AEs in 
each treatment arm. AEs reports were subdivided into: 
serious AEs, AEs leading to treatment suspension, and 
AEs which were described as possibly, probably or highly 
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probably related. The mean haemoglobin results at base-
line and follow-up are also presented.
Patients were encouraged to seek unscheduled assess-
ments if any AE was suspected. All clinical or laboratory 
abnormalities were categorized as Grade I to IV accord-
ing to the Common Terminology Criteria for Adverse 
Events (CTCAE) of the National Cancer Institute [21]. 
Any suspected serious AE (standard definitions) was 
reported to the sponsor and the Ethical Review Commit-
tee. Recognized drug-related events were recorded as an 
AE, even if it could be related to malaria.
Parasitological densities were estimated using 
Giemsa-stained blood slides at a magnification of 
1000× using WHO recommended methods [18]. Two 
trained microscopists read slides independently. The 
final density was calculated as the mean of the two read-
ings. A third microscopist examined slides if the two 
readers disagreed over whether there were parasites 
present, the species, or the parasite density (more than 
50% difference). In such cases, the final density was con-
sidered as the average of the two closest counts. A slide 
was considered as negative only after examining 1000 
leucocytes in microscopic fields. Gametocyte presence 
was also recorded.
Results
Baseline characteristics of the study population
A total of 2475 malaria thick smear positive patients were 
screened for inclusion in the two trial sites (CEPEM and 
FMT-HVD) from August 2012 to February 2015. 264 
(10.7%) were randomized (1:1:1) to one of three different 
treatment arms: CQ + Pq; ASMQ + Pq and AL + Pq. The 
same number of patients was allocated to each arm. The 
main reasons for not including patients were unavailabil-
ity for follow-up (19.9%), parasitaemia lower than 250/
μL (15.5%) and malaria treatment within the past 63 days 
(15.2%). Figure 1 shows the CONSORT flow diagram, see 
Additional file 1 for reasons not to be included. Twenty-
three patients did not complete the study; there was no 
difference in the proportions that discontinued between 
the arms. Only one protocol deviation occurred: the 
inclusion of a patient with a mixed infection, confirmed 
by PCR. The baseline characteristics of the patients were 
similar among the treatment groups (Table  1), and the 
ITT and PP populations.
There were 495 reports of concomitant medication 
use in the study. Analgesic and antipyretic were most 
frequently used (287 reports); there was no difference in 
use between the three arms. Use of anti-ulcer and anti-
spasmodic drugs were more common in the AL arm; 
accounting for 40.5% (15/27) and 69.6% (16/23) of the 
patients that used these classes, respectively.
A table presenting the medication used (grouped by 
therapeutic class) in each study arm, and a figure illus-
trating the most commonly used medications used per 
study visit and treatment group are provided (see Addi-
tional file 2).
Treatment adherence was 100% for ASMQ and CQ, as 
the dose during the initial 3 days was supervised. Nine-
teen patients reported AL non-adherence to the sec-
ond daily dose: 16 patients reported one missing dose, 
2 patients reported two missing doses, and one patient 
missed doses on three occasions. However, only one 
patient with incomplete AL adherence presented a treat-
ment failure at day 63. Patients were asked about Pq 
adherence at D7 visit. Only five patients reported incom-
plete treatment; two in each ASMQ + Pq and CQ + Pq 
arms and one in the AL +  Pq arm. None of them pre-
sented treatment failure.
Efficacy evaluation
The primary objective was to demonstrate cure rate 
above 90% in each study arm. The cure rate was defined 
as the proportion of the population with an adequate 
clinical and parasitological response (ACPR) at day 63. 
Cure rates were below 90% in all three treatment groups 
at day 63 in the PP population, although the 95% CI did 
include 90% for all three drugs: 85% (95% CI [77–93%]) 
of the ASMQ group, 88% (95% CI [81–95%]) of the CQ 
group, and 84% (95% CI [76–92%]) of the AL group 
achieved an ACPR at day 63. The cure rate of all the three 
treatment arms was greater than 90% at 28 and 42 days in 
the PP population (Table 2).
Cure rates in the ITT analysis were slightly lower (see 
Additional file 3) predominantly reflecting the very con-
servative approach to missing data. Secondary efficacy 
endpoints included the success rate at day 3 (72  h after 
first drug administration) and the cumulative success rate 
at days 28, 42 and 63, calculated using a Kaplan–Meier 
survival curve. These results are summarized in Fig. 2.
Parasitological success rates at day 3 were 100% for 
all arms in both PP and ITT analyses, apart from the 
AL + Pq arm where two dropouts (one informed consent 
withdraw, and one lost to follow-up) meant that the ITT 
success rate at day 3 was 98% (95% CI [98–100]).
Fever clearance is an important surrogate for cure in 
malaria. Only one patient in the CQ + Pq arm and two in 
the AL + Pq arm had an axillary temperature higher than 
37.5 °C at day 3. Four fever episodes were reported after 
day 7. One patient had fever at day 63 and was consid-
ered as a treatment failure. The other three patients com-
pleted 63 days follow up without evidence of parasites on 
microscopy. All patients cleared gametocytes by day 3. 
The five patients that had gametocytes present on day 2 
had all been treated with CQ + Pq (Fig. 3).
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Safety results
Three serious adverse events (SAE) were reported. One 
patient in the CQ arm had treatment suspended because 
of haemolytic anaemia on day 3. Qualitative calorimet-
ric test confirmed glucose-6-phosphate dehydrogenase 
(G6PD) deficiency. Another in the AL arm had a rise 
Fig. 1 CONSORT flow diagram
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in alanine aminotransferase (ALT) detected on day 12 
after treatment. The third SAE reflected elective surgery 
and was not related to the trial. All patients recovered 
completely.
The safety analysis was conducted in the ITT popula-
tion. A total of 1593 adverse events were reported. 1379 
of them (86.5%) were classified as grade I and 208 events 
(13.1%) were classified as grade II. The distribution of 
adverse events by age and weight range, and treatment 
arm is shown in Table 3.
749 events (41.0%) were reported as possible, probable/
likely or highly probably related to the treatment drug; 
48.9% were grade I, 35.1% were grade II, none grade III 
and one SAE (grade IV). The distribution of all adverse 
events according with their intensity and causality are 
presented at Table  4. The AE distribution per causality 
and treatment group is shown in Additional file 4.
The distribution of all adverse events according with 
their intensity and causality per treatment group is pro-
vided (see Additional file 5).
All adverse events (1593) were grouped based on the 
main body system affected and treatment allocation (see 
Additional file  6). Non-specific complaints were most 
common (483), followed by gastrointestinal (450). As 
these symptoms could reflect the clinical illness or an AE, 
they were only considered as AE, if they were not pre-
sent before dosing or they got worse after treatment. This 
overlap with symptoms may have led to an over estima-
tion of AE. Tables listing all AE with a frequency higher 
than 3% per regimen allocation are provided (see Addi-
tional file 7).
The study treatment AE profile was very similar 
between study groups with the only category showing 
any difference being the occurrence of insomnia and 
abdominal pain (p < 0.04 and p < 0.03 respectively), using 
Pearson’s Chi squared test.
Changes in haemoglobin (Hb) were a secondary out-
come. There was a slight decrease in all groups at day 
14 followed by recovery (Fig.  4). The median difference 
in haemoglobin at day 14 (Hb at day 14 −  Hb at base-
line/Hb at baseline) [22] in ASMQ + Pq, AL + Pq, and 
CQ +  Pq were −  0.74 (95% CI −  1.13; −  0.36), −  0.49 
(95% CI −  0.87; −  0.09), and −  0.58 (95% CI −  0.91; 
−  0.24), respectively. These were not statistically dif-
ferent. A drop of more than 20% from baseline was 
observed in 6 patients in each of the arms, ASMQ + Pq 
and AL + Pq and in 3 CQ + Pq patients. No patient had 
a drop of more than 30% from baseline. The mean and 
range haemoglobin at day 0, 14, 28, 42, and 63 is shown 
in Additional file 8. Unfortunately, haemoglobin was not 
Table 1 Baseline characteristics
Absolute number and percentage (%) were used to present categorical 
variables. Quantitative data presented using means, standard deviations (SD), 
and ranges [min–max]. Parasitaemia presented using geometric mean
Baseline characteristics Treatment group
ASMQ + Pq CQ + Pq AL + Pq
N (%) 88 (33.3%) 88 (33.3%) 88 (33.3%)
Study site
 CEPEM 66 (75.0%) 66 (75.0%) 66 (75.0%)
 FMT-HVD 22 (25.0%) 22 (25.0%) 22 (25.0%)
Gender
 Female 32 (36.4%) 22 (25.0%) 24 (27.3%)
 Male 56 (63.6%) 66 (75.0%) 64 (72.7%)
Age (years)
 > 59 3 (3.4%) 4 (4.5%) 3 (3.4%)
 18–39 45 (51.1%) 34 (38.6%) 49 (55.7%)
 39–59 40 (45.4%) 50 (56.8%) 36 (40.9%)
Weight (kg)
 > 80 25 (28.4%) 22 (25.0%) 27 (30.7%)
 50–65 27 (30.7%) 21 (23.9%) 23 (26.1%)
 65–80 36 (40.9%) 45 (51.1%) 38 (43.2%)
Fever
 < 37.5 48 (54.5%) 54 (61.4%) 53 (60.2%)
 > 37.5 40 (45.4%) 34 (38.6%) 35 (39.8%)
Weight (kg) 71.59 (10.99)
[51–90]
72.7 (10.34)
[53–90]
72.53 (10.59)
[50–90]
Temperature 37.45 (1.38)
[34.7–40.5]
37.31 (1.21)
[35.0–39.9]
37.38 (1.22)
[35.2–40.6]
Parasitaemia 2145 (2516.4)
[258–13,340]
2155 (2908.5)
[285–17,680]
2444 (3974.6)
[270–20,080]
Age (years) 38.75 (10.9)
[19.5–65.8]
41.88 (10.5)
[19.7–64.9]
37.24 (11.8)
[18.4–64.3]
Table 2 Proportion of treatment success per treatment arm in PP population at day 28, 42 and 63
Visit day Study treatment
ASMQ + Pq CQ + Pq AL + Pq
% (n) 95% CI % (n) 95% CI % (n) 95% CI
D28 100 (85) – 100 (82) – 96 (84) 92–100
D42 98 (83) 95–100 93 (82) 87–99 94 (82) 89–99
D63 85 (79) 77–93 88 (81) 81–95 84 (81) 76–92
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measured between 48  h and day 14; the lack of a day 7 
measurement is a limitation of this study.
The effect of the study population’s baseline charac-
teristics and the use of concomitant medication on the 
frequency of AE in each treatment arm was assessed. In 
this generalized linear model (Poisson distribution), the 
dependent variable was the count of possible, probable/
likely or highly probable AE related to the study treat-
ments per person. Adverse events were less common 
in males (OR 0.78; 95% CI 0.60–0.99; p = 0.04), but use 
of antipyretic or antihypertensive was associated with 
high rates of adverse events (OR 1.64; 95% CI 1.29–2.10; 
p  <  0.01 and OR 1.55; 95% CI 0.92–2.44; p  =  0.07, 
respectively).
Exploratory analyses
This study was not powered to detect differences in cure 
rates between treatment regimens and no statistically sig-
nificant difference could be detected between the treat-
ment arms at any time point.
A generalized linear model (binominal distribu-
tion) was used to explore the influence of baseline vari-
ables and concomitant treatments upon failure at day 
63, using a significance level of 5%. There was a strong 
association between the use of antipyretic medications 
Fig. 2 Kaplan–Meier survival analysis of the three treatment arms
Fig. 3 Clearance of gametocytes
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and treatment failure (OR 3.2; 95% CI 1.3–8.3; p = 0.01). 
A trend towards an association between the use of anti-
ulcerative drugs and treatment success was also observed 
(OR 0.12; 95% CI 0.001–0.73; p = 0.06).
The effect of the treatment on the time to clearance of 
gametocytes was evaluated in the three arms. Patients in 
the ASMQ + Pq and AL + Pq arm had all cleared game-
tocytes by day 2. In the CQ + Pq arm, 5 out of 43 patients 
(11.6%) had gametocytes present of day 2. Gametocytes 
only reappeared in five of the 103 patients, making mean-
ingful conclusions impossible.
Discussion
There has been recent international agreement that 
the importance of vivax malaria has been neglected 
[11, 23, 24], and that there is a need for new treatment 
approaches [25]. For most of the world, the first-line 
treatment recommendation of CQ + Pq has not changed 
since the 50s [11], despite the concerns about the emer-
gence of CQ-resistance [17]. Standard treatment has 
been based upon the need to clear both the red cell forms 
and the hepatic forms and the relatively slow emergence 
of resistance of P. vivax to chloroquine may be due to 
the fact that standard CQ +  Pq treatment has been an 
effective combination therapy [1]. In addition to clearing 
Table 3 Adverse events by  age, weight range, and  treat-
ment arm
Treatment group
n (%)
ASMQ + Pq CQ + Pq AL + Pq
Age (years)
 > 59 14 (30.4) 21 (45.7) 11 (23.9)
 18–39 190 (25.4) 255 (34.0) 304 (40.6)
 39–59 199 (24.9) 367 (46.0) 232 (29.1)
Weight (kg)
 50–70 131 (20.2) 238 (36.8) 278 (43.0)
 70–80 118 (25.8) 214 (46.7) 126 (27.5)
 80–90 154 (31.6) 191 (39.1) 143 (29.3)
Table 4 Distribution of all adverse events (1593) by intensity and causality
Italic values indicate the relevant safety outcomes
Grade Causality
n (%)
Total
Doubtful Unlikely Possible Probable/likely Highly probable
I 597 (37.5) 107 (6.7) 538 (33.8) 118 (7.4) 19 (1.2) 1379 (86.6)
II 86 (5.4) 49 (3.1) 62 (3.9) 10 (0.6) 1 (0.1) 208 (13.1)
IV 0 (0) 0 (0) 0 (0) 1 (0.1) 0 (0) 1 (0.1)
NA 3 (0.19) 2 (0.13) 0 (0) 0 (0) 0 (0) 5 (0.31)
Total 686 (43.1) 158 (9.9) 600 (37.7) 129 (8.1) 20 (1.3) 1593 (100)
Fig. 4 Haemoglobin per regimen allocation at day 0, 14, 28, 42, and 63
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hypnozoites, primaquine is active against blood stages of 
vivax [26] and chloroquine use also increases primaquine 
blood levels [27]; concomitant use of chloroquine and 
primaquine is more effective than sequential use [28].
ACT has been recommended by the WHO to treat 
vivax since 2010 [29], as it appears to have equivalent P. 
vivax schizonticidal activity to chloroquine [30] and it is 
recommended as the first-line treatment in areas of CQ-
resistant P. vivax emerges. There are compelling argu-
ments to look for a simpler and unified ACT treatment 
for both species of malaria. A single radical treatment 
would be useful in co-endemic areas where species 
diagnosis is difficult [31] or mixed infections occur that 
are misdiagnosed as P. falciparum. The use of ACT and 
primaquine for the treatment of P. falciparum infec-
tion also has the advantage of eradicating hypnozoites 
and preventing relapses from previous P. vivax infection 
that can happen following a P. falciparum infection [32]. 
There are also considerable logistic advantages for the 
use of ACT to treat both falciparum and vivax malaria 
with efficiencies of stock and supply management 
and an incentive to maintain ACT production as the 
requirement for falciparum treatment courses reduces.
In this study, all three treatment arms demonstrated 
cure rates > 90% in all treatment arms at day 42 but by 
day 63, cure rates had dropped below 90% (although all 
the 95% CI includes the 90% cure rate). It demonstrates 
the importance of a longer follow-up time in detecting 
failures, particularly in vivax when reinfection or relapse 
can occur [33]. This study did not detect any advantage 
from the use of an ACT with a longer half-life partner 
drugs, as has been shown previously; this may be due 
to the concomitant use of primaquine in our study [34]. 
Further studies with PCR analysis in an attempt to dis-
criminate reinfection from relapse would be of interest.
Drug interactions and the safety profile are important 
factors in choosing the optimum first line treatment, in 
addition to pill burden and food restrictions. This trial 
evaluated the efficacy and safety of three vivax treat-
ment regimens, and provides additional reassurance 
about the safety of ASMQ and AL when given with pri-
maquine; information that is considered important by 
WHO as strategies for control and elimination of P. vivax 
malaria are developed [1]. Most of the AE with ACT regi-
mens were mild to moderate (CTCAE grade I or II), and 
required minimal intervention. The frequencies of possi-
bly, probably/likely or highly probably related AE did not 
substantially vary between the CQ + Pq regimen and the 
ACT + Pq regimens.
Despite this low level of adverse events, the ACT and 
primaquine combination still has significant drawbacks. 
Its use is limited in pregnancy, breastfeeding and G6DP-
deficient population. The one SAE in this study was 
related to G6PD deficiency. These restrictions impose 
serious limitations to its use as an elimination tool in 
many parts of the world, although the primaquine regi-
men used in this study is the 7-day regimen currently 
recommended by the Brazilian National Malaria Control 
Programme. This regimen delivers a total dose from 3 
to 4.2 mg/kg [13]. This is the WHO recommended total 
dose (although suggested over 14 days) and this regimen 
retains efficacy in some parts of the world [35–37]. The 
7 day regimen has been suggested to improve adherence 
[13], although this has never been clearly demonstrated.
This study was not sufficiently powered to detect dif-
ferences between the three arms and only followed up 
patients for 63 days, meaning that late relapses would not 
have been detected. The study population did not include 
children, limiting the conclusions of efficacy in this pop-
ulations. The absence of PCR also meant that relapses 
could not be distinguished from reinfection; a critical 
issue in assessing vivax treatment. Nevertheless, this 
study demonstrates the efficacy and safety of two ACT 
and CQ in combination with 7  days of primaquine to 
treat uncomplicated vivax malaria in Brazil and demon-
strated the feasibility and utility of a standardized treat-
ment approach for all malaria cases.
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Introduction Chapter III 
Ancillary results of ACT vivax trial 
 
 
There is an undeniable need for new treatment for vivax (Price et al., 2011) with higher 
acceptability and a better safety profile. The emphasis on tolerability of a new vivax 
treatment is critical, as this disease can present mild symptoms (in the partially immune 
population) and have a low lethality. In Brazil, the vivax mortality was 11/140000  
patients in amazon region (Secretaria de Vigilância em Saúde, 2015), in 2014. Thus, 
serious adverse events related to any new treatments are unacceptable. For instance, this 
is the main reason for holding back the wide deployment of the single dose long half-life 
8-aminoquinoline, tafenoquine.  
 
ACTs with concomitant use of primaquine short course (0.5 mg/kg/day for 7-9 days) is 
the first choice to treat mixed malaria in Brazil (Ministério da Saúde do Brasil., 2010) 
and was prescribed to approximately one thousand patients over one year alone (Daher et 
al., 2019). Nevertheless, even in Brazil, there is a relative lack of data on the safety of 
ACTs for the radical cure of P. vivax (World Health Organization., 2015a), as 
programmatic use relies on passive pharmacovigilance to detect adverse events (AEs). 
Further evaluation on the safety of these regimens is opportune as they might became a 
therapeutic option to treat @171 thousand P. vivax cases per year (Secretaria de Vigilância 
em Saúde, 2019)  in Brazil.   
 
The study Efficacy and safety of Artemisinin-based Combination Therapy and 
chloroquine with concomitant primaquine to treat Plasmodium vivax malaria in Brazil: 
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an open label randomized clinical trial (Daher et al., 2018a)   was the first time that fixed 
dose combinations of artesunate plus mefloquine and artemether plus lumefantrine were 
evaluated with concomitant use of primaquine during 7-9 days for the radical treatment 
of P. vivax in clinical trial conditions in Brazil. These conditions allowed a careful record 
of efficacy and safety outcomes. This current analysis links this high quality clinical data 
with new laboratory results that characterize the parasites, the patients’ drug metabolism 
and their pharmacokinetics parameters. 
 
The characterization of the parasites was performed by genotyping three microsatellite 
loci and two polymorphic loci of Merozoite surface antigen-1. This allowed classifying 
recurrence as related relapses or reinfections/unrelated hypnozoite activation. The 
patients’ drug metabolism was assessed by genotyping and classifying the activity of 
cytochrome P450 enzymes CYP2D6 (Bennett et al., 2013) (Baird et al., 2018) and 
CYP2C8 (Gil and Gil Berglund, 2007), as both are known to participate in the metabolism 
of the primaquine and chloroquine, respectively. The pharmacokinetic parameters (Area 
Under the Curve (3-63d) and the terminal elimination half-life) of mefloquine, 
chloroquine and lumefantrine were measured in whole blood using a validated high 
performance liquid chromatography-tandem mass spectrometry method. 
 
Initially, we explore the influence of pharmacokinetics upon the safety of these regimens, 
as higher drug exposures could be associated with a higher frequency of adverse events. 
Throughout this trial, 1593 adverse events were recorded from 251 patients allocated in 
three treatment arms during 63 days follow up. Only one serious adverse event was 
related to the treatment: a patient in the chloroquine arm presented haemolytic anaemia 
on day 3 due to confirmed glucose-6-phosphate dehydrogenase (G6PD) deficiency. Most 
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of the events (86.6%) were grade I (institute, 2010) highlighting the commitment of the 
research team in defining the treatments’ safety profiles.  
 
The adverse events classified as possible, likely and highly probable related to the test 
drugs were grouped by body system. The influence of the pharmacokinetic parameters, 
gender and weight in the frequency of AEs were assessed. The single statistically 
significant association was the relative risk of having pruritus and the chloroquine half-
life (RR 1.09, 95% CI 1.03-1.14, p= 0.001). Although this association is well known, the 
result was an indicative that this assessment could detect the relation of AEs and drug 
exposure.  
 
The study also explored the influence of pharmacokinetics upon the therapeutic success 
of these regimens, as the drug exposure under the therapeutic threshold could potentially 
explain the relapses and recrudescence; lower parasite clearance by day-3; or shorter time 
to failure. No influence of pharmacokinetics upon the efficacy outcomes could be 
detected. Nevertheless, these evaluations were conducted in small samples meaning that 
a true association may not be stablished due to lack of power. 
 
Finally, the most interesting results were the influence of characterization of parasites and 
patients’ drug metabolism upon the therapeutic failures. Relapses are a major contribution 
to the global P. vivax burden and a central target to improve the efficacy of the radical 
treatment. The characterization of parasites often demonstrates that relapses are due to 
heterologous activation of hypnozoites (de Araujo et al., 2012, Imwong et al., 2007), 
although, in this study most of the relapses were due to homologous parasites, excluding 
re-infection. The study also shown that impaired primaquine metabolism (reduced 
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activity of the enzyme CYP2D6) was higher in population with homologous relapses 
(26%) than in the general population (@ 11%) (Gaedigk et al., 2017). These results 
highlighted the importance of primaquine in the efficacy of radical treatment of vivax, as 
they linked impaired bioavailability of primaquine active metabolites to high failures 
rates, although with no statistical significance (RR= 1.23, CI 95% 0.88-1.72, p=0.40).   
 
The results also suggest that the efficacy of the radical treatment may not be critically 
related to the long half-life drugs in the doses administered in the study. Therefore, the 
Brazilian effort to improve the efficacy of the vivax treatment can benefit from a new 
formulation of primaquine that ensure drug exposure comparable to the FDA reference 
product (FDA, 2019). A new primaquine formulation has been developed, and it may 
increase the bioavailability of the drug and its active metabolites, even in those patients 
with impaired CYP2D6 activity. The ongoing primaquine bioequivalence study might lay 
the basis needed to further explore the influence of primaquine exposure upon the 
therapeutic success of these regimens. 
 
Overall, these results provided further reassurance about the safety of the combined use 
of ACTs and short course primaquine to treat malaria vivax. Despite the encouraging 
results, the study has several limitations, specially a small sample size. Lastly, the need 
for strengthening the pharmacovigilance system and conducting phase IV studies to 
ensure safety of thousands of patients when deploying a new treatment in remote areas 
must be reiterated. 
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Abstract 
Background 
 
Activation of hypnozoites of Plasmodium vivax malaria causes multiple clinical relapses, 
which contribute to the P. vivax burden and continuing transmission. Artemisinin-based 
combination therapies (ACT) are effective against blood-stage P. vivax but require co-
administration with primaquine to achieve radical cure. The therapeutic efficacy of 
primaquine depends on the generation of a therapeutically active metabolite via 
cytochrome P450 2D6 (CYP2D6). Impaired CYP2D6 metabolism has been associated 
with primaquine treatment failure. This study investigated the association between 
impaired CYP2D6 genotypes, drug-exposure to the long-acting ACT component 
(schizonticidal drugs) and tolerance and efficacy.  
Methods 
Adult patients with acute P. vivax malaria were enrolled in a recently completed trial and 
treated with artesunate-mefloquine; chloroquine; or artemether-lumefantrine. All 
received concomitant primaquine (0.5 mg/kg/day for 7–9 days). The association between 
efficacy and safety and drug exposure was explored using Area-Under-the-Curve (AUC) 
and half-life (t1/2) estimates obtained by non-compartmental analysis of the long half-life 
drugs. Parasite recurrences by day-63 were categorized as related relapses or 
reinfections/unrelated hypnozoite activation by genotyping three microsatellite loci and 
two polymorphic loci of Merozoite surface antigen-1. The CYP2D6 genotype was 
identified with Taqman Assays by Real-Time PCR to 9 polymorphisms (eight SNPs and 
one deletion). Impaired CYP2D6 activity was inferred using the Activity Score System. 
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Results  
Most recurrences in the ASMQ (67%), CQ (80%) and AL (85%) groups were considered 
related relapses. 8/9 (88.9%) of the patients with impaired CYP2D6 activity relapsed with 
related parasite compared to 18/25 (72%) with normal activity (RR= 1.23, 0.88;1.72, 
p=0.40). There were no associations between the measured PK parameters and 
recurrence.  Patients with longer chloroquine half-lives had more pruritus (RR=1.09, 
1.03;1.14, p=0.001). Higher CQ AUCs were associated with reduced falls in haemoglobin 
by day 14 (Coef -0.02, -0.005;-0.03, p=0.01). All regimens were well tolerated. 
Conclusion 
Genotyping of P. vivax showed that activation of related (homologous) hypnozoites was 
the most frequent cause of recurrence. The high proportion of the impaired CYP2D6 
activity among patients with recurrent infections suggests that slow primaquine 
metabolism might influence related relapse rates in Brazil among patients receiving 
primaquine for radical cure, although confirmatory studies are needed. There was no 
association between drug exposure of the long-acting ACT component (schizonticidal 
drugs) and risk of related relapse. ACTs were well tolerated. These results provide further 
re-assurance about the safety and efficacy of ACTs when combined with short course 
primaquine to treat uncomplicated malaria vivax in Brazil.  
Trial registration RBR-79s56s (http://www.ensaiosclinicos.gov.br/rg/RBR-79s56s/) 
 Keywords 
Malaria, Plasmodium vivax, antimalarial treatment, chloroquine, mefloquine, 
lumefantrine, primaquine, artemisinin-based combination therapies, ACT, 
pharmacokinetics, clinical trial. 
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Background 
 
The biological features of Plasmodium vivax malaria provide major challenges for pre-
elimination and elimination programmes in areas co-endemic for P. falciparum and P. 
vivax [1] [2] [3]. These features include the early appearance of gametocytes, a high 
proportion of asymptomatic or chronic carriers [4] and the parasite latent form, 
hypnozoites, that produces relapses. Relapses make a major contribution to the global of 
the P. vivax burden [5]. It was estimated that relapses constituted 76–90% and 79% of 
total infections in a Papua New Guinea and Thailand respectively [6]. To eliminate this 
reservoir of latent infections, simple, effective radical treatment of vivax using 8-
aminoquinolines such as primaquine or the recently approved analogue tafenoquine is 
required.  
In most countries with endemic P. vivax, the preferred first-line radical treatment for P. 
vivax remains chloroquine, combined with 7 to 14-day primaquine regimens, and this has 
barely changed since the 50’s [7]. Chloroquine is no longer recommended for the case-
management of  P. falciparum malaria due to the spread of parasite resistance [8] 
resulting in the use of different treatment regimens for P. vivax and P. falciparum in areas 
where these species are co-endemic. This is programmatically complicated. The use of a 
single regimen to treat all species of malaria would simplify malaria treatment guidelines 
[9]. Artemisinin-based combination therapies (ACT) are emerging as the best option in 
this context, particularly in settings where there are concerns about chloroquine-resistant 
P. vivax [10]. ACTs are effective against the blood stage of P. vivax [11] but must be co-
administered with primaquine to eliminate P. vivax hypnozoites [10, 12]. Short course 
primaquine regimens are preferable as they have been proven to have an efficacy not 
inferior to the standard 14 days’ regimens [13-16]. However, there is a relative lack of 
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data on the safety, pharmacodynamics and pharmacokinetics of ACTs when provided in 
combination with daily primaquine regimens for the radical cure of P. vivax [17]. Safety 
is a major concern when deploying new treatments, but in the case, there are also concerns 
that primaquine / ACTs drug interactions may reduce the overall regimen efficacy, by 
inhibiting CYP2D6 or reducing synergistic effect of the current regimen. There are 
uncertainties about the best partner ACT, as drugs with a longer half-life may prevent 
early relapses.  
Characterization of parasites and patients’ drug metabolism is needed to ascertain the 
pharmacodynamics, pharmacokinetics and therapeutic success of these regimens. The 
main malaria clinical trials outcomes are parasitological clearance and recurrence rate 
[21]. Vivax recurrence includes (i) recrudescence of parasites that have been previously 
cleared and microscopically undetectable; (ii) re-infection from another mosquito bite; 
(iii) relapses, i.e. activation of hypnozoites, genetically related (homologous) or unrelated 
(heterologous). The primaquine metabolite that is active against human hypnozoite is 
unknown  [22], but the metabolism of primaquine to its active metabolite is dependent on 
the cytochrome P450 enzyme CYP2D6 [22-24]. Low CYP2D6 activity results in slow 
metabolism of primaquine to the active metabolite. CYP2D6 activity  may be a proxy of 
primaquine’s active metabolite exposure and a risk factor for relapse among primaquine 
recipients [25-27]. Similarly, the cytochrome P450 enzymes CYP2C8 was investigated 
as it is known to participate in the metabolism of chloroquine [28]. 
A previous randomized clinical trial in Brazil of the treatment of uncomplicated P. vivax 
malaria compared the safety and efficacy of the fixed-dose ACTs artemether-
lumefantrine and artesunate-mefloquine against the standard treatment with chloroquine, 
all three in combination with short course primaquine (0.5 mg/kg/day for 7–9 days) [29]. 
This current study investigated the pharmacokinetics of the long-acting ACT component 
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(schizonticidal drugs) with concomitant primaquine upon the safety and efficacy of these 
three treatment regimens and the influence of genetic variability of parasite and host, 
including the frequency of mutations in CYP2D6 gene over relapse rate.  
 
Methodology 
Overview study design 
The patients included in the current analysis were enrolled in a larger clinical trial 
previously published and designed in accordance with WHO guidelines [21]. The trial 
was designed to evaluate the safety and efficacy of the schizonticidal drugs with 
concomitant use of primaquine for vivax cure. The details of the trial design and methods 
have been reported elsewhere [29]; In brief, patients were eligible if they had acute 
uncomplicated malaria due to P. vivax mono-infection confirmed by microscopy with 
fever or a history of fever in the previous 48 hours, were aged 18 to 70 years old, weighed 
between 50 and 90 kg, and had parasite densities >250/µL and haemoglobin levels >7.0 
g/dL. G6DP deficiency was not an exclusion criterion. They were randomly allocated to 
three treatment groups: a) artesunate-mefloquine (100+200 mg QD for 3 days) (ASMQ); 
b) chloroquine (CQ) (600 mg on day 1, and 450 mg on days 2 and 3), and c) artemether-
lumefantrine (20+1 20 mg BID for 3 days) (AL). All three arms received the same 
concomitant primaquine regimen (7–9 days: 0.5 mg/kg/day).  
Patients were assessed on the day of enrolment and days 1, 2, 3, 7, 14, 21, 28, 42 and 63. 
The main end-points were either treatment failure or adequate clinical and parasitological 
response. Blood samples were collected for parasite counts at every scheduled visit, on 
any day of treatment failure and for drug levels on days 0, 3, 7, 14, 21, 28, 42 and 63. 
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Samples (100 µL) were transferred to Whatman (USA) ET 31 CHR E 3MM filter papers 
for later pharmacokinetic analysis and parasite genotyping [30].  
Parasitological densities were estimated using Giemsa-stained blood slides at a 
magnification of 1,000x using WHO-recommended methods [21]. Adverse events (AE) 
were assessed at each follow-up visit, and patients were encouraged to return to the clinic 
if they were ill in between scheduled visits. All AEs, including laboratory abnormalities, 
were categorized by body system. 
Pharmacokinetics/ Pharmacodynamics 
Whole blood concentrations of mefloquine (MQ), chloroquine (CQ) and lumefantrine 
(LMF) were measured using a validated HPLC-MS/MS method in accordance with 
Brazilian [31] and international regulatory requirements for bioanalytical methods [32]. 
The pharmacokinetics assays were conducted at the Equivalence and Pharmacokinetics 
Service (SEFAR)/Oswaldo Cruz Foundation, which is accredited by the Brazilian 
regulatory agency, Agência Nacional de Vigilância Sanitária (ANVISA). Non-
compartmental analysis was performed for chloroquine, lumefantrine and mefloquine 
using the Pmetrics® [33] package to estimate two main parameters; the overall Area 
Under the Curve (AUC) (3-63d) and the terminal elimination half-life (t1/2). The terminal 
elimination half-life was only calculated for subjects with five or more available samples. 
These two parameters were used as proxy indicators for overall drug exposure for 
correlation analyses with drug efficacy and safety profiles.  
The correlation between drug exposure and treatment failure was evaluated using the 
Mann-Whitney test. The effect of pharmacokinetic parameters on the frequency of 
adverse events likely or probably related to the test drug was expressed as the relative 
risks (RR) obtained from random effects Generalized Estimation Equation (GEE) log-
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binomial regression models. Linear regression was used to test the effects of PK 
parameters on the fall in haemoglobin (Hb) concentrations by day 14 relative to enrolment 
values [34]. The effects of these pharmacokinetic parameters on treatment failure (both 
early and later failures) were evaluated as odds ratios (OR) from binomial logit link 
regression models, using Generalized Linear Models (GLM). Time to failure was tested 
using standard Cox regression. The proportion of clonal variability at recurrence was 
compared between treatment arms using Fisher’s exact test. Two-sided p-values of <0.05 
were considered statistically significant. 
DNA extraction and Genotyping of the Parasites microsatellites and 
polymorphic blocks of MSP-1 and patients´ CYP2D6 and CYP2C8  
DNA was extracted from dried blood using QIAamp DNA blood mini kit (Qiagen, 
Hilden, Germany) following the instructions of the manufacturer. Three microsatellite 
loci (MS2, MS6, MS7) and two polymorphic loci (blocks 2 and 10) of Merozoite surface 
antigen 1 (MSP-1) were amplified using specific primers and conditions as previously 
described [35, 36]. The exact length and relative abundance (fluorescence levels) of each 
PCR product were determined in the DNA automatic sequencer (ABI 3730, Applied 
Biosystems, Thermo Fischer Scientific, Waltham, MA, USA) with fluorescein labelled 
forward primers and an internal size standard (GeneScan 500 LIZ, Applied Biosystems). 
The predominant allele for each locus was identified as the highest peak of fluorescence 
in the electropherogram using GeneMapper 4.1 software (Applied Biosystems). The 
multiplicity of parasite variants was estimated measuring extra peaks in the 
electropherogram with fluorescence above the cut off (150 arbitrary fluorescence units) 
and at least one third the high of the main peak. Parasite recurrences within 63 days were 
categorized as ‘related’, including totally identical (homologues) if all five polymorphic 
loci (MS2; MS6; MS7; MSP1B2; MSP1B10) were identical and ‘similar’ if 80% of their 
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alleles were identical; and otherwise as unrelated (heterologous) (eTable 1). Number of 
alleles and heterozigosity expected were calculated in Arlequim software v. 3.5.2.2 
(http://cmpg.unibe.ch/software/arlequin35/). 
The cytochrome P450 enzymes CYP2D6 [24] [22] and CYP2C8 [28] are known to 
participate in the metabolism of the primaquine and chloroquine, respectively. Two SNPs 
(G416A[rs11572080] and A805T [rs11572103]) were genotyped in the CYP2C8 gene. In 
the CYP2D6 gene eight SNPs were genotyped; (G-1584C [rs1080985], C100T 
[rs1065852], C1023T [rs28371706], G1846A [rs3892097], C2850T [rs16947], G2988A 
[rs28371725], G3183A [rs59421388] and G4180C [rs1135840]) and one deletion (2615-
2617delAAG [rs5030656]) were genotyped. The copy number was also determined. All 
SNPs genotyping were performed by Real-time PCR using specific hydrolysis probe [37] 
in ViiA 7 Real-time PCR system (Applied Biosystems). Haplotypes and CYP2D6 star 
alleles were inferred using the Phase software (version 2.1). CYP2D6 gene copy number 
was determined with Hs00010001_cn assay (Applied Biosystem) in Real-time PCR [38]. 
Each allele got one value that was used to calculate the CYP2D6 activity score (AS). 
Patient were categorised based on their AS score into normal metabolizer fast (gNM-F) 
(AS=1.5 or 2.0), normal metabolizer slow (gNM-S) (AS=1), intermediate metabolizer 
(gIM) (AS=0.5), poor metabolizer (gPM) (AS=0), and ultra metabolizer (gUM) (more 
than 2 copies of the normal allele) (AS³2.0) [35]. Impaired CYP2D6 activity was defined 
as AS scores less than 1.5. 
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Results 
Population 
 
These study is based on a subset of samples from the original trial. Only 2/3 of samples 
(1400 samples of 175 patients) were evaluated in Pharmacokinetics/ Pharmacodynamics 
analysis due to logistical issues, however the baseline characteristics of this subset were 
similar across the three arms (Table 1). Characterization of parasites and drug metabolism 
was conducted in all 35 patients with parasite recurrence within 63 days. 
TABLE 1. BASELINE CHARACTERISTICS OF THE STUDY POPULATION 
  ASMQ CQ AL 
N of patients 60  58  57 
Male n (%) 35 (58) 46 (79) 39 (68) 
Weight in kg 70 (11) 73 (10) 73 (10) 
Haemoglobin in g/dL 13.4 (1.8) 14.0 (3) 13.6 (2) 
Parasitaemia/uL* 2145.56 [258-13335]  2155.78 [285-17685]  2444.71 [270-19815]  
Age in years 39.0 (11) 42.1 (10.5)  38.7 (11)  
Data represent n (%) and means and (SD).  
*Parasitaemia was expressed by geometric mean and [min-max]. 
 
Characterization of parasites and drug metabolism in the population with 
treatment failure. 
The frequency of ‘related’ (homologous and similar) and unrelated (heterologous) 
parasites among 35 patients with parasite recurrence within 63 days by study arm is 
shown in Table . Overall, 67%, 80% and 85% of the recurrent malaria in the ASMQ, CQ 
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and AL groups respectively were considered related relapses.  Among the recurrences the 
pooled percentage of related relapses across the three arms was 77.1%. 
TABLE 2. CLINICAL OUTCOMES AGGREGATED BY DRUG TREATMENT (%). 
Clinical outcome 
(%) 
PCR results ASMQ CQ AL overall 
Homologous 
relapse  
homologous 6 66.7
% 
6  80.0
% 
8  84.6
% 
20 77.1
% similar 2 2 3  7 
Reinfections or 
Heterologous 
hypnozoites’ 
activation 
heterologous 4 
33.3
% 2  
20.0
% 2  
15.4
% 8  
22.9
% 
 
Genetic analysis of the parasite populations comparing all recurrences also demonstrated 
that 77.1% (27/35) of patients presented with a single clonal infection at the initial 
infection and at the recurrence. The number of parasite variants between initial infection 
and recurrence remained the same in 23 (65.7%) of the 35 patients with recurrent 
infections and increased in 10 (28.5%) and decreased in 2 (5.7%). There was no 
difference in multiplicity of parasite clones at recurrence between treatment arms 
(p=0.51).  
CYP2D6 
TABLE 3. INFERRED PHENOTYPE OF CYP2D6 BASED ON GENOTYPING BY 
TREATMENT ARM (%). 
CYP2D6 metabolism  AS Phenotype ASMQ CQ AL* 
Normal 1.5 
or 2 
gNM-F 5 50.0% 9  90.0% 9 81.8% 
 ≥ 2 gUM 1  0  0  
Impaired  1 gNM-S 5 50.0% 0  10.0% 2 18.2% 
 0.5 gIM 0  1  0  
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Eight of nine (88.9%) patients classified to have reduced enzymatic activity for 
primaquine metabolism based on their CYP2D6 genotypes relapsed with related parasites 
(RR= 1.23 95%CI (0.88-1.72) p=0.40) (Table). Eighteen out of 25 (72%) normal 
metabolisers had related relapses.  
CYP2C8 
The frequency of two polymorphisms in CYP2C8 gene in the population who failed is 
presented in Table. Out of the ten patients in the CQ arm with parasite recurrence, one 
had the SNP G416A genotype indicative of reduced enzyme activity of CYP2C8. The 
AUC and half-life for chloroquine of this patient were 91.9 µg/mL.h and 11.32 days 
respectively, compared with 102.3 µg/mL.h and 19.3 days in the nine CYP2C8 non-
mutated genotypes in the CQ arm. These results for the patient with the mutated genotype 
fall within the 95% CI for the overall population (Table).  
TABLE 4. INFERRED PHENOTYPE OF CYP2C8 BASED ON GENOTYPING BY DRUG 
TREATMENT GROUP. 
CYP2C8 (SNP) Genotype MQ CQ LMF 
G416A Normal 7 9 13 
Mutant* 5 1 0 
A805T Normal 12 10 13 
Mutant 0 0 0 
*All mutants are heterozygotes. 
 
 0 gPM 1  0  0  
AS = Activity Score; gNM-F = normal-fast metabolizer; gUM = ultrarapid 
metabolizer; gNM-S = normal-slow metabolizer; gIM = intermediate metabolizer 
and gPM = poor metabolizer. 
*CYP2D6 phenotype of two patients (ID 33 and 231) could not be defined. 
* CYP2D6 genotype of two patients (ID 33 and 231) could not be defined 
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Pharmacokinetics/Pharmacodynamics 
AUC0d-63d values were calculated for each patient in each arm; the terminal elimination 
half-life (t1/2) could only be calculated for those receiving chloroquine or mefloquine. 
Figure 1 shows the terminal PK profile generated for mefloquine, chloroquine and 
lumefantrine.  
FIGURE 1 PHARMACOKINETIC PROFILE OF MEFLOQUINE (MQ), LUMEFANTRINE (LMF) 
AND CHLOROQUINE (CQ). PROFILES WERE GENERATED FROM 58-60 SUBJECTS FOR EACH 
DRUG. DATA SHOWS MEDIAN WITH 95 CONFIDENCE INTERVAL (CI).  
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Drug exposure (defined by AUC3d-63d or elimination half-life) under the therapeutic 
threshold could potentially explain the relapses and recrudescence, but not re-infections. 
The relationship of drug exposure (defined by AUC3d-63d or elimination half-life) to 
recurrence was investigated by comparing the PK parameters in the cured population with 
those with confirmed related relapse (homologous + similar). There were no statistically 
significant differences in AUC3d-63d or elimination half-life for MQ, CQ or LMF 
between patients without recurrent infections by day-63 and those with relapses in 
univariate (Table). Weight and gender were also not associated with parasite recurrence 
by day 63 (eTable 3); parasite clearance by day-3 (eTable 4); or time to failure (eTable 
5).  
TABLE 5. MEDIAN OF PHARMACOKINETIC PARAMETERS FOR MEFLOQUINE, CHLOROQUINE 
AND LUMEFANTRINE IN  PATIENTS WITH HOMOLOGOUS PARASITES BY TREATMENT 
OUTCOME. 
  Mefloquine Chloroquine Lumefantrine 
 Cure Relapse p-
value 
Cure Relapse p-
value 
Cure Relapse p-
value 
N of patients 53 6 - 52 7 - 52 7 - 
AUC  (0d-
63d) 
(µg/mL.h) 
Per 
outcome 
338.6 302.0 0.67 105.9 95.8 1.0 7.3 3.73 0.96 
overall 338.6 [256.0-
408.0] 
- 103.8 [83.0-126.3] - 6.7 [2.7-12.0] - 
Half-life 
(days) 
Per 
outcome 
17.7 25.6 0.58 18.5 19.3 0.42 NA NA - 
overall 17.8 [15.0-24.8] - 18.7 [15.4-27.8] - NA  - 
Overall values are median with 25-75 percentiles in square brackets and N=59. NA= Non-
Applicable 
 
Higher drug exposures could be associated with a higher frequency of adverse events. 
The influence of AUC, half-life and weight on the frequency of adverse events likely and 
probably related to the treatment per body systems (n ≥30) are presented in eTable7. The 
relative risk of having pruritus increased as the half-life of chloroquine increased (RR 
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1.09, 95% CI 1.03-1.14, p= 0.001). Conversely, the influence of drug exposure on the 
haemoglobin drop (defined as Hb at day 14 − Hb at baseline/Hb at baseline) shown that 
the higher the AUC of CQ the lower the reduction in the haemoglobin decline (Coef -
0.02, 95% CI -0.03;-0.00, p=0.01) (eTable 6). 
Discussion 
This study showed by genotyping polymorphic loci of P. vivax that relapse due to related 
parasites  was the most frequent cause of recurrence by day-63 in all three treatment arms 
of our previous trial [20] where 13-16% of infections recurred by day-63. The current 
study also showed that the treatment failure rate in patients with reduced inferred 
CYP2D6 activity (26%) was higher than in the general population (@ 11%) [39]. 
Moreover, eight out of nine recurrences among patients with low CYP2D6 activity were 
related relapses  compared to 18 out of 25 with inferred normal CYP2D6 activity. Low 
CYP2D6 activity and presumptive low exposure to the active metabolite of primaquine 
or disruption of the PQ-enzyme interactions might influence related relapse rates in 
Brazil, although further studies are need to elucidate this effect. Likewise, the impaired 
activity of CYP2C8 may result in a lower exposure to desethylchloroquine, the 
chloroquine active metabolite. The PK parameters and clinical outcomes of the single 
patient with impaired CYP2C8 in chloroquine arm did not differ from the overall 
population. 
Other causes of low exposure to primaquine are also potential risk factors for relapses, 
such as low adherence or impaired bioavailability. Similarly, others factors which affect 
the success of anti-infective therapeutics may influence the responses to the radical 
treatment, such as differences in the biology of the parasite, the immune status of the 
patients and the density of latent hypnozoites [3].  
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This was the first time it was evaluated that some of the ACT combinations, namely 
ASMQ, were evaluated for the cure of P. vivax in clinical trial conditions, and thus in 
combination with daily primaquine (0.5 mg/kg/day for 7-9 days) regimens. The 
correlation between drug exposure to the long-acting components of the ACTs and the 
risk of recurrence and adverse events was also assessed. Potential interactions between 
primaquine and the ACTs and also, the safety of these regimens have not been extensively 
assessed [17].  Drug interactions such as lumefantrine inhibiting CYP2D6 [40] may 
reduce the overall regimen efficacy;  on the other hand, drugs with a longer half-life may 
prevent early relapses. This study could not demonstrate a significant associations 
between the PK parameters of the long half-life drugs and the risk of recurrence, or the 
risk of relapse due to either homologous and heterologous relapses or time to recurrence 
(eTable3, eTable4, and eTable5, respectively), although the numbers of relapses were 
small.  Patients with longer chloroquine elimination half-life estimates were more likely 
to report pruritus. Transient, mild to moderate pruritus is a well-known adverse effect of 
chloroquine [41] and a threat to treatment adherence. A smaller drop in haemoglobin by 
day 14 was associated with higher CQ exposure (AUC), which may reflect better 
therapeutic efficacy achieved with higher concentrations of CQ [42].  
This study has several limitations. The blood sampling schedule was designed to evaluate 
the blood levels of the long half-life drugs; the pharmacokinetic data allowed the 
prediction of the drug exposures up to 63 days post-treatment with up to eight sample 
points available for each patient. It did not allow a proper modelling of primaquine levels 
and limited the calculation of the elimination half-life of lumefantrine. The absence of 
desethylchloroquine blood levels measurement is another study limitation. A trial 
designed with six month follow up would have been able to evaluate relapses with more 
accuracy, as the median time to vivax recurrence in Brazil is 71 days [15]. The 
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characterization of parasites and drug metabolism were conducted only in 35 patients 
with treatment failure limiting the comparisons. Genotyping vivax parasites to infer 
relapse frequencies also presents limitations. Genotyping in vivax does not allow 
differentiation between new infections (reinfections) or activation of unrelated 
(heterologous) hypnozoites. In this study, only recurrences with homologous and similar 
parasites were considered relapses. However, relapses are often heterologous activation 
of hypnozoites [36, 43]. The recrudescence of submicroscopic parasite population [44] is 
also a biologically plausible explanation for homologous parasites in two samples. Future 
use of more sensitive parasite detection strategies, such as ultrasensitive PCR of all 
consecutive samples of the patients who failed could elucidate these results.  
Conclusion 
The genotyping of polymorphic loci of P. vivax showed that relapse due to genetically 
related parasites was the most frequent cause of recurrence in all three treatment arms. 
The high proportion of CYP2D6 genetic polymorphisms among patients with recurrent 
infections suggests that impaired primaquine metabolism might influence the related 
relapse rates in Brazil among patients receiving primaquine for radical cure, further 
studies are needed to confirm this finding. The three ACT regimens were very effective, 
and there was no association between drug exposure levels of the long-acting components 
of the ACTs and risk of relapse. The ACTs were well tolerated overall. These results 
provided further reassurance about the safety of the combined use of ACTs and short 
course primaquine (0.5 mg/kg/day for 7-9 days) to treat uncomplicated malaria vivax in 
Brazil.  
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Conclusion 
 
 
Vivax malaria is a neglected disease. Recent reversal of the trend towards declining 
incidence emphasizes the importance of sustainable control strategies to move towards 
elimination. Although a more holistic approach will be needed to eliminate this poverty 
related disease, there is an irrefutable and urgent need for new treatments. Optimizing the 
current therapeutic regimens is the first step to meet this demand.  
 
This thesis presents evidences for the safety and efficacy of a patient friendly regimen 
namely Artemisinin based Combination Therapies (ACT) with concomitant use of short 
course primaquine.   
 
Short course primaquine regimen (0.5 mg/kg/day 7 days) using the same total dose 
recommended worldwide has been the standard of care in Brazil for some time, but until 
now the evidence has been regarded insufficient to support the shortening of 14 days that 
is seen in the World Health Organization (WHO) treatment recommendation. A 
systematic review including 1211 patients was conducted to compare the efficacy of both 
regimens and concluded that was little or no difference in P. vivax recurrence rates at 6 
months when using the same total dose (210 mg) over 7 days as compared to 14 days 
(chapter 2), two new major randomized clinical trials in the south-east Asia have also 
confirmed similar efficacy with short course regimens (Taylor, 2018).  
 
My work has led to similar conclusions. The evaluation of 154,970 patients’ data recorded 
in the Brazilian national surveillance system demonstrated no difference in time to 
recurrence or recurrence frequency between patients treated with 14-day or 7–9 day 
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primaquine regimens (HR = 1.02, 95%CI 0.96–1.09) and (RR = 0.97, 95%CI 0.90–1.04), 
respectively.  
 
The data presented here increased the body of evidence to support the recommendation 
that  primaquine short course regimens can be adopted into WHO treatment guideline. 
However, shorter course primaquine may improve adherence and the effectiveness of 
vivax treatment worldwide, there is still room for further improvements in treatment. One 
potential approach is to replace chloroquine by ACTs. 
 
Previous work suggested that ACTs have a similar efficacy in the treatment of vivax as 
standard treatment with chloroquine. Several studies support this, including a systematic 
review, and in clinical practice, ACTs have been extensively used as the first line 
treatment for mixed infection or chloroquine-resistant vivax.  This thesis further 
investigated the efficacy of ACTs in a randomized clinical trial with two ACTs and 
chloroquine, all with concomitant use of primaquine short course in Brazil. All three 
regimens had 42 day cure rates above 90%.  The cohort study also suggested that 
Plasmodium vivax recurrence took longer in patients taking ACT than chloroquine (both 
with primaquine) HR = 1.27 (0.97–1.66, p = 0.08). 
 
Finally, we explored the influence of drug exposure, and both parasite and host 
characteristics upon the clinical outcomes. The evaluation of the pharmacokinetics and 
pharmacodynamics interactions suggested that exposure to the long half-life drugs were 
not associated with any of the efficacy outcomes, including treatment failure within 63 
days follow up and time to failure. However, in this study there was a high frequency of 
failures due to homologous parasite relapses, meaning that the hypnozoites may have not 
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been cleared by primaquine. There was also a trend towards an association between 
impaired CYP2D6 enzyme activity and relapse with homologous parasites, in line with 
the evidence that the efficacy of primaquine depends on the generation of a 
therapeutically active metabolite via cytochrome P450 2D6 (CYP2D6).   
 
One approach to overcoming the issue of decreased primaquine exposure in impaired 
CYP2D6 populations would be to increase the primaquine dose. This approach has been 
adopted in the latest clinical trials in the south-east Asia. Our systematic review compared 
the recurrence rate at 6 months follow up of the WHO high standard (0.5 mg/kg/day) 
versus standard (0.25 mg/kg/day) 14 days’ treatment and showed no difference (RR 0.82, 
95% CI 0.47-1.43), but as only two studies (639 participants) were available.  
 
The potential limitation of increasing primaquine exposure is the risk of adverse events 
(AE). In our review, 8 out of 380 participants in the high-dose 14-day group discontinued 
treatment due to adverse events, compared to 2 out of 398 in the standard 14-day group 
(RR 4.19, 95% CI 0.90 -19.60). No serious adverse events were reported in either study 
arms, but none of the studies included the population with G6DP deficiency, which is the 
most frequent enzyme deficiency in humans, and causes haemolytic anaemia.  
 
The other major safety issue was the relative lack of information about the safety of the 
concomitant use of ACT and multi-day primaquine. We endeavoured to addressed this in 
the randomized clinical trial and the subsequent pharmacokinetic and pharmacodynamics 
study. The only serious adverse event related to the treatment was haemolysis in a G6DP 
deficient patient treated with chloroquine and primaquine. The AEs were reported 
meticulously and 86.5% were grade I, i.e. they do not need any medical intervention. 
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Drug exposure was not related to increasing the risk of AE, except that an increased half-
life of chloroquine was associated with higher risk of having pruritus (RR 1.09, 95% CI 
1.03-1.14, p= 0.001), providing further assurance that exposure of both ACT and multi-
day primaquine regimen remain within the safety margins when co-administered.  
 
Once the similarity of the safety, efficacy and effectiveness profiles of the standard 
chloroquine plus primaquine and these new approaches to treat vivax were established, 
there are other factors rather than safety, efficacy and effectiveness that may drive the 
update of the treatment guidelines were identified.  
 
There are several advantages of ACT plus primaquine as a unified treatment for both P. 
vivax and P. falciparum species. This approach (i) surpass the need of species 
identification in co-endemic areas ; (ii) treats mixed infections; (iii) prevent P. vivax 
relapse following P. falciparum infections; (iv) simplifies drug stock and supply 
management; (v) sustains  of ACT production in industrial scale if falciparum treatment 
purchases fade out; (vi)  avoids selective pressure, making more than one vivax treatment 
available; (vii) has small pill burden, depending on the ACT ; (vii) and finally, it provides 
a children friendly formulation where liquid chloroquine is not available, as in Brazil. 
 
The effectiveness study identified that the younger patients are the most susceptible to 
recurrences. There are several potential explanations for this in addition to differences in 
acquired immunity, but the inadequate doses and the absence of child-friendly 
formulations may play a major role in poor adherence and reduced effectiveness. The 
ACTs tested here are available in dispersible tablets, and if administered with a new 
 
163 
primaquine tablet (5mg) could address this neglected population reducing the overall 
reservoir in the population in risk. 
 
Finally, the deduplication methodology of the data of the national surveillance system 
based on bloom filters can be used as a way of recording patients’ follow up, as it links 
successive observations of the same individual over a period of time. This use of routine 
health information systems allows evaluating the impact of large scale interventions in 
public health, building capacity and strengthening a sustainable surveillance systems. 
Future prospective research designs using this methodology may demonstrate causal 
inferences of the proposed treatment optimizations upon the recurrence incidence 
providing evidence to the policy change, even in a low endemicity setting, as Brazil. This 
study gives a basis to future studies to evaluate the effectiveness of the deployment of 
these approaches and of new ones nationwide in Brazil.  
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Additional material 2. National System of Malaria Surveillance 
form (SIVEP-malaria)  
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Additional material 3. Data flowchart  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 Visual inspection 
SIVEP malaria dataset 
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(records) 
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patients  
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Patients with 
recurrences 
26,295 recurrences 
(records) 
 
1,767 recurrences 
until D2 
153,203 
(records) 
291 
False matches 
493 
New matches 
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Additional material: Efficacy and safety of Artemisinin-based 
Combination Therapy and chloroquine with concomitant 
primaquine to treat Plasmodium vivax malaria in Brazil: An 
open label randomized clinical trial. Malaria Journal, 2017 
Additional material 1.  
Table S 1	Reasons to not be included- Consort Diagram 
 
 
  
Reasons to not be included numbers of patients           (%) 
Unavailability for follow-up 492 (19.9%) 
Parasitaemia lower than 250/µL 394 (15.9%) 
Malaria treatment within the past 63 days 376 (15.2%) 
Residency in rural area 187 (7.6%) 
Weight range, i.e., <50kg or > 90kg 139 (5.6%) 
Age range, i.e., < 18 or > 70 years old 122 (4.9%) 
Falciparum malaria or mixed infection 113 (4.6%) 
Other 89 (3.6%) 
Declined to participate 69 (2.8%) 
Pregnancy 44 (1.8%) 
Haemoglobin < 7 g/dL 03 (0.1%) 
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Additional material 2.  
Table S 2 Distribution of use of concomitant medication (grouped in 
therapeutic class) in each study arm, parenthesis presents the percentage 
of the line. 
Therapeutic class 
of concomitant 
medication 
study arm  
N (%)  
  
ASMQ+Pq 
 
Cq+Pq 
 
AL+Pq 
 
Total       115(23.23) 189(38.18) 191(38.59) 
              
             
    
analgesic/ 
antipyretic   74(25.78) 117(40.77) 96(33.45) 
    antispasmodic   5(17.24) 3(10.34) 21(72.41) 
    antifungal   1(33.33) 1(33.33) 1(33.33) 
    antiemetic   7(29.17) 3(12.5) 14(58.33) 
    antihistaminic   2(33.33) 4(66.67) 0(0) 
    antipsychotic   0(0) 1(100) 0(0) 
    antiulcer    5(14.29) 10(28.57) 20(57.14) 
    antibiotic   4(19.05) 7(33.33) 10(47.62) 
    antidepressant   0(0) 1(50) 1(50) 
    antihypertensive   4(10.53) 21(55.26) 13(34.21) 
    anti-vertigo   0(0) 1(50) 1(50) 
    antiviral (topic)   1(50) 0(0) 1(50) 
    anti-dyslipidaemia   1(50) 1(50) 0(0) 
    expectorant   0(0) 5(100) 0(0) 
    hepatic-protector   4(36.36) 3(27.27) 4(36.36) 
    hydration   1(100) 0(0) 0(0) 
    
hypoglycaemic 
drug   0(0) 6(54.55) 5(45.45) 
    traditional drugs   2(40) 1(20) 2(40) 
    vitamins   4(40) 4(40) 2(20) 
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Figure S 1. Distribution of most frequent medications used per study visit 
and treatment group 
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Additional material 3.  
Table S 3. Proportion of treatment success per treatment arm in ITT 
population (n = 88 per arm) at day 28, 42 and 63 
 
	
Table S 4.  Proportion of treatment success per treatment arm in PP 
population at day 07, 14 and 21. 
 
 
  
Visit day Study treatment 
  
ASMQ+Pq CQ+Pq  AL+Pq 
% IC 95% % IC 95% % IC 95% 
           
D28 97%  [91-100] 93%  [88-98] 92%  [86-98] 
           
D42 92% [86-98] 86% [79-94] 88% [81-94] 
           
D63 76% [67-85] 81% [72-89] 77% [69-86] 
Visit day Study treatment 
  
ASMQ+Pq Cq+Pq AL+Pq 
% 
(n) 
IC 95% % 
(n) 
IC 95% % 
 (n) 
IC 95% 
           
D07 100%  
      (87) 
- 100%  
(85) 
- 100%  
(86) 
- 
 
D14 
      
100%  
(87) 
- 100%  
(84) 
- 100%  
(84) 
- 
 
D21 
      
100%  
(86) 
- 100%  
(84) 
- 99% 
(84) [97-101] 
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Table S 5. Proportion of treatment success per treatment arm in ITT 
population (n=88 per arm) at day 07, 14 and 21. 
	
 
Additional material 4.  
Table S 6. Distribution of adverse events per causality and treatment 
group. 
 
Causality   
Treatment group 
n (%) 
    
ASMQ+P
q CQ+Pq AL+Pq Total 
    Doubtful   160 (23.3) 
283 
(41.2) 
243 
(35.4) 686 
    Unlikely   35 (22.1) 70 (44.3) 53 (33.5) 158 
    Possible   163 (27.2) 
238 
(39.7) 
199 
(33.2) 600 
    
Probable/ 
Likely    36 (27.9) 43 (33.3) 50 (38.8) 129 
    
Highly 
Probable   9 (45) 9 (45) 2 (10) 20 
 
  
Visit day Study treatment 
  
ASMQ+Pq CQ+Pq  AL+Pq 
% IC 95% % IC 95% % IC 95% 
           
D07 99%  [97-101] 98%  [95-101] 98%  [95-101] 
           
D14 99%  [97-101] 97%  [93-101] 98%  [95-101] 
           
D21 98% [95-101] 95% [91-100] 94% [89-99] 
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Additional material 5.  
Table S 7. Distribution of adverse events per causality and intensity 
(grade) in the treatment group ASMQ + Pq. 
 
Grade 
Causality (N,%)  
ASMQ+Pq   
  Doubtful Unlikely  Possible  
Probable/ 
Likely 
Highly 
Probable Total 
1 141(34.99) 27(6.7) 151(37.47) 34(8.44) 8(1.99) 361(89.58) 
2 18(4.47) 8(1.99) 12(2.98) 2(0.5) 1(0.25) 41(10.17) 
4 0(0) 0(0) 0(0) 0(0) 0(0) 0(0) 
NC* 1(0.25) 0(0) 0(0) 0(0) 0(0) 1(0.25) 
Total 160(39.7) 35(8.68) 163(40.45) 36(8.93) 9(2.23) 403(100) 
* Non-classified  
Table S 8. Distribution of adverse events per causality and intensity 
(grade) in the treatment group CQ + Pq 
 
 
 
Grad
e 
Causality (N,%)  
CQ+Pq   
  Doubtful Unlikely  Possible  
Probable/ 
Likely 
Highly 
Probable Total 
1 
254 
(39.5) 
52 
(8.09) 
212 
(32.97) 
37 
(5.75) 
9 
(1.4) 
564 
(87.71) 
2 28(4.35) 17(2.64) 26(4.04) 5(0.78) 0(0) 
76 
(11.82) 
4 0(0) 0(0) 0(0) 1(0.16) 0(0) 1(0.16) 
NC* 1(0.16) 1(0.16) 0(0) 0(0) 0(0) 2(0.31) 
Total 283 
(44.01) 
70 
(10.89) 
238 
(37.01) 
43 
(6.69) 
9 
(1.4) 
643 
(100) 
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Table S 9. Distribution of adverse events per causality and intensity 
(grade) in the treatment group AL + Pq. 
 
Grade 
Causality (N,%)  
AL+Pq   
  Doubtful Unlikely  Possible  
Probabl
e/ Likely 
Highly 
Probable Total 
1 202(36.93) 28(5.12) 
175 
(31.99) 47(8.59) 2(0.37) 454(83) 
2 40(7.31) 24(4.39) 24(4.39) 3(0.55) 0(0) 
91 
(16.64) 
4 1(0.18) 1(0.18) 0(0) 0(0) 0(0) 2(0.37) 
Total 243(44.42) 53(9.69) 
199 
(36.38) 50(9.14) 2(0.37) 547(100) 
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Additional material 6.  
Table S 10. All adverse events (1,593) per body system and treatment 
allocation 
 
        
Treatment allocation 
 n (%)   
Variable   
ASMQ+Pq 
 
CQ+Pq 
 
AL+Pq 
 
Total 
Total       403(25.3) 643(40.36) 547(34.34) 1593 
                
Body 
System               
    Cardiovascular   4(28.57) 3(21.43) 7(50) 14 
    Dermatological   28(25) 55(49.11) 29(25.89) 112 
    Digestive   110(24.44) 158(35.11) 182(40.44) 450 
    General Status   115(23.81) 203(42.03) 165(34.16) 483 
    Excretory    1(10) 7(70) 2(20) 10 
    Musculoskeletal   28(25) 43(38.39) 41(36.61) 112 
    
Central nervous 
System   77(31.3) 107(43.5) 62(25.2) 246 
    
Peripheral 
nervous System   3(50) 1(16.67) 2(33.33) 6 
    
Reproductive 
female   2(66.67) 0(0) 1(33.33) 3 
    Respiratory   34(22.08) 66(42.86) 54(35.06) 154 
    Trauma   1(33.33) 0(0) 2(66.67) 3 
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Additional material 7.  
Table S 11. Adverse events with frequency higher than 3% in the 
ASMQ+Pq arm (n total=403)  
 
ASMQ+Pq 
Symptoms   n(%) 
headache 51(12.66) 
insomnia 39(9.68) 
nauseas 36(8.93) 
asthenia 31(7.69) 
dizziness  28(6.95) 
dyspnoea 27(6.7) 
pruritus 24(5.96) 
abdominal pain 22(5.46) 
muscle articular pain 21(5.21) 
vomitus 16(3.97) 
	
	
	
Table S 12. Adverse events with frequency higher than 3% in the CQ+Pq 
arm (n total=643)  
 
 Cq+Pq 
    
Symptoms   n(%) 
headache 84(13.06) 
insomnia 62(9.64) 
pruritus 53(8.24) 
abdominal pain 52(8.09) 
asthenia 49(7.62) 
nauseas 42(6.53) 
anorexia 39(6.07) 
dyspnoea 38(5.91) 
muscle articular pain 32(4.98) 
cough  22(3.42) 
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Table S 13. Adverse events with frequency higher than 3% in the AL+Pq 
arm (n total=547) 	
	
AL+Pq 
    
Symptoms   n(%) 
headache 62(11.33) 
abdominal pain 57(10.42) 
asthenia 54(9.87) 
nauseas 40(7.31) 
dyspnoea 33(6.03) 
vomitus 33(6.03) 
insomnia 32(5.85) 
pruritus 26(4.75) 
muscle articular pain 25(4.57) 
epigastric pain 24(4.39) 
cough 21(3.84) 
anorexia 19(3.47) 
dizziness  17(3.11) 
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Additional material 8.  
	
Table S 14. Haemoglobin mean per regimen allocation at day 0, 14, 28, 
42, and 63 
 
 
  
Days Regimen allocation 
  ASMQ+Pq CQ+Pq AL+Pq 
  Mean 
(SD) 
Range  
(min-max) 
Mean   
(SD) 
Range  
(min-max) 
Mean  
(SD) 
Range  
(min-max) 
D1 13.33 
(1.66) 
(8.6-17.3) 13.58 
(2.6) 
(8.7-32.6) 13.59 
(2.01) 
(9-18.2) 
D14 12.49 
(1.46) 
(9.9-16.2) 12.76 
(1.33) 
(10.3-16.4) 13.01 
(1.42) 
(8.4-16.3) 
D28 13.48 
(1.27) 
(10.9-16) 13.5 
(1.17) 
(10.7-16.3) 13.76 
(1.2) 
(10.1-16.2) 
D42 13.82 
(1.18) 
(11.5-16.4) 14.03 
(1.45) 
(10.3-18.8) 14.06 
(1.3) 
(10.4-17.1) 
D63 13.83 
(1.33) 
(11.1-16.4) 14.22 
(1.41) 
(10.9-17.6) 14.27 
(1.15) 
(11.3-16.7) 
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Additional material:	Pharmacokinetics/ Pharmacodynamics 
of chloroquine and Artemisinin-based Combination 
Therapies with primaquine 
Additional material 1. 
Table S 15. Genotyping of Plasmodium vivax polymorphic loci from 
patients during initial infection and recurrence 
 
ID sample# MS2 MS6 MS7 MSP1B2 MSP1B10 
11 d0 294 bp 233 bp 349 bp 410 bp 290 bp 
11 d42 294 bp 233 bp 349 bp 410 bp 290 bp 
20 d0 298 bp 209 bp 349 bp 426 bp 255 bp 
20 d63 298 bp 209 bp 349 bp 426 bp 255 bp 
24 d7 342 bp 199 bp 385 bp NA 255 bp 
24 d63 298 bp 199 bp 349 bp 410 bp 223 bp 
33 d0 298 bp 209 bp 349 bp 426 bp 255 bp 
33 d62 298 bp 209 bp 385 bp 426 bp 255 bp 
35 d0 292 bp 209 bp 355 bp 426 bp 290 bp 
35 d62 300 bp 257 bp 358 bp 426 bp 255 bp 
43 d0 294 bp 233 bp 349 bp 410 bp 290 bp 
43 d51 294 pb 233 bp 349 bp 410 bp 290 bp 
50 d0 312 bp 209 bp 361 bp 397 bp 242 bp 
50 d41 302 bp 209 bp 355 bp 410 bp 237 bp 
53 d0 298 bp 209 bp 361 bp 397 bp 233 bp 
53 d49 298 bp 209 bp 361 bp 397 bp 233 bp 
60 d0 298 bp 209 bp 361 bp 397 bp 242bp 
60 d63 292 bp 199 bp* 388 bp 397 bp 255 bp* 
67 d0 294 bp 230 bp 349 bp 410 bp 290 bp 
67 d54 294 bp 230 bp 349 bp 410 bp 290 bp 
69 d0 298 bp 209 bp 349 bp 414 bp 223 bp 
69 d28 298 bp 209 bp 349 bp 414 bp 223 bp 
73 d0 292 bp 209 bp 358 bp 397 bp 255 bp 
73 d37 292 bp 209 bp 358 bp 397 bp 255 bp 
102 d0 298 bp 209 bp 349 bp 410 bp 223 bp 
102 d63 298 bp 209 bp 349 bp 410 bp 223 bp 
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103 d0 294 bp 230 bp 349 bp 410 bp 290 bp 
103 d40 294 bp 230 bp 349 bp 410 bp 290 bp 
111 d0 300 bp 209 bp 355 bp 426 bp 237 bp 
111 d50 292 bp* 209 bp 349 bp 409 bp* 237 bp 
119 d0 300 bp 209 bp 349 bp 408 bp 290 bp 
119 d27 300 bp 209 bp 349 bp 408 bp 290 bp 
126 d0 298 bp 209 bp 355 bp 410 bp 237 bp 
126 d47 298 bp 209 bp 355 bp 426 bp* 237 bp 
133 d0 298 bp 209 bp 355 bp 410 bp 237 bp 
133 d62 298 bp 209 bp 355 bp 410 bp 237 bp 
136 d0 298 bp 209 bp 355 bp 426 bp 237 bp 
136 d63 298 bp 209 bp 355 bp 426 bp 237 bp 
153 d0 298 bp 209 bp 358 bp 397 bp 242 bp 
153 d63 292 bp 209 bp 358 bp 397 bp 242 bp 
156 d0 300 bp 209 bp 349 bp 397 bp 255 bp 
156 d63 300 bp 209 bp 349 bp 397 bp 255 bp 
157 d0 298 bp 209 bp 361 bp 381 bp 242 bp 
157 d63 298 bp 199 bp* 358 bp NA 242 bp 
160 d0 298 bp 230 bp 349 bp 426 bp 255 bp 
160 d61 298 bp 230 bp 349 bp 426 bp 255 bp 
162 d0 294 bp 209 bp 349 bp 397 bp 242 bp 
162 d56 292 bp 209 bp 349 bp 397 bp 242 bp 
163 d0 298 bp 209 bp 361 bp 405 bp 223 bp 
163 d42 298 bp 209 bp 361 bp 405 bp 223 bp 
166 d0 294 bp 230 bp 349 bp 392 bp 290 bp 
166 d57 294 bp 230 bp 349 bp 410 bp 290 bp 
182 d0 298 bp 224 bp 343 bp 426 bp 255 bp 
182 d21 298 bp 224 bp 343 bp 426 bp 255 bp 
198 d0 292 bp 209 bp 358 bp 397 bp 255 bp 
198 d62 292 bp 209 bp 358 bp 397 bp 255 bp 
207 d0 300 bp 209 bp 393 bp 410 bp 290 bp 
207 d56 300 bp 209 bp 390 bp 410 bp 290 bp 
214 d0 298 bp 209 bp 352 bp 426 bp 264 bp 
214 d42 298 bp 209 bp 352 bp 426 bp 264 bp 
216 d0 298 bp 199 bp 427 bp 397 bp 327 bp 
216 d55 292 bp 209 bp 430 bp 414 bp 249 bp 
231 d0 298 bp 209 bp 355 bp 410 bp 290 bp 
231 d63 298 bp 209 bp 355 bp 410 bp 290 bp 
246 d0 298 bp 209 bp 352 bp 410 bp 223 bp 
246 d39 298 bp 209 bp 352 bp 410 bp 223 bp 
250 d0 298 bp 209 bp 352 bp 426 bp 264 bp 
250 d63 298 bp 233 bp 352 bp 426 bp 264 bp 
251 d0 294 bp 209 bp 349 bp 410 bp 290 bp 
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251 d63 294 bp 199 bp 340 bp 410 bp 290 bp 
Size of PCR products in base pairs (bp). #Number of patient and day of sample 
collection: d0 – diagnosis and treatment, dX – the day of recurrence. *Allele similar 
to initial infection present in lower intensity. NA – non-amplified. 
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Additional material 2. 
Table S 16. Genotyping of CYP2C8 gene and CYP2D6 gene and predicted phenotype of CYP2D6 activity 
 
ID 
patient 
CYP2C8    CYP2D6  
G1846A G2988A   
G-
1584C C100T C1023T C2850T G3183A G4180C 
2615_2617 
del AAG 
 Haplotypea Allele 1 Allele 2 Copy number 
ASb 
Allele 
1 
AS 
Allele 
2 
Total 
activity 
Scorec 
Phenotypeb 
11  GG  GA    CG  CC  CC  TT  GG  CC  AA PV011: (4,7) *2/*35 *41 2 1 0.5 1.5 gNM-F 
20  GG  GG    CC  TC  CC  CC  GG  GC  AA PV020: (2,6) *1 *10/*10x2 2 1 0.5 1.5 gNM-F 
24  GG  GG    CG  CC  CT  TT  GG  CC  AA PV024: (4,5) *2/*35 *17 2 1 0.5 1.5 gNM-F 
33  GA  GG    CC  TC  TT  TC  GG  CC  AA PV033: (5,10) *17 NP 2 0.5 NP NP NP 
35  GG  GG    CC  CC  CC  CC  GG  GG  AA PV035: (2,2) *1 *1 2 1 1 2 gNM-F 
43  GA  GG    CC  TC  CC  CC  GG  GC  AA PV043: (2,8) *1 *4/*4x2 2 1 0 1 gNM-S 
50  GG  GG    CC  CC  CC  CC  GG  GG  AA PV050: (2,2) *1 *1 2 1 1 2 gNM-F 
53  GG  GG    CC  TC  CC  CC  GG  GC  AA PV053: (2,6) *1 *10 2 1 0.5 1.5 gNM-F 
60  GG  GG    GG  CC  CC  TT  GG  CC  AA PV060: (4,4) *2/*35 *35xN/*2xN 3 1 2 3 gUM 
67  AA  GG    CC  TT  CC  CC  GG  CC  AA PV067: (8,8) *4 *4 2 0 0 0 gPM  
69  GG  GG    CC  CC  CC  CC  GG  GG  AA PV069: (2,2) *1 *1 2 1 1 2 gNM-F 
73  GG  GG    CG  CC  CC  TC  GG  GC  AA PV073: (2,4) *1 *2/*35 2 1 1 2 gNM-F 
102  GG  GA    CC  CC  CC  TC  GG  GC  AA PV102: (2,7) *1 *41 2 1 0.5 1.5 gNM-F 
103  GG  GA    CG  CC  CC  TT  GG  CC  AA PV103: (4,7) *2/*35 *41 2 1 0.5 1.5 gNM-F 
111  GG  GG    CC  CC  CC  CC  GG  GG  AA PV111: (2,2) *1 *1 2 1 1 2 gNM-F 
119  GG  GG    CG  CC  CT  TT  GG  CC  AA PV119: (4,5) *2/*35 *17 2 1 0.5 1.5 gNM-F 
126  GA  GG    CC  TC  CC  CC  GG  GC  AA PV126: (2,8) *1 *4 2 1 0 1 gNM-S 
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133  GG  GG    CC  CC  CC  CC  GG  GG  AA PV133: (2,2) *1 *1 2 1 1 2 gNM-F 
136  GA  GG    CC  TC  CC  CC  GG  GC  AA PV136: (2,8) *1 *4 2 1 0 1 gNM-S 
153  GG  GG    CC  CC  CC  CC  GG  GG  AA PV153: (2,2) *1 *1 2 1 1 2 gNM-F 
156  GG  GG    GG  CC  CC  TT  GG  CC  AA PV156: (4,4) *2/*35 *2/*35 2 1 1 2 gNM-F 
157  GG  GG    GG  CC  CC  TT  GG  CC  AA PV157: (4,4) *2/*35 *5 1 1 1 2 gNM-F 
160  GA  GG    CC  TC  CC  CC  GG  GC  AA PV160: (2,8) *1/*1xN *4/*4x2 NP 1 0 1 gNM-S 
162  GG  GG    CG  CC  CC  TC  GG  GC  AA PV162: (2,4) *1 *2/*35 2 1 1 2 gNM-F 
163  GA  GA    CC  TC  CC  TC  GG  CC  AA PV163: (7,8) *41 *4/*4x2 NP 0.5 0 0.5 gIM  
166  GG  GG    CG  CC  CC  TT  GG  CC  AA PV166: (1,4) *2D *2/*35 2 1 1 2 gNM-F 
182  GG  GA    CC  CC  CC  TC  GG  GC  AA PV182: (2,7) *1 *41 2 1 0.5 1.5 gNM-F 
198  GG  GG    CC  TC  CC  CC  GG  GC  CA PV198: (3,6) *9 *10 2 0.5 0.5 1 gNM-S 
207  GG  GG    CG  CC  CC  TC  GG  GC  CA PV207: (3,4) *9 *2/*35 2 0.5 1 1.5 gNM-F 
214  GG  GG    GG  CC  CC  TT  GG  CC  AA PV214: (4,4) *2/*35 *2/*35 2 1 1 2 gNM-F 
216  GA  GG    CC  TC  CC  CC  GG  GC  AA PV216: (2,8) *1/*1xN *4/*4x2 3 2 0 2 gNM-S 
231  GA  GG    GG  TC  CC  TC  GG  CC  AA PV231: (4,9) *2/*35/*2xN NP 3 1 NP NP NP 
246  GA  GG    CC  TC  CC  CC  GG  GC  AA PV246: (2,8) *1 *4 2 1 0 1 gNM-S 
250  GG  GG    CC  CC  CC  CC  GG  GG  AA PV250: (2,2) *1 *1 2 1 1 2 gNM-F 
251  GG  GA    CG  CC  CC  TT  GG  CC  AA PV251: (4,7) *2/*35 *41 2 1 0.5 1.5 gNM-F 
a CYP2D6 haplotype inferred using Phase software. b Activity score  and inferred phenotype of CYP2D6: AS = 1.5 or 2 – normal metabolizer 
fast (gNM-F); AS ≥ 2 - ultra metabolizer (gUM) (more than 2 copies of the normal allele); AS = 1 – normal metabolizer slow (gNM-S); AS = 
0.5 – intermediate metabolizer (gIM); AS = 0 – poor metabolizer (gPM), according to Gaedigk et al. 2008 [20]. c Sum of AS attributed to allele 
1 and 2 of CYP2D6 gene.  NP - not performed. 
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 Table S 17. Evaluation of pharmacokinetics’ parameters, gender and weight as predictors of failures per treatment 
drug (Generalized Linear Model, binomial logit link) 
 
 
 MQ CQ LMF 
n failures (%) 7 (8) 7 (13) 8 (14) 
  OR (95% CI) p-value 
Female 0.73 (0.15-3.53), p=0.7 2.13 (0.09-50.66), p=0.64 0.35 (0.06-1.94), p=0.23 
Half-life (days)  - 1.04 (0.87-1.23), p=0.69  - 
Weight 0.94 (0.88-1.02), p=0.13 0.92 (0.84-1.01), p=0.09 0.93 (0.83-1.03), p=0.16 
AUC (mcg) 1 (0.99-1.01),    p=0.71 0.99 (0.96-1.02), p=0.63 0.97 (0.87-1.07), p=0.52 
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Table S 18. Evaluation of pharmacokinetics’ parameters and weight as predictors of D3 failures per treatment drug 
(Generalized Linear Model, binomial logit link)  
 
 MQ CQ LMF 
n failures (%) - 3 (6) - 
 OR (95% CI), p-value 
Weight - 0.93 (0.84-1.03), p=0.18 - 
AUC (mcg) - 1.00 (0.99-1.02), p=0.70 - 
Half-life (days) - 1.05 (0.9-1.23), p=0.52 - 
Only available to chloroquine, all males. ASMQ and AL 100% presented clearance at D3. 
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Table S 19. Evaluation of pharmacokinetics’ parameters, gender and 
weight as predictors of time to failures per treatment drug (Cox 
regression) 
	
	
  MQ CQ LMF 
n events (%) 7 (8) 7 (8) 8 (9) 
  HR (95% CI), p-value 
Weight 0.95 (0.89-1.02), p=0.18 
0.93 (0.85-1.03), 
p=0.15 0.93 (0.86-1.02), p=0.11 
AUC (mcg) 1 (0.99-1.01), p=0.95 
0.99 (0.96-1.02), 
p=0.65 0.96 (0.87-1.07), p=0.46 
Half-life (days) - 1.02 (0.89-1.17), p=0.8 - 
Gender 0.74 (0.14-3.83), p=0.72 
1.87 (0.2-17.84), 
p=0.59 0.38 (0.06-2.42), p=0.31 
Additional material 6 
Table S 20. Evaluation of pharmacokinetics’ parameters and weight as 
predictors of the drop in haemoglobin* at day 14 using ordinary least 
squares. 
 
  Mefloquine 
(N=52) 
Chloroquine 
(N=52) Lumefantrine (N=53) 
  Coefficient (95%CI), p-value 
AUC (0d-63d) 
(µg/ml.h) 
0.00 (-0.24-0.33), 
p=0.17 
-0.02 (-0.03;-
0.005), p=0.01 0.00 (-0.16-0.33), p=0.42 
Half-life (days) 0.00 (0-0), p=0.87 -0.03 (-0.1-0.04), p=0.42 NA 
Weight 0.00 (0-0), p=0.77 ** 0.00 (0-0), p=0.37 
*Hb at day 14 − Hb at baseline/Hb at baseline  
**CQ AUC and weigh correlation is significant at the 0.01 level (2-tailed). Weight 
was excluded as a covariate. NA= Non-Applicable 
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Table S 21. Evaluation of pharmacokinetics’ parameters as predictors of frequent (n³30) adverse event (possible and 
likely related to treatment) per system and drug using Generalized Estimation Equation log-binomial regression. 
 
Treatment 
group 
 Adverse event (System)  
RR (95% CI), p-value 
  Dermatological 
(pruritus) 
Overall state CNS Digestive 
MQ AUC - - 1 (1-1), p=0.49 1 (1-1), p=0.61 
Half-life - - 0.99 (0.95-1.04), 
p=0.71 
1 (0.96-1.03), p=0.81 
Weigh - - 1.00 (0.97-1.03), 
p=0.93 
1 (0.97-1.03), p=0.93 
CQ* AUC 1 (0.99-1.01), p=0.73 - 1.01 (1-1.02), p=0.07 0.99 (0.98-1), p=0.06 
Half-life 1.09 (1.03-1.14), 
p<0.01 
- 1.02 (0.97-1.08), 
p=0.43 
0.99 (0.95-1.04), 
p=0.73 
LMF AUC - 0.96 (0.91-1.01), 
p=0.15 
- 0.98 (0.95-1.01), 
p=0.24 
Weigh - 1.01 (0.98-1.04), 
p=0.57 
- 0.97 (0.94-1.01), 
p=0.11 
*CQ AUC and weigh correlation is significant at the 0.01 level (2-tailed). Weight was excluded as a covariate 
 
